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Summary 
Infection with human cytomegalovirus (HCMV) is usually asymptomatic in 
normally healthy individuals although about 50-85% of adults are infected during their 
lifetime. However, it can cause severe or fatal disease in infants and immunocompromised 
patients. The generation of a potent protective vaccine is a necessity to protect vulnerable 
people. Because of host restriction, murine cytomegalovirus (MCMV) is used as a model 
for HCMV to study genes involved in pathogenicity. Previously, we have generated a 
temperature-sensitive mutant, tsm5, which failed to replicate to detectable levels in mice. 
Several mutations have been identified in this mutant. In a previous study in our laboratory, 
a mutation (C890Y) introduced into the M70 primase gene resulted in reduced viral 
replication at 40ºC in vitro and the mutant was severely attenuated in vivo. Two other 
previously identified mutations may also contribute to this lack of replication in vivo, 
namely an A658S mutation in a protein expressed by the M27 ORF, which is involved in 
interference with interferon- signalling, and a V54I mutation in the anti-apoptotic protein 
expressed by the M36 ORF.  
Further mutations have been identified in this study using Comparative Genome 
Sequencing (GCS) (Roche NimbleGen). A total of 10 synonymous and 15 non-
synonymous single nucleotide polymorphisms (SNPs) have been identified in tsm5 and 14 
of the non-synonymous mutations were confirmed by sequencing. Among these genes are 
m139 (Y565X) and m141 (V195M), which have been shown to be essential for replication 
in macrophages but not in fibroblasts, and m143 (M232I), shown to play an important role 
in the inhibition of the PKR-mediated host antiviral response.   
   
 
In the present study, the above mentioned mutations in M27, M36, m139, m141, and 
m143 were introduced individually into the MCMV K181 (Perth) variant bacterial artificial 
chromosome (BAC) using RecE/T homologous recombination. In addition, the M27 and 
M36 mutations were introduced together into the wt virus BAC.  
An in vitro phenotypical analysis revealed that, apart from the double mutant 
(Mt[M27
A658S
M36
V54I
]) and the m139 (Mt[m139
Y565X
]) mutant, the introduced mutations in 
the above mentioned genes did not show a temperature sensitive phenotype in MEF cells 
compared to their revertants or the wt virus. The M27 and M36 single mutants and the 
m141 and m143 mutants also showed similar growth kinetics to wt virus in Raw 264.7 
macrophages. In contrast, replication of the M27/M36 double mutant was drastically 
reduced in MEFs at 40ºC and in macrophages at 37ºC. Replication of the m139 mutant was 
slightly reduced in MEF cells at 40ºC but not in macrophages.  
 Interestingly, the attenuated replication of the M70 (Mt[M70
C890Y
]) mutant, 
previously noted only at 40
o
C in MEF cells, was also observed in Raw 264.7 macrophages 
at 37ºC. This M70 mutation however, was unstable.  
In an attempt to stabilise this mutation, many synonymous mutations have been 
introduced into this ORF by changing codon preferences that should reduce the efficiency 
of gene translation but not change protein structure. Two mutant BACs were constructed in 
which 403 of the 964 codons were changed to codons used less optimally in mouse cells 
but with either cysteine (BAC[M70
SO403Cys
]) or tyrosine (BAC[M70
SO403Tyr
] ) at residue 
890. Another two BAC constructs were produced with only 155 codons (at the distal third 
of M70 gene) changed to mouse cell suboptimal codons and with either cysteine 
(BAC[M70
SO155Cys
]) or tyrosine (BAC[M70
SO155Tyr
]) at residue 890. Upon transfection of 
   
 
these BACs into MEF cells, none produced infectious progeny viruses except 
BAC[M70
SO155Cys
] which produced mutant Mt[M70
SO155Cys
] virus. In vitro, 
Mt[M70
SO155Cys
] replicated similarly to its revertant and the wt MCMV K181 (Perth) 
variant. 
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Chapter 1:  Introduction  
1.1 The Herpesviridae: 
The taxonomy of herpesviruses has been revised recently by the international 
committee on Taxonomy of Viruses (ICTV), where the former Herpesviridae family has 
been divided into three families; the Herpesviridae retains the mammal, bird, and reptile 
viruses, the Alloherpesviridae, includes fish and frog viruses, while the 
Malacoherpesviridae holds a bivalve virus. The three families have been placed in the new 
Herpesvirales order (Davison et al., 2009). This introduction will consider the mammalian 
Herpesviridae only. 
The Herpesviridae have a characteristic morphology. They have a large linear 
double-stranded DNA genome (127-290 kb) in a T=16 icosahedral capsid surrounded by a 
tegument. The tegument is a proteinaceous matrix composed of more than fourteen viral 
proteins and some cellular proteins (Varnum et al., 2004). The tegument is enclosed in a 
lipid envelope containing membrane-associated proteins (Varnum et al., 2004).  Electron 
microscopic studies of the envelope has a typical trilaminar appearance (Figure 1.1) 
(Morgan et al., 1968). Furthermore, mammalian viruses of the Herpesviridae have common 
characteristic features, such as host restriction, they encodes for a large collection of 
enzymes involved in nucleic acid metabolism (e.g. thymidine kinase, thymidylate 
synthetase, dUTPase, ribonucleotide reductase), DNA synthesis,  (e.g. DNA polymerase, 
helicase, primase) and protein processing (e.g. protein kinases), they replicate in the 
nucleus (viral DNA synthesis and capsid formation), and usually results in lytic infection of 
permissive cells and they enter a latent state (Pellett & Roizman, 2006).  
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Figure  1.1: The morphology of a Herpesviridae virion: (A) Schematic representation of the 
HCMV virion. (www.biografix.de/). (B) A high resolution, computer-enhanced electron 
microscopy image of frozen viral capsids of Herpes simplex virus (HSV) 
(www.dbc.uci.edu/~faculty/wagner/hsv2f.html). 
Based on their biological properties, sequence homology, arrangement of the 
genome and viral protein similarity, human-infecting members of the Herpesviridae are 
classified into three subfamilies; the Alphaherpesvirinae (), the Betaherpesvirinae (), and 
the Gammaherpesvirinae () (Table 1.1).  
Members of Alphaherpesvirinae subfamily are neurotropic and characterized by 
variability in host range, short reproductive cycle, ability to spread rapidly in culture, 
destruction of infected cells and their ability to produce latent infection in sensory ganglia. 
Betaherpesvirinae members are found in a wide range of mammalian species, HCMV as a 
member of Betaherpesvirinae is characterized by its restricted host range, long reproductive 
cycle and slow progress of infection in tissue culture. The characteristic common cytopathic 
effect (CPE) of members of this subfamily is the enlargement of infected cells 
(cytomegalia). The secretory glands, lymphoreticular cells and kidneys are the main sites of 
virus persistence as the latent form of infection. Gammaherpesvirinae subfamily members 
are characterized by their ability to infect either T or B lymphocytes (lymphotropic) and to 
induce latency in lymphoid tissue. The experimental host range is limited to members of the 
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family or order of the natural host. In vitro they can replicate in lymphoblastoid cells and 
some can cause lytic infection. 
Table  1.1: Human diseases caused by Herpesviridae members. 
 
Taxon and Name Common name Disease 
Subfamily: Alphaherpesvirinae 
Genus:  Simplexvirus   
Human herpesvirus 1 Herpes simplex virus type 1 
Facial (skin sores), labial and ocular lesions, 
conjunctivitis, and encephalitis 
Human herpesvirus 2 Herpes simplex virus type 2 Genital lesions 
Genus:  Varicellovirus   
Human herpesvirus 3 Varicella-zoster virus 
Chicken pox 
shingles 
Subfamily: Betaherpesvirinae   
Genus: Cytomegalovirus   
Human herpesvirus 5 Cytomegalovirus 
In Immunocompetent individuals:   
Infectious mononucleosis,  enteritis, 
thrombocytopenia, severe anaemia and rarely 
encephalitis 
Congenital CMV: birth defects including 
hearing and vision loss, and mental 
retardation,  
In Immunocompromised patients:     
retinitis and vision loss in AIDS patients and 
lymphadenopathy, hepatitis, 
thrombocytopenia, pneumonitis, nephritis, 
gastrointestinal invasion and rarely 
encephalitis in transplant patients 
Genus: Roseolovirus   
Human herpesvirus 6 Human herpesvirus 6 
Skin condition in infants called 
Rosella infantum  or Exanthema subitum 
Human herpesvirus 7 Human herpesvirus 7 
Skin condition in infants called 
Rosella infantum  or Exanthema subitum 
Subfamily: Gammaherpesvirinae 
Genus: Lymphocryptovirus   
Human herpesvirus 4 Epstein-Bar virus 
Infectious mononucleosis 
Associated with two rare forms of cancer: 
Burkitt's lymphoma, and nasopharyngeal 
carcinoma. 
Genus: Rhadinovirus   
Human herpesvirus 8 
Kaposi’s sarcoma-
associated herpesvirus 
Associated with Kaposi’s sarcoma 
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1.2 Cytomegalovirus: 
1.2.1 Human Cytomegalovirus: 
Cytomegaloviruses (CMVs) belong to the Betaherpesvirinae subfamily of the 
Herpesviridae family. HCMV is strictly species-specific infecting only humans and 
generally producing subclinical and persistent infections in healthy people. However, in 
some cases, primary infection might cause an acute febrile illness with features of 
mononucleosis. Studies showed that 90% primary HCMV infections in pregnant women 
are clinically silent, where only 3 out of 63 pregnant women with primary cytomegalovirus 
infection  developed CMV mononucleosis and another three showed mild febrile illnesses   
(Stagno et al., 1986). Primary CMV infection or reactivation of latent infection in 
immunocompromised patients, may cause a severe illness and multiorgan dysfunctions and 
symptoms of hepatitis, enteritis, pneumonia and cerebrospinal infection (Eddleston et al., 
1997).  
Furthermore, HCMV has gained more importance because of the expansion in organ 
transplantation, immunosuppressive treatment and acquired immune deficiency syndrome 
(AIDS)(Moore & Chaisson, 1996; Singh, 2006). HCMV is also one of the most serious 
infectious diseases of infants, where 40-58%. infants with symptomatic CMV will have 
birth defects including hearing loss, vision impairment, and mental retardation (Dollard et 
al., 2007). 
1.2.1.1 Transmission and pathogenesis of cytomegalovirus: 
Seroepidemiologic studies showed that HCMV is widely distributed in human 
population with an overall seroprevalence of about 60% in persons 20 years and older and 
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increases with age. Blood screening study showed that the base rate of CMV IgG 
seroprevalence in blood donors increases with age, from 34.9% at less than 20 years of age 
to 72.4% after the age of 50 years (Munro et al., 2005).  
In the United States and Western Europe, the seroprevalence of HCMV was linked 
to the socioeconomic status of the population where rates in young women of childbearing 
age range from 40% for women of middle to upper socioeconomic status to 83% for 
women of lower socioeconomic status (Gaytant et al., 2002). In 1996, epidemiological 
studies showed that more than 17,000 cases of HCMV-induced sequelae or death occurred 
in Europe and the United States (Plotkin, 1999). For that reason, the majority of transplant 
donors and recipients will have had exposure to HCMV (Fishman & Rubin, 1998).  
Following initial infection, HCMV infectious virus is present in   body fluids such as 
saliva, tears semen, cervical secretions and urine for months to years (Dworsky et al., 1983; 
Stagno et al., 1982). Horizontal transmission of CMV infection usually occurs following 
exposure to infected body fluids which mainly occurs during sexual activity or following 
contact with infected young children (Chandler et al., 1985; Handsfield et al., 1985). 
Horizontal transmission of CMV also occurs via transfusion of whole blood (containing 
white blood cells) or transplantation of cells (Chou et al., 1987; Chou, 1987). Vertical 
transmission of HCMV occurs either transplacentally to foetus during gestation period or at 
the time of birth through contact with genital organ secretions or through breast milk 
feeding (Dworsky et al., 1983; Stagno et al., 1982). Transmission of the HCMV virus can 
be reduced via application of good hygienic practice (such as hand washing with soap and 
water following exposure to contamination), which might have sufficient effect on primary 
infection especially in women and hence might reduce congenital infection (Cannon & 
Davis, 2005).   
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Following invasion and the lytic cycle of replication, the virus remains inactive in a 
latent state in infected cells, which serve as a reservoir of infection. Chronic low-grade 
reactivation can occur at intervals throughout the infected life span of the individual. CMV 
reactivation from latency to the productive virus cycle usually occurs due to a defect in the 
body‟s cell-mediated immune system, which can be due to drug-induced 
immunosuppression (e.g. in organ transplantation) or infection by certain pathogens (e.g. 
HIV) (Adler, 1983; Rubin, 1990). 
Primary infection, reactivation of latent virus, and reinfection are possible and often 
are clinically silent. Three groups of immunocompromised hosts are susceptible to severe 
HCMV disease: (a) the immunologically immature foetus, (b) the transplant recipient as a 
result of anti-rejection treatment; and (c) AIDS patients with loss of adaptive immune 
response (Table 1.2)   (Adler, 1983; Gaytant et al., 2002; Rubin, 1990) 
1.2.1.2 HCMV infection in immunocompetent individuals: 
In healthy individuals, a primary CMV infection usually is clinically unapparent or 
subclinical and only about 10% of primary infections are symptomatic. Symptoms of 
HCMV disease are clearly observed in immunocompromised human (and in animal hosts 
with their respective CMV) after acute infection or after reactivation of latent infection 
(Stagno et al., 1986).  
The symptomatic HCMV infection result in illness similar to mononucleosis caused 
by Epstein-Barr virus infection. Studies showed that CMV is responsible for 20- 50% of 
heterophile-negative mononucleosis and it accounts for 8% of all cases of mononucleosis 
(Klemola et al., 1970). Symptoms of CMV mononucleosis include malaise, persistent 
fever, myalgia and cervical lymphadenopathy and less common pneumonia and hepatitis. 
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Whereas laboratory findings include atypical lymphocytes, mild  thrombocytopenia and 
elevated liver enzymes (Klemola et al., 1970; Pannuti et al., 1985; Stagno et al., 1986). 
CMV infection can rarely cause serious complications involving specific organ 
system and even life-threatening illness. CMV infection involving specific organ system in 
immunocompetent patients with problems similar to CMV in immunocompromised 
patients have been reported where CMV infection resulted in enteritis (Maiorana et al., 
2003), thrombocytopenia (Ichiche et al., 2003), severe anaemia (Veldhuis et al., 2004), or 
encephalitis (Phillips et al., 1977; Studahl et al., 1994) in healthy individuals. 
1.2.1.3 Congenital HCMV infection: 
HCMV infection in pregnant women, usually, occurs through exposure to 
contaminated saliva or urine via close contact with young children or through sexual 
transmission. After primary infection, which is usually subclinical in more than 90%, 
women tend to shed the virus for months to years in body fluids and excretions (Gandhi et 
al., 2010). The high prevalence of HCMV infection in population means more pregnant 
women at risk of reactivation and even though reactivation is relatively infrequent for any 
given woman on a population level the number of affected women could be substantial as 
the congenital HCMV prevalence increases with maternal seroprevalence (Kenneson & 
Cannon, 2007). Studies showed that the rate of HCMV transmission to infants born to 
mothers who acquired a primary infection during pregnancy was 32% compared to only 
1.4% of mothers with recurrent or past infection (Kenneson & Cannon, 2007; Lazzarotto et 
al., 2008).  
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Worldwide, the prevalence of congenital HCMV is 0.7% of overall births and the 
percentage of infected children with CMV-specific symptoms at birth was 12.7% and 
symptomatic children with permanent sequelae was 40-58%. Among children with 
asymptomatic or subclinical CMV, 13.5% developed permanent sequelae (Dollard et al., 
2007). 
Most of new-borns with symptomatic congenital HCMV infection will have some 
combination of defects, including, mental retardation, cerebral palsy, sensorineural hearing 
loss (SNHL), and impaired vision. The symptoms of acute congenital HCMV include 
premature birth (less than 37 months), petechiae, jaundice associated with 
hyperbilirubinemia, hepatospleenomegaly, thrombocytopenia, chorioretinitis, seizures, 
microcephaly, intracranial calcifications or fetal hydrops. In many cases, babies with 
subclinical CMV, develop permanent health problems or disabilities including hearing loss, 
visual disorder, brain disorders such as mental retardation, seizures, lack of coordination 
and epilepsy (Dollard et al., 2007). Hearing loss following congenital CMV infection was 
reported in approximately 22%–65% of symptomatic and 6%–23% of asymptomatic 
children and CMV-related SNHL may be present at birth or occur later in childhood 
(Fowler & Boppana, 2006). 
1.2.1.4 HCMV infection in sold-organ transplant recipients:  
Even though  considerable progress has been made in preventing HCMV infection 
and disease in the early stages post-transplant through the use of preventive antiviral drugs, 
it is still considered to be one of the main infectious agents causing complications in solid-
organ transplant patients and can result in death (Fishman, 2007; Hodson et al., 2005; 
Rowshani et al., 2005; Singh, 2006).   
Chapter 1: Introduction 
9 
HCMV primary infection, reactivation, or viral superinfection may develop in 
transplant recipients. Primary infection usually occurs when seronegative recipients who 
have not previously received immunologic therapy receive allografts from latently infected, 
seropositive donors (i.e., D+/R– combinations) which can result in a severe infection. Most 
of solid organ transplant develop CMV infection if they did not recive antiviral prophylaxis 
and the newly infected patients have asymptomatic viremia, although invasive disease 
develops in a subgroup of patients. During the first year after transplantation, 
seroconversion occurs in 75%  of the seronegative transplant recipients who have received 
allografts from seropositive donors and only 25% of recipients benefit from prolonged 
prophylaxis where they do not undergo seroconversion (Humar et al., 2005). 
Cytomegalovirus infection exerts its effect in transplant patients via the direct effects 
of CMV replication (invasive disease) and may also results in a variety of secondary 
immune phenomena (Fishman & Rubin, 1998; Rubin, 1989). The direct effect of CMV or 
the invasive disease generally occurs within the first year following the completion of 
prophylaxis and usually results CMV syndrome which characterised by fever and 
neutropenia. In some cases, patients may also develop lymphadenopathy, hepatitis, 
thrombocytopenia, pneumonitis, nephritis, gastrointestinal invasion (with diffuse colitis, 
gastritis, ulcers, and bleeding), pancreatitis, chorioretinitis (in late stages), or rarely 
meningoencephalitis (Fishman, 2007).  
The indirect effect of CMV infection results from the interaction of virus with the 
host immune response (Fishman, 2007). It is characterized by low rates of viral replication 
over a prolonged periods of times which are associated with an increased risk of rejection 
or graft dysfunction, accelerated atherosclerosis, opportunistic infections (including 
infections with other viruses and EBV-associated post-transplantation lymphoproliferative 
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disorder), malignancies, and post-transplant diabetes mellitus (Hodson et al., 2005; 
Rowshani et al., 2005; Rubin, 2000; Singh, 2006). Furthermore, CMV infection may results 
in vasculopathy in heart-allograft recipients and to the bronchiolitis obliterans syndrome in 
lung-allograft recipients (Fishman, 2007). 
1.2.1.5 HCMV in patients with Acquired Immunodeficiency Syndromes: 
CMV is one of the most common opportunistic diseases among the acquired 
Immune deficiency (AIDS) disease patients. It was linked to the impairment of immune 
system, resulted from low CD4
+
 T-cells count. Before the use of highly active antiretroviral 
therapy (HAART), CMV infection occurs in approximately 20-40% of adult AIDS patients 
(Gallant et al., 1992).  The frequency of clinical manifestations of CMV infection largely 
depends on the CD4+ T-cell count. CMV end-organ disease in HIV infection is usually 
observed when the CD4+ T-cell count drops below 50 cells/mm
3
 or when other signs of 
severe immunodeficiency, such as other opportunistic infections, are present (Moore & 
Chaisson, 1996). 
Studies showed that the most common CMV end organ disease was retinitis, 
esophagitis, colitis and less commonly encephalitis, peripheral neuropathy, 
polyradiculoneuritis, pneumonitis, gastritis and hepatitis (Moore & Chaisson, 1996). CMV 
retinitis in HIV-1 infection was the most frequent CMV end-organ disease where it 
represents approximately 80–90% of all CMV end-organ manifestations (Gallant et al., 
1992). Cytomegalovirus infections of the gastrointestinal tract are the second most common 
CMV end-organ manifestation where oesophagus and the colon are most commonly 
affected. Intestinal involvement might results in ulcers and in rare cases complications such 
as bleeding, rupture or perforation of intestine (Gallant et al., 1992). Neurological diseases 
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caused by CMV infection in AIDS patients include meningoencephalitis, polyradiculopathy 
and Guillian–Barré syndrome. Although involvement of the CNS in CMV-related organ 
disease inn HIV infection is a rare to occur (˂1% of CMV-related manifestations), the 
mortality of untreated cases reaches almost 100% (Gallant et al., 1992; McCutchan, 1995). 
HIV-infected patients with low CD4+ T-cell counts are at highest risk for necrotizing focal 
encephalitis and ventriculoencephalitis (Morgello et al., 1987). In HIV patients with 
advanced immunodeficiency, CMV pneumonitis mostly presents as interstitial pneumonia, 
and pathological studies might reveal inclusion bodies in the absence of other pathogens 
that are more frequently the cause of pneumonia in HIV-infected patients (Rodriguez-
Barradas et al., 1996). 
Table  1.2  Clinical manifestations of HCMV infection Britt, 2008 with modification). 
 
Population  
Diseases associated with acute 
infection 
Diseases associated with chronic 
infection 
Immunocompetent   
All ages 
Asymptomatic infection, 
mononucleosis-like illness 
Atherosclerotic vascular disease: 
inflammatory bowel disease, 
periodontal disease, rheumatologic 
disorders. 
Elderly Unknown 
Immune senescence with potential 
decrease in immune 
responsiveness. 
Immunocompromised    
Foetal and newborn 
infants (congenital 
infection) 
90% asymptomatic infection, 
10% can have hepatitis, retinitis, 
thrombocytopenia, neurologic 
disease. 
Hearing loss (5-15%), neuron 
developmental abnormalities. 
 
Allograft recipients 
Fever, decreased bone marrow 
function, hepatitis, pneumonitis, 
bacterial super-infection.  
Vascular disease (transplant 
vasculopathy), interstitial 
tubulosclerosis (renal allograft), 
loss of bile ducts (liver allografts); 
chronic graft rejection and graft 
loss.  
Immunodeficiency 
syndrome 
(inherited and acquired) 
Gastrointestinal disease 
(oesophagitis, colitis) retinitis, 
encephalitis. 
Colitis (in inherited 
immunodeficiency) 
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1.3 Genetics of human cytomegalovirus: 
HCMV has the largest genome (235 kb) among the eight human herpesvirus species (Dolan 
et al., 2004). The virion‟s linear double stranded DNA has single unpaired bases at both 
ends to facilitate its circulation upon release from the capsid in infected cells (Tamashiro & 
Spector, 1986). The HCMV genome, like Chimpanzee cytomegalovirus (CCMV), consists 
of two covalently linked long and short segments designated as L and S respectively; this 
type of genome organization is called class E. Each segment presents a central unique 
region (UL and US) flanked with terminal inverted repeats at both ends (TRL, IRL, TRS, IRS) 
giving the HCMV genome the general organization TRL - UL -IRL -IRS - US - TRS (Cha et 
al., 1996; Chee et al., 1990; Davison et al., 2003; Tamashiro & Spector, 1986). The TRL 
region consist of an and b sequences, the IRL -IRS region consist of b’ɑ’n c’ sequences and 
the TRS region consist of c and an sequences where prime designations indicate sequences 
in reverse alignment to sequences without primes. The resultant repeat organization of the 
genome is thus ɑn b -UL-b’ɑ’n c’ -US– cɑn. The two domains of HCMV and CCMV can 
generate genomic isomers as a result of the ability of the terminal an sequences to 
recombine with the internal ɑ’n sequence (Figure 1.2) (Cha et al., 1996; Chee et al., 1990; 
Davison et al., 2003; Tamashiro & Spector, 1986). 
The ɑ segments of the HCMV genome consist of multiple head-to-tail repeats in the 
ɑ sequences that can vary in number among strains and different passages of the same strain 
(Dollard et al., 2007; Tamashiro & Spector, 1986). These include two cis-acting packaging 
elements, pac1 and pac2 (Kemble & Mocarski, 1989),  conserved among all herpes virus 
genomes that direct cleavage and packaging of viral genomes. Since MCMV lacks ɑ 
sequences, pac-1 and pac-2 are located at opposite ends of the genome outside the terminal 
repeats (McVoy et al., 2000). 
Chapter 1: Introduction 
13 
The complete genome sequence of HCMV (strain AD169varUK) showed that it is 
230,283 bp in length and was predicted to contain 189 open reading frames (ORFs), of 
which fourteen are duplicated in an inverted repeat (Chee et al., 1990). A later study 
revised the  annotation of the AD169 HCMV ORFs and  revealed that it contains only 145 
genes (Davison et al., 2003). Furthermore, another laboratory HCMV strain (Towne) was 
sequenced and found to encode at least 162 unique ORFs and that most of them have 
homologues in the AD169 strain (Dunn et al., 2003). 
HCMV AD169, clinically isolated from the adenoids of a child, was passaged under 
certain conditions in fibroblasts to attenuate the virulence of the virus so that it could be 
used as a live attenuated vaccine (Elek & Stern, 1974; Rowe et al., 1956). After 25 years of 
serial passage of the virus in different laboratories, its genome was plasmid cloned for 
sequencing (Chee et al., 1990). Studies comparing the prototype laboratory strain AD169 
with other laboratory and wild type isolates of human cytomegalovirus showed that AD169, 
as a result of these many passages, contains frame-shift mutations in three genes (Akter et 
al., 2003), and 19 genes at the right end of the UL region (UL133–UL150) have been lost 
by a reversed duplication of the a sequence close to the left genome end, leading to a 
substantial expansion of IRL (Cha et al., 1996; Prichard et al., 2001). In other stocks of the 
virus it was found that a replacement of a nucleotide results in inactivation of the UL36 
gene (Skaletskaya et al., 2001) while deletions of UL42 and UL43 genes have been 
observed in other virus stocks (Dargan et al., 1997). 
Comparative studies with other low passaged human cytomegalovirus strains 
showed that three of five isolates passaged in cell culture have defects in certain genes, 
UL128, UL130 and UL131 (Akter et al., 2003), leading to the conclusion that there is no 
laboratory strain with an intact genome. In another comparative study, four clinical isolates 
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(Toledo, FIX, PH and TR) have been passaged to a limited extent in the laboratory were 
cloned into Bacterial Artificial Chromosomes (BACs). Sequences comparison of these four 
isolates to the AD169 and Towne strains, showed that as many as 252 ORFs with the 
potential to encode proteins were preserved in the four clinical isolates (Murphy et al., 
2003b). A fifth clinical isolate, Merlin, has been sequenced after only three serial passages 
in fibroblasts and is thought to represent the wild-type complement of 165 ORFs, 
comprising no noticeable mutations apart from a single
 
base substitution that results in 
truncation of the UL128 gene (Dolan et al., 2004). 
Using the whole-genome shotgun technique, the complete DNA sequence of the 
laboratory passaged Smith strain of MCMV was determined from virion DNA. The 
sequence showed that the genome consists of 230,278 bp, arranged as a single unique 
sequence (Figure  1.2) with short (31-bp) terminal direct repeats and several short internal 
repeats; its G/C content was 58.7%. MCMV was suggested to encode more than 170 ORFs. 
It was also demonstrated that there is considerable similarity between MCMV and the 
HCMV strain AD169 genome sequence, especially in the central part of the genome that 
encodes 78 ORFs. In addition, both murine and human cytomegalovirus genomes showed 
similarity in distribution of G+C content (Rawlinson et al., 1996). In contrast to the 
observed variations in the HCMV sequence (among different strains and passages), the 
genomic sequence of the K181 (Perth) laboratory strain of MCMV, as well as three low 
passaged wild derived strains, showed that there was no major genetic rearrangements in 
MCMV. Furthermore, the study showed that the genome size was extremely conserved 
between these MCMV strains with no major deletions or insertions (Smith et al., 2008). In 
addition, there are only a few changes in 2 isolates of the K181 strain, K181 (Perth) and 
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K181 (Birmingham), passaged in 2 different laboratories over many years (Smith et al., 
2008; Timoshenko et al., 2009a). 
 
Figure  1.2: A diagram representation showing (A) The HCMV genome  (class E) composed 
of the unique long sequence (UL), flanked by terminal repeat long (TRL) and inverted repeat 
long (IRL), and unique short sequence (US), flanked by terminal repeat short (TRS) and 
inverted repeat short (IRS). (B) The MCMV genome (class F) contains a single unique 
sequence with two terminal direct repeats (DR) (Mocarski et al., 2006; Rawlinson et al., 
1996) Not to scale. 
1.4 The Virus Replication Cycle, Entry: 
HCMV has a wide cellular tropism where many cell types such as endothelial cells, 
epithelial cells, smooth muscle cells, fibroblasts, monocytes/macrophages, stromal cells, 
neutrophils, hepatocytes, and neuronal cells, as well as tissue culture cell lines of these 
cells, are susceptible to HCMV infection. Like other herpesviruses, HCMV  entry into cells 
occurs at neutral pH through direct fusion of the viral envelope with the plasma membrane 
(Compton et al., 1992). In contrast, in certain cell lines, including retinal pigmented 
epithelial and endothelial cells, HCMV enters the cell through receptor-mediated 
endocytosis that requires low-pH  (Bodaghi et al., 1999; Ryckman et al., 2006).  
 
a a 
(A) 
b 
TRL                                    UL                                  IRL                IRS           US         TRS 
ɑn b’ c c’ ɑn ɑ’n 
DR DR 
(B) 
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Analysis of the proteins from purified HCMV AD169 virion preparations revealed 
that the envelope contain at least 19 virally encoded glycoproteins (Varnum et al., 2004).  
The laboratory HCMV AD169 strain suffer from deletions and rearrangements as a result 
of the long-term passage in tissue culture (Akter et al., 2003; Cha et al., 1996; Davison et 
al., 2003). Analysis of other minimally passaged HCMV strains predicted that  HCMV 
encodes more than fifty proteins that are potentially glycosylated or contain predicted 
transmembrane domains (Davison et al., 2003; Dolan et al., 2004; Murphy et al., 2003a). 
Among them, only 5 glycoproteins, glycoprotein B (gB UL55), gM/gN (UL100/UL73) and 
gH/gL (UL75/UL115), participate in virus replication in vitro (Compton et al., 1993; Kari 
& Gehrz, 1992; Kari & Gehrz, 1993; Navarro et al., 1993). The major envelope 
glycoprotein, glycoprotein M, together with gN interacts to form the gM/gN complex that 
serves as an attachment protein. Glycoprotein B is considered to be an attachment and 
fusion protein (Compton et al., 1993; Kari & Gehrz, 1992). Another complex formed from 
gH, gL and gO (gH/gL/gO), where gH acts as a fusion protein and gL is an essential 
chaperone for gH localization.  The gH/gL/gO complex enhances HCMV entry (Huber & 
Compton, 1997; 1998; Keay & Baldwin, 1991). A recent study has showed that interaction 
of UL131A-UL128 gene products with gH and gL resulting in a gH/gL/UL131A-UL128 
complex,  is involved in HCMV entry into endothelial/epithelial cells (Dolan et al., 2004; 
Revello & Gerna, 2010; Wang & Shenk, 2005). 
The capability of HCMV to infect a broad range of cells indicated the existence of a 
great number of cellular receptors and/or ubiquitous molecules on the cell surface that 
allow the recognition and entrance of HCMV into the host.  The current attachment model 
for HCMV starts with the initial tethering step to heparan sulphate proteoglycans (HSPGs) 
on the cell surface with viral glycoprotein complexes, the heterodimer gM/gN and the gB 
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homodimer of the virion (Compton et al., 1993; Kari et al., 1992; Kari & Gehrz, 1992). A 
recent study showed that gB is essential for virus entry and cell-to-cell spread of the virus 
but it is not essential in attachment to the cell surface where gB-null virions (∆ UL55) were 
able to attach to the cell surface like wild-type virions (Isaacson & Compton, 2009).This 
suggests that the initial binding is mediated by the gM/gN complex to the HSPGs followed 
by a high affinity binding to one or more cellular receptors. Epidermal growth factor 
receptors (EGFR) are thought to play a role in attachment and entry of HCMV as it has 
been shown that attachment and entry of HCMV was repressed following EGFR-
neutralizing antibody treatment of fibroblasts (Wang et al., 2005). On the other hand, many 
cell types permissive to HCMV, such as haematopoietic cells, do not express EGFR 
suggesting that it is not a universal receptor for HCMV. Furthermore, EGFR-neutralizing 
antibody treatment of epithelial and endothelial cells followed by challenge with a clinical 
isolate did not affect viral gene expression (Isaacson & Compton, 2009). Interaction of gB 
and gH with integrins may result in several downstream signalling processes essential for 
entry of virus and/or gene expression (Feire et al., 2004; Wang et al., 2005). Finally, 
interaction of gB and gH in the gH/gL/gO complex with cellular integrins facilitates the 
fusion of the viral envelope and the cellular membrane enabling the deposition of viral 
components (virion and tegument proteins) into the cytoplasm (Figure 1.3) (Feire et al., 
2004; Wang et al., 2005). 
Following fusion of the viral envelope to the cell membrane and entry of the virus 
into the cytoplasm of a permissive cell, capsids containing DNA are transported to the 
nucleus utilizing the intact cell microtubules (MTs) (Sinzger et al., 2000). Indirect 
immunofluorescence showed that the tightly associated tegument protein pp150 is detected 
associated with MTs. Nocodazole, a drug causing microtubule de-polymerization, results in 
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detection of pp150 diffusely distributed in the cytoplasm inhibiting virions from delivering 
HCMV DNA to the nucleus and consequently  block the immediate early gene expression 
(Ogawa-Goto et al., 2003).  
 
Figure  1.3: Model for entry of HCMV: Initial attachment of HCMV in tethering 
interactions to heparan sulphate proteoglycans (HSPGs) through gM/gN and/or gB 
glycoproteins. A stable docking step allows gB to cooperate with the epidermal growth 
factor receptor (EGFR) in HCMV permissive cell types and other receptors in 
haematopoietic cells. HCMV envelope glycoproteins and cellular integrins allow receptor 
clustering that leads to fusion facilitating internalization of virion components (Isaacson et 
al., 2008).  
Tegument proteins pUL47 and pUL48 interact to form the UL47/UL48 complex, 
which can play a role in the transport of capsids to the cell nucleus and possibly injecting 
the viral DNA into the nucleus through the nuclear pore complex. Mutants lacking the 
UL47 protein were found to be less infectious than the wild-type virus and have a delayed 
onset of IE gene expression  (Bechtel & Shenk, 2002).  
gB
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1.4.1 Regulation of gene transcription: 
Transcription of CMV genes takes place in the nucleus of infected cells by host cell 
RNA-polymerase II and the associated basal transcription machinery (Fortunato & Spector, 
1999). Like other herpesviruses genes expressions of cytomegaloviruses is conventionally 
divided into three kinetic phases which are defined on the time of expression and sensitivity 
to inhibition by protein or viral DNA synthesis inhibitors. The phases are: immediate-early 
(IE or ), early (E or ), and late (L or ) (Fortunato & Spector, 1999). 
1.4.1.1 IE gene regulation: 
In the nucleus, the viral genome is associated with cellular histones and packaged 
into chromatin. Some viral genomes are deposited adjacent to a subnuclear structures 
named PML (promyelocytic leukaemia) nuclear bodies (PML-NBs) [or the nuclear domain 
10 (ND10)] (Ishov et al., 1999). The PML-NBs are dynamic intranuclear domains bound to 
the nucleare matrix and contain cellular proteins that involved in many cellular functions, 
including regulation of gene transcription and expression, chromatin structure, DNA repair, 
mitosis and apoptosis (Bernardi & Pandolfi, 2003; Dellaire & Bazett-Jones, 2004). Studies 
showed that PML-NBs are preferred sites for  HCMV genome expression where only the 
HCMV genome found next to PML-NBs can be transcribed (Ishov et al., 1999). Many 
cellular proteins are associated with the PML-NBs including Sp100, hDaxx, SUMO-1, p53, 
STAT1, STAT2, ATRX (Choi et al., 2006; Ishov et al., 2004; Lukashchuk et al., 2008; 
Negorev & Maul, 2001; Paulus et al., 2006; Tang et al., 2004).  
PML-bodies are now recognized to act as an intrinsic barrier to virus infection where 
RNAi knockdown of either PML or hDaxx significantly enhanced HCMV or HSV-1 
replication (Everett, 2006; Lukashchuk et al., 2008; Tavalai et al., 2006; 2008). The HCMV 
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tegument protein pp71 counteracts the repression effect hDaxx where it  promotes 
proteosome-mediated degradation of hDaxx, and thereby relieves hDaxx-mediated 
repression of IE gene expression (Saffert & Kalejta, 2006). 
The human major IE protein (IE1-72) found to be associates with metaphase 
chromatin, recruiting both PML and STAT2. hDaxx, STAT1 and IE2-86K did not re-locate 
to metaphase chromatin; the fate of hDaxx is particularly important as this protein 
contributes to an intrinsic barrier to HCMV infection. While IE1-72K participates in a 
complex with chromatin, PML, STAT2 and Sp100, IE1-72K releases hDaxx from ND10 
1.4.1.2 Immediate-early gene expression 
IE gene expression occurs immediately after entry and does not rely on the 
expression of any viral genes or viral protein synthesis. Proteins produced during the IE 
phase are important for initial viral gene expression by acting as autostimulators of their 
own gene expression or as transactivators and stimulators for other viral genes, especially 
those of the next phase.  
Following virus entry and delivery of viral DNA to the cell nucleus, the tegument 
phosphoprotein pp71 encoded by UL82 is released from the virion and transported to the 
nucleus, where it is detected at ND10 (Hofmann et al., 2002). pp71 can activate expression 
from the major immediate-early promoter (MIEP) and other promoters and may stimulate 
the expression from the entire HCMV genome. Studies showed that UL82 null HCMV is 
severely impaired for IE expression especially at low multiplicity of infection (MOI) which 
proves the importance of pp71 in initiation of IE gene expression (Bresnahan & Shenk, 
2000). It has been shown that pp71 binds to Daxx at ND-10 sites resulting in the reversal of 
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Daxx-mediated repression of viral IE gene expression (Cantrell & Bresnahan, 2005; 
Lukashchuk et al., 2008).  
IE genes include the major IE genes (MIE) UL123 (IE1) and UL122 (IE2) and 
auxiliary genes (UL 36-UL38, UL115-UL119, IRS1/TRS1 and US3) (Colberg-Poley, 1996; 
Stenberg, 1996). Expression of IE genes is controlled by a composite DNA component, the 
MIEP, which is composed of multiple sequence motifs that function as binding sites for 
cellular proteins that regulate transcription (such as NF-κB/Rel, Sp1, NF-1, AP-1, 
CREB/ATF, YY1 and others), both positively and negatively. The MIEP is located down-
stream from a strong enhancer located between ~-50 and -550 bp from the transcription 
start site. The MIE region produces a primary transcript that undergoes differential splicing 
to produce numerous mRNA species. The predominant gene products are IE72 (IE1) and 
IE86 (IE2). They share exons 2 and 3 but vary in having either exon 4 (IE1) or exon 5 (IE2) 
(Akrigg et al., 1985; Kerry et al., 1995; Stenberg et al., 1985). 
Both IE72 and IE86 act as transactivators of viral and cellular proteins. IE72 also 
associates with PML-NB and disrupts their integrity (Dimitropoulou et al., 2010; 
Wilkinson et al., 1998). IE86 also acts as an autorepressor, by binding to the cis repression 
sequence located between the TATA box and the transcription initiation sites of these genes 
that results in repressing transcription of the IE1 and IE2 genes (Liu et al., 1991). IE86 
plays a role in down-regulation of cellular cytokine and chemokine promoters, controlling 
cell cycle progression and is necessary for viral DNA synthesis (Taylor & Bresnahan, 2005; 
2006b). In addition to that, IE86 plays a main role in regulation of the transition from the IE 
to the E and L phases of HCMV expression (Kalejta & Shenk, 2002; Lu & Shenk, 1996).  
In addition to the importance of the MIE products in viral replication, auxiliary IE genes 
play roles in regulation (IRS1/TRS1), inhibition of apoptosis (UL36 and UL37) and 
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modulation of host cell MHC class I expression (US3(Child et al., 2004; Colberg-Poley et 
al., 1992; Colberg-Poley, 1996; Jones & Sun, 1997).  
In MCMV, genes ie1 (m123) and ie3 (M122) are the functional homologues of the 
HCMV IE1 and IE2 genes, respectively (Cardin et al., 1995). IE2, the third MCMV IE 
gene product, has no functional and or sequence homology with the HCMV genome. 
MCMV ie1 protein is involved in overcoming the cellular repression of viral DNA 
replication. Temporal analysis of MCMV ie1 protein shown its initial segregation into 
ND10 by binding to PML and/or Daxx and IE1-dependent recruitment of the transcriptional 
repressor histone deacetylase-2 (HDAC-2) to this site (Tang & Maul, 2003). IE1 binding to 
HDAC-2 resulted in decrease in deacetylation activity. Studies shown that HDAC 
inhibition by trichostatin-A resulted in an increased viral protein synthesis, formation of 
prereplication compartments and increase in the progeny virus yields (Tang & Maul, 2003). 
The IE3 protein encoded by MCMV gene ie3 is the important transactivator of viral E-
phase genes (Angulo et al., 2000). 
1.4.1.3 Early gene expression 
Early gene expression is dependent on the availability of IE gene products. Genes of 
this phase are not a target of viral DNA replication inhibitors, i.e. they do not require viral 
DNA synthesis to be expressed. Depending on the time of expression, the early phase may 
be divided into two subclasses, β1 (or true early) and β2 (early-late), where expression of 
β1 genes for HCMV occurs within 4-8 hrs post infection, while β2 gene expression occurs 
8-24 hr post infection. E genes encode mostly non-structural proteins, including viral DNA 
replication factors [UL112-UL113, DNA polymerase (UL54), polymerase accessory 
protein (UL44), single-stranded DNA binding protein (UL57), helicase-primase complex 
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(UL70, UL105, UL102)] (McMahon & Anders, 2002; Pari, 2008b; Pari & Anders, 1993; 
Park et al., 2006), repair enzymes, proteins involved in immunomodulation (US2 and 
US11) and an early glycoprotein (UL4/gp48) involved in transcriptional and 
posttranscriptional controls (Jones & Sun, 1997; Wiertz et al., 1996). A family of 
phosphoproteins (encoded by the UL112-UL113 genes) regulates expression of core DNA 
replication genes and organizes viral DNA replication compartments within the nucleus 
(Park et al., 2006). 
1.4.1.4 Late gene expression 
In a similar way late or  phase genes are subdivided into two subsets designated as  
1 (partial-late) genes, where their expression is amplified by the onset of viral DNA 
synthesis, and 2 (true-late) genes, whose expression is  inhibited by DNA synthesis 
inhibitors  and thus are  totally dependent on viral DNA synthesis. The L genes encode 
structural proteins and are involved in the assembly and morphogenesis of virions 
(Chambers et al., 1999; Fortunato & Spector, 1999). 
1.4.2 DNA replication  
Replication of the HCMV genome, virus particle assembly and packaging occurs in 
the nucleus of the infected cell. Within 4 hours post infection (hpi) the linear HCMV 
genome circularizes in the nucleus of permissive cells. DNA replication starts about 16 hpi 
and reaches its optimal level at 60-80 hpi yielding thousands of viral genome copies per 
infected cell. DNA synthesis requires six herpesvirus-conserved replication-fork proteins; 
the DNA polymerase (UL54), polymerase accessory protein that prevents dissociation of 
the polymerase from the template (UL44), a single-stranded DNA-binding protein (UL57) 
that prevents  the re-annealing of DNA strands following unwinding by the three subunit 
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proteins of the helicase-primase complex (UL70, UL102, UL105) (McMahon & Anders, 
2002). For optimal replication, the products of additional HCMV genes (UL36-38, UL84, 
UL112/UL113, UL114, IRS1/TRS1, and IE1/2) are also required. UL84 is a 
multifunctional protein that plays an important role in the regulation of transcriptional 
activation mediated by IE2, and is required for the initiation of oriLyt-dependent DNA 
synthesis (Pari, 2008a). UL114 protein has a functional uracil DNA glycosylase activity 
required for efficient viral DNA replication in post-mitotic cells (McMahon & Anders, 
2002; Pari et al., 1993; 2008b; Pari & Anders, 1993; Park et al., 2006) 
Replication occurs via a bidirectional theta (θ) mechanism from a single origin 
(oriLyt) of replication, that initiates binding of the replication complex and the rolling cycle 
mechanism is followed by viral DNA synthesis in the form of large head-to-tail genome 
concatemers (Masse et al., 1992; Zhu et al., 1998b). In HSV-1 the alkaline nuclease, the 
product of the UL12 gene (HCMV homologue UL98), is required for resolving these 
recombination intermediates prior to DNA packaging (Goldstein & Weller, 1998). 
1.4.3 Virion assembly, maturation, egress: 
HCMV capsid formation and packaging of viral DNA takes place in the nucleus of 
infected cells. Nucleocapsid particles accumulate in the nucleus as nuclear inclusion bodies 
giving infected cells the typical cytopathic effect (owl‟s eye). Synthesis of nucleocapsid 
proteins occurs in the cytoplasm where the major capsid protein (MCP pUL86) interacts 
with the scaffolding assembling protein precursor (pAP, pUL80.5) and proteinase precursor 
(pPR, pUL80a) to form putative complexes. The putative complexes are then translocated 
into the nucleus. Similar to MCP, a homodimer of the minor capsid protein (mCP, pUL85) 
interacts with mCP-binding protein (mCBP, pUL46) to produce triplexes that then 
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translocate into the nucleus. The HCMV portal protein (pUL104) may also interact with 
pAP in a way similar to that in HSV or it may be translocated to the nucleus via its own 
nuclear localization sequence (Figure 1.4) (Dittmer et al., 2005). 
In the nucleus, procapsids form from the interaction of pAP, pPR and MCP 
complexes with the triplexes (mCP and mCBP). The procapsids are less angular than 
mature capsids and they contain the scaffolding protein but not viral DNA (Newcomb et 
al., 1999; Newcomb et al., 2000). The immature capsids undergo proteolytic maturation to 
form some B-capsids that have an angular appearance and contain cleaved scaffolding 
proteins but not viral DNA. These B-capsids are ready for packaging viral DNA and further 
mature into infectious C capsids. Correct timing of scaffolding protein cleavage and release 
is very critical where delayed scaffold protein processing might result in sealing of capsid 
pores prior to release of cleaved protein and B capsid formation. While quick or premature 
scaffolding processing and release of scaffolding protein before recruiting DNA to the 
procapsid results in empty A capsids (Gibson, 2008; Yu et al., 2005).  
Newly synthesized genomes mature through an inversion process and cleavage to 
unit lengths at specific cleavage/packaging signals pac1 and pac2 located within the a 
sequence of the genomic DNA (Landolfo et al., 2003). This cleavage utilizes ATP and is 
believed to proceed concurrently with insertion of the DNA into the preformed B capsids 
leading to the formation of mature C capsids (Adamo et al., 2004). This may not be true in 
all cases as the MCMV temperature-sensitive mutant (tsm), tsm5, makes few capsids at 
40
o
C and these lacked DNA. DNA synthesis was significantly reduced in tsm5-infected 
cells at 40
o
C but DNA cleavage occurred with close to wild type (wt) efficiency (Sweet et 
al., 2007).Two gene products (pUL56 and pUL89) form the herpesvirus DNA 
cleavage/packaging enzyme (terminase). pUL56 (96 kDa) is the larger subunit of the 
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terminase and has similar properties to the bacteriophage terminase large subunit 
(Scheffczik et al., 2002). It mediates specific binding to the  pac sequences on the 
concatemers, has an ATPase activity essential for providing energy for translocation of unit 
length DNA into the procapsids, and binds to capsid (Hwang & Bogner, 2002). pUL89 (77 
kDa), the smaller subunit, has nuclease activity essential for cleavage of viral DNA 
(Scheffczik et al., 2002).  In HCMV, retention of viral DNA in the capsid is stabilized by 
the HSV pUL25 homologue, the portal capping protein pUL77 (71 kDa), as mutant viruses 
with defective pUL77 were not able to stably package DNA (Ogasawara et al., 2001; 
Sheaffer et al., 2001). It is unlikely that this is the reason for the lack of DNA  packaging in 
tsm5-infected cells as no mutations were identified in M77, the MCMV homologue of 
UL77 (Timoshenko et al., 2009a). 
After packaging of a unit length linear DNA genome, mature nucleocapsids 
accumulate in the nucleus and gather at the inner nuclear membrane prior to budding into 
the perinuclear space cisternae thus acquiring a primary envelope (Buser et al., 2007). Two 
conserved viral proteins (in HCMV, pUL50 and pUL53) are required for this process where 
they form a complex at the nuclear envelope, referred to as the nuclear egress complex 
(Sanchez & Spector, 2002).  
HCMV-encoded protein kinase UL97 and cellular protein kinase C (PKC) are 
involved in phosphorylation of many kinds of nuclear lamins. The activity of pUL97 in 
lamin-phosphorylation is associated with a recognition of nuclear lamin A/C and targeted 
by Cdc2/cyclin-dependent kinase 1 (Hamirally et al., 2009). Studies showed that in 
transiently transfected or HCMV-infected cells, either pUL97 or PKC has the ability to 
induce distinct punctate lamin-depleted areas at the periphery of the nuclear envelope 
(Milbradt et al., 2010). In MCMV, it was shown that the homologue of pUL34 (MCMV 
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M50) interacts with cellular protein kinase C for phosphorylation and dissolution of the 
nuclear lamina that facilitates viral budding (Muranyi et al., 2002). In addition, M53 viruses 
with mutations in their M53 ORF, the homologue of UL53, were affected in their nuclear 
distribution and steady-state levels of the nuclear egress complex and export of viral 
capsids was completely blocked (Popa et al., 2010). 
The enveloped nucleocapsids then fuse with the outer nuclear membrane or the 
endoplasmic reticulum (ER) membrane resulting in release of de-enveloped nucleocapsids 
into the cytoplasm. The nucleocapsids acquire tegument proteins in the nuclear and the 
cytoplasmic phases (Eickmann et al., 2006).  In the cytoplasm, HCMV nucleocapsids 
acquire their tegument, and tegumented capsids obtain their final envelope by budding into 
vesicles of the trans-Golgi network. Enveloped capsids leave the cell to the extracellular 
environment via an exocytotic-like pathway (Eickmann et al., 2006; Mettenleiter, 2002). 
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Figure  1.4: Capsid assembly model showing: (1) Major capsid protein (MCP, pUL85, 
narrow trapezoids) interaction with assembly protein precursor (pAP, pUL80.5, lines with 
red filled circles) and protease precursor (pPR, pUL80a, lines with black filled circles) 
results in the formation of putative complexes. (2). Minor capsid protein (mCP, pUL85, 35 
kDa, light ovals) interaction with mCP-binding protein (mCBP, pUL46, 33 kDa, dark 
ovals) results in formation of heterotrimers, called triplexes (3). Translocation of the two 
formed oligomers into the nucleus (4). Interaction of the oligomers in the nucleus to form 
the procapsid (Pro), incorporating the portal-protein complex (pUL104) (5). Maturation 
process of the procapsid into the B capsid involves proteolytic cleavage and elimination of 
the scaffolding proteins (pPR and pAP) from the capsid (6), before or during the process of 
DNA packaging (7). Viral DNA packaging and formation of C capsids completes virion 
assembly. (From Gibson, 2008, with modification). 
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1.5 Activation of Immune Responses: 
1.5.1 Activation of innate immunity:  
Upon HCMV binding to permissive cell membrane receptors, HCMV glycoproteins 
result in triggering and activation of signal transduction pathways leading to the activation 
of cellular transcription factors including nuclear factor κB (NF-κB), Sp1 and interferon 
regulatory factor 3 (IRF3) (Boehme et al., 2004; Boehme et al., 2006; Navarro et al., 1993; 
Yurochko et al., 1997). Studies have revealed that HCMV entry can affect hundreds of 
cellular genes, the most strongly induced are genes involved in antiviral responses which 
belong to the inflammatory cytokine (IC) family and the interferon-stimulated gene (ISG) 
family including RANTES, interleukin-6 (IL-6), IL-8, ISG-45-kDa protein, and IRF-7 
(Browne et al., 2001; Simmen et al., 2001; Zhu et al., 1997; Zhu et al., 1998a). Stimulation 
of these two classes of molecules, which play a role in innate immunity, is triggered by 
structural viral components and does not require virus replication or cellular protein 
synthesis (Browne et al., 2001; Zhu et al., 1997). The innate immune response play a role 
in limiting viral replication and spread of virus to adjacent cells and organs. It also recruits 
immune cells to the infection site, and initiates and modulates adaptive immune responses 
by T and B lymphocytes to clear the infection.  
In HCMV infected fibroblasts and monocytes, NF-κB is activated as shown by its 
nuclear translocation and increased DNA-binding activity. Activation of NF-κB results in 
stimulation of inflammatory cytokines such as IL-1, IL-6, IL-8, IL-12 , IL-18 and TNF , 
essential for recruitments of phagocytic leukocytes to the site of infection (Laroux, 2004). 
Studies show that induction of transcription of NF-κB can be inhibited by pre-treatment of 
HCMV with neutralizing antibodies to gH and gB. Furthermore, the use of purified soluble 
Chapter 1: Introduction 
30 
gH and anti-idiotypic antibody to imitate gH resulted in stimulation of NF-κB and Sp1 
(Yurochko et al., 1997). 
NF-κB can also be activated by many other stimuli including ligand stimulation of 
the Toll-like receptors (TLRs) that can identify microbial pathogens on the bases of 
structural motifs designated as pathogen-associated molecular patterns (PAMPs) that vary 
from those found in the host cell (Takeda & Akira, 2003).  PAMPs can be detected in a 
wide range of viruses, bacteria, and fungi and initiate immune responses HCMV‟s gB and 
gH can activate TLR2, which in turn can induce IC synthesis via TLR2-dependent 
activation of NF-κB (Boehme et al., 2006; Compton et al., 2003). 
Interactions of gBs with members of the TLR family can also result in activation of 
interferon (IFN)-α/β responses. Activation of TLRs results in the activation of the key 
regulatory transcriptional factor, IRF3, which is the primary factor in controlling  HCMV-
induced interferon signalling  (DeFilippis et al., 2006; Navarro et al., 1998). Signal 
transduction results in virus-mediated phosphorylation of IRF3 followed by 
homodimerization and translocation of IRF3 to the nucleus. IRF3 then interacts with the co-
activators, CREB binding protein (CBP), and p300, to form a complex that results in 
transcription of IFN-β and a subset of ISGs (Simmen et al., 2001). In an autocrine and 
paracrine manner, the secreted IFN-β acts through the IFN-α/β receptor resulting in the 
activation of the janus kinases (JAK) and the signal transducers and activators of 
transcription (STAT) signal transduction cascade to induce expression of the full 
complement of ISGs. This event leads to the expression of the IFN-α genes. Like IFN-β, 
IFN-α, can stimulate ISG expression, which results in a rapid amplification of the interferon 
response that can lead to an antiviral state (Stark et al., 1998). 
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Apart from TLR4, which resides on the surface of cells, the majority of TLRs are 
intracellular (Akira et al., 2006). They are involved in IFN activation where they are able to 
recognize viral ligands early through uncoating or degradation processes and require low 
pH for their activation (Ahmad-Nejad et al., 2002). TLR9 can recognize HSV-1, HSV2 and 
MCMV via their CpG-rich genome (2004b; Krug et al., 2004a; Lund et al., 2003). In 
MCMV, TRL3, which is activated by dsRNA formed during bidirectional transcription of 
the viral genome during the late stage of infection, stimulates IFN production (Tabeta et al., 
2004).  
One of the innate immunity first lines of defence is natural killer (NK) cells that play 
an essential role in primary CMV infection before the onset of the adaptive immune 
response. A case study reported that humans having a defect in NK cells are more 
susceptible to HCMV infection (Biron et al., 1989). The same was demonstrated 
experimentally in mice, where newborn mice and mice with genetic deficiencies in NK 
cells are more susceptible to MCMV and transfer of NK cells protects against MCMV 
infection (Bukowski et al., 1985). Some mouse strains are comparatively resistant to 
MCMV such as C57BL/6, while other mouse strains including BALB/c and DBA/2 are 
more susceptible to MCMV infection (Scalzo et al., 1990). It was attributed to the Cmv1 
genetic locus on chromosome 6 encoding Ly49 NK cell inhibitory and activation receptors 
that recognize MHC class I-like molecules on target cell surface (Scalzo et al., 1995). m157 
gene product of the MCMV is a ligand for both the activating receptor Ly49H and 
inhibitory receptor Ly49I (Smith et al., 2002). Therefore, the effects of m157 gene 
expression rely on Ly49 receptor expressed on NK cell surface, which varies in mouse 
strains. In C57BL-6 mice, Ly49H is expressed on about 50% of NK cell. The MCMV-
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encoded protein m157 on the surface of infected cells can be recognized by the Ly49H 
receptor resulting in a MCMV-specific NK response (Arase et al., 2002).   
1.5.1.1 Humoral immune response: 
In general, antiviral antibodies exhibit their protective activity either by direct 
neutralization or indirectly by complement activation and activation of antibody-dependent 
cellular cytotoxicity (Hangartner et al., 2006). Therefore, antibodies against CMV may 
suppress the spread of virus either by direct virus neutralization or by cytotoxicity of cells 
carrying the virus. Experimental and clinical studies showed that humoral immunity to 
CMV plays an essential role in prevention of virus dissemination following reactivation 
from latency or reinfection (Jonjic et al., 1994; Polic et al., 1998). While viral envelope 
glycoproteins and tegument components are able to induce antibody responses, the 
envelope glycoprotein gB is considered to be the major target for neutralising antibodies 
(Landolfo et al., 2003). A recent study showed that the antibody response to infected  
endothelial cells is potent,  happens very early and is directed mainly to combinations of 
two or three gene products of the UL131A, UL130, UL128 genes. Whereas the antibody 
response elicited by infected fibroblasts appears late and relatively weak in potency and the 
neutralizing antibodies are  directed against gH and gB (Revello & Gerna, 2010). 
Despite the fact that maternal seropositivity against HCMV prior to pregnancy does 
not necessarily provide full protection against prenatal infection and disease (Boppana & 
Britt, 1995), congenital transmission of HCMV infection to the foetus is at a lower rate than 
in women with primary infections (Fowler et al., 1992). Studies also showed that CMV-
specific hyperimmune globulin treatment of pregnant women was effective in prevention of 
congenital CMV infection (Nigro et al., 2005). In adult AIDS and transplant patients, the 
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presence of antiviral antibodies has been associated with slower progression of HCMV 
disease  (Boppana & Britt, 1995; Schoppel et al., 1998).  
Mice immunized against MCMV gB were protected from a lethal dose challenge of 
MCMV (Rapp et al., 1992) and pregnant guinea pigs immunised with GPCMV gB showed 
reduced infection and disease of their foetuses (Schleiss et al., 2004). In the mouse, 
memory B-cell transfer offers long-term protection from lethal viral challenge in immune 
deficient animals (T-cell- and B-cell-deficient RAG-1(-/-) mice). Furthermore, transfer of 
memory B-cells was also effective in protection from an already on-going viral infection, 
which demonstrated the therapeutic importance of virus-specific memory B-cells while T-
cells were not involved in this process (Klenovsek et al., 2007).  
1.5.1.2 Cellular immune response: 
The evidence for the importance of cell-mediated immunity was provided by the 
observations that HCMV infection is most severe in patients with dramatically impaired 
cell-mediated immunity, such as bone marrow transplant recipients and patients with AIDS. 
The severity of CMV disease parallels the degree of T cell impairment in AIDS patients 
(Tamarit et al., 2004). Early studies in the murine model showed that cytotoxic T 
lymphocytes (CTL) immunity played a central role in control of active viral disease and in 
reactivation from latency. Mice were protected from lethal challenge after adoptive transfer 
of virus specific CD8
+
 cytotoxic T cell clones (specific for both structural and non-
structural proteins) and this protection was independent of CD4
+
 T helper cells (Reddehase 
et al., 2004). In contrast, in humans adoptive transfer of protective CD8
+
 cytotoxic T cells 
(with specificity for HCMV tegument proteins) was dependent on the presence of CD4
+
 T 
helper cells (Hakki et al., 2003). HCMV gene products of UL123 (IE-1), UL122 (IE-2), and 
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UL83 (pp65) are the most immunodominant antigens to which HCMV-specific CD8
+
 T 
cells respond (Crough & Khanna, 2009).  
In mice, depletion of CD4
+
 T-lymphocytes resulted in an increase in the incidence of 
recurrent infection (Polic et al., 1998). In humans, children with a persistent and selective 
deficiency of HCMV-specific CD4
+
 T-cell immunity, when infected with HCMV usually 
have prolonged viral urinary and salivary virus shedding (Tu et al., 2004). Furthermore, in 
lung transplant recipients, decreased levels of HCMV-specific CD4
+
 T-cells resulted in 
higher susceptibility to infectious complications (Sester et al., 2005). 
Studies showed that a large proportion of CD8
+
 and CD4
+
 T-cells is dedicated to the 
anti-HCMV response. Therefore, up to 10% of CD8
+ 
and 9.1 % of CD4
+ 
circulating T-
lymphocytes are HCMV-specific in healthy virus-carriers. In donors of different ages, the 
magnitude of the cellular immune response to virus pathogens such as influenza virus and 
varicella-zoster virus decreases with progressing age (Asanuma et al., 2000; Deng et al., 
2004). In contrast, the cellular immune response (HCMV-specific CD8
+ 
T-lymphocytes) to 
HCMV may expand up to 40% in elderly individuals, causing what is called immune 
inflation (Khan et al., 2002; Khan et al., 2004a; Ouyang et al., 2003). The HCMV-specific 
CD4
+
 cell response is also increased in the elderly (Pourgheysari et al., 2007). 
Consequently, this immune inflation and expansion of HCMV-specific CD8
+
 T cells, in 
which a large fraction of the entire CD8
+
 T cell subset may be directed to one single viral 
epitope, results in shrinking of the T cell stock available for responses to other antigens. 
Therefore, it may contribute to immune senescence, which characterize by a reduction in 
levels of naive cells, the accumulation of clonally expanded CD28 memory T cells, a 
decline in immune responsiveness and increases in the incidence of infectious disease in 
elderly people (Ouyang et al., 2003; Pawelec et al., 2005). 
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1.6 Cytomegalovirus Immune Evasion: 
CMV is considered to be a classic example of viral immune evasion because of its 
distinctive and varied immune-modulatory strategies that enable the virus to avoid 
elimination by the immune system. Many CMV gene products are capable of modulating 
both innate and adaptive immune responses at different stages of the virus replication cycle. 
Antiviral interferon-induced genes were downregulated during cytomegalovirus infection. 
The HCMV IE86 protein inhibits IFN-β, TNF- and other NF-κB- dependent cytokine and 
chemokine gene expression by blocking the binding of the transcription factor NF-κB to 
their promoters (Taylor & Bresnahan, 2005; 2006a; 2006b). Binding of the IE1 (IE72)  
protein to STAT1 (signal transducer and activator of transcription 2) and STAT2 resulting 
in formation of a physical complex in the nuclei if infected cells and in vitro, prevents 
association of STAT1, STAT2 and IFN regulatory factor 9 (IRF9) with the promoters of 
IFN-responsive genes in vivo (Paulus et al., 2006). 
In HCMV infection, an effective immune response is critically dependent upon the 
recognition of infected cells by CTL via presented antigenic peptides in complex with 
major histocompatibility complex (MHC) class I molecules (Groothuis et al., 2005). One of 
the most important HCMV evasion mechanisms relies on the inhibition of MHC class I-
restricted antigen presentation. Many HCMV genes are involved in inhibition of antigen 
presentation to cytolytic T cells by retention of MHC class I heavy chain/-2 microglobulin 
complexes in the endoplasmic reticulum (US3) (Ahn et al., 1996) or even destruction of 
MHC class I heavy chain molecules by interference with antigen presentation and by 
phosphorylation of a potentially important CTL target, the 72-kd immediate-early protein, 
preventing antigen processing (Gilbert et al., 1996; Jones & Sun, 1997; Lehner et al., 1997; 
Wiertz et al., 1996). In addition, US2 genes are involved in degradation of MHC class II 
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proteins, which consequently prevent the presentation of antigen and the host CD4
+
 T 
lymphocyte response to CMV (Tomazin et al., 1999). The most surprising is the ability of 
CMV to activate or inhibit activatory and inhibitory receptors found on NK cells, NKT 
cells and T cells as well as auxiliary cells of the immune system. Passage of MCMV in 
mice lacking adaptive immunity but carrying the Cmv1r allele, which encodes the Ly49H 
activation receptor on NK cells, resulted in emergence of viruses carrying mutations in 
m157 ORF (encoding the only known ligand for Ly49H). These mutants were characterized 
by an increased virulence in naive Cmv1r mice which was attributed to the presence of 
single-amino-acid substitutions or premature stop codons (French et al., 2004). Whereas the 
adjacent ORFs (m156 and m158) show no mutations which suggests that mutation 
emergence (and may be reversion) of mutation in both HCMV and MCMV occurs under 
selective pressure (Cheng et al., 2010). 
CMV‟s other immune evasion mechanisms are binding and sequestration of -
chemokines (US27, UL28, UL33) (Bodaghi et al., 1998), competition with the TNF 
receptor superfamily through its viral homologue (UL144) (Benedict et al., 1999), 
interference with apoptosis (Zhu et al., 1995), down-regulation of MHC class II expression 
on the surface of macrophages (Fish et al., 1996)  and protection of infected cells from 
complement-mediated lysis (Spiller et al., 1996). 
1.6.1 Interference with the induction of interferons: 
Interferons (IFNs) are a large family of multifunctional secreted proteins that play a 
role in the antiviral response, cell growth and regulation, and immune activation. IFNs 
induce the expression of many IFN-stimulated genes (ISGs) whose products limit the 
growth and replication of virus at different stages (Samuel, 2001). The IFNs are classified 
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into two types. Members of type I IFNs, IFN- and IFN- are synthesized in response to 
viral infection. IFN- is mainly produced by leukocytes, while IFN- is produced by many 
cell types but especially by fibroblasts. IFN- represents the type II IFNs that are produced 
in response to virus infection, and synthesized by activated T lymphocytes and NK cells 
upon recognition of infected cells (Goodbourn et al., 2000).  The biological activity of IFNs 
is a result of binding of IFN- and IFN- to their receptors on the cell surface. The result 
of this signalling is the activation or upregulation of transcription of IFN-dependent ISGs. 
Binding of IFN-/ to type I IFN receptors (IFNAR1 and IFNAR2) results in 
phosphorylation of tyrosine kinase 2 (Tyk2) and Janus kinase 1(JAK1) that then 
phosphorylate STAT2 and STAT1 respectively. Phosphorylation of STAT1 and STAT2 
results in formation of STAT1/STAT2 heterodimers. The STAT1/STAT2 heterodimers 
then disassociate from the receptor and are translocated to the nucleus where they bind 
IRF9 to form the ISGF3 complex (IFN-stimulated gene factor 3) that accumulates in the 
nucleus. Binding of ISGF3 to IFN-stimulated response elements (ISREs) contained in the 
promoters of many ISGs leads to upregulation of their transcription (Shuai & Liu, 2003) 
(Figure 1.5). Most IFN-/ inducible genes have a conserved upstream regulatory sequence 
AGTTTCNNTTCNC/T, while IFN- inducible genes have a unique constituent named as 
the gamma activation sequence (GAS) that contains the consensus sequence 
TTC/ANNNG/TAA. 
The biological outcome of the activation of the IFN signalling pathways is the 
activation of the transcription of the target genes. Products of these genes have antiviral 
activity. Protein kinase R (PKR) and the 2‟-5‟ oligoadenylate synthetases are two well-
known IFN-inducible components that exert the antiviral response. Other factors, such as 
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molecules involved in the cell cycle or in cell death may also be induced. These factors 
limit viral replication. Usually these IFN-inducible enzymes are in an inactive form that can 
be activated when the cells are virally infected. It is thought that viral co-factors such as 
dsRNA can play a role in the IFN-inducible enzyme activation (Jacobs & Langland, 1996). 
For viruses to replicate efficiently in vivo, they need to develop means to limit the 
production, or block the actions, of interferons (Goodbourn et al., 2000). Cytomegalovirus 
is an example of viruses that have developed means to interfere with IFN-signalling 
pathways at several points. In HCMV infected cells, JAK1 levels are decreased compared 
to non-infected cells resulting in inhibition of IFN--stimulated signal transduction. In 
HCMV-Towne infected fibroblasts, levels of phosphorylated IFNAR-1, STAT2, STAT1α, 
and Tyk2 are all reduced, with JAK1 overall levels very impaired. Studies showed that 
JAK1 mRNA levels were constant during HCMV infection and JAK1 degradation is 
mediated by the proteasome. Consequently, loss of JAK1-mediated signal transduction, 
results in inhibition of both ISGF3-dependent and –independent gene expression. 
Furthermore, in HCMV infection the level of p48 is also reduced which will further disrupt 
the formation of the ISGF3 complex  (Miller et al., 1998; 1999). STAT protein function is 
another target of HCMV at different levels. During HCMV infection of fibroblasts, the 
STAT2 level is reduced due to proteasomal degradation (Le et al., 2008).  
The HCMV immediate-early 86 kDa protein (IE2-86) inhibits transcription of IFN 
by blocking NF-κB DNA-binding and NF-κB-induced gene expression (Taylor & 
Bresnahan, 2006a). In addition, HCMV has been shown to interfere with JAK/STAT signal 
transduction. HCMV IE 72 kDa protein interacts with STAT2 and hinders association of 
the activated ISGF3 complex with ISRE elements in the nucleus, thus preventing 
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upregulation of IFN-/ gene stimulation  (Paulus et al., 2006). Rather than interfering 
with STAT2 protein levels, phosphorylation, or formation of the ISGF3 complex, IE72 acts 
after nuclear translocation of ISGF3. The acidic domain close to the carboxy-terminal end 
of IE72 is responsible for the interaction with STAT2, and studies have showed that this 
domain is essential for efficient viral growth especially in IFN-treated cells (Huh et al., 
2008).  
Beside inhibition of IFN--stimulated genes, which is linked to JAK1 degradation, 
HCMV interferes with IFN- signalling by impairing STAT1 phosphorylation. Upon IFN- 
signalling, levels of phosphorylated STAT1 in HCMV-infected cells are reduced as is 
activation of GAS-mediated transcription (Baron & Davignon, 2008).  
The M27 protein product of MCMV binds to and degrades STAT2, and 
subsequently blocks both IFN type I and II signalling (Zimmermann et al., 2005). In 
contrast, UL27, the HCMV homologue of M27, is not involved in the induction of STAT2 
downregulation and is not required for viral growth in cell culture, suggesting that the 
HCMV mechanisms for STAT2 interference are UL27-independent (Le et al., 2008). 
Furthermore, HCMV was shown to interfere with ISG function, where HCMV 
proteins pTRS1 and pIRS1 block the 2‟-5‟oligoadenylate synthetase mediated eIF2 
phosphorylation and decrease RNA degradation by RNase L (Child et al., 2004; 
Zimmermann et al., 2005). 
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Figure  1.5: IFN-/ and IFN- signalling pathways. IFNs bind to their respective receptors 
on cell surfaces and this results in activation of receptor-associated tyrosine kinase and 
consequent phosphorylation of STAT1 and STAT2. STAT1/STAT2 heterodimers are then 
translocated into the nucleus where they bind to IRF9 to form the ISGF3 complex that then 
binds to the ISREs contained in the promoters of many ISGs leading to their activation. 
HMCV (red) and MCMV (green) counteract these pathways at multiples steps as detailed 
in the text (Marshall & Geballe, 2009). 
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1.7 Control of apoptosis: 
Another means of controlling viral infection of cells is programmed cell death 
(PCD) or apoptosis, which is a genetically regulated cell suicide process. A result of 
apoptosis is the elimination of damaged and infected cells that subsequently limits viral 
replication (Meier et al., 2000). Cell morphology is changed during apoptosis, which 
involves cell volume reduction, chromatin condensation, membrane blebbing, and lastly the 
fragmentation of the cell into vesicles called apoptotic bodies  (Kroemer et al., 2009). In 
contrast, cell morphology in necrosis is characterized by enlargement of cytoplasmic 
organelles, moderate chromatin condensation, loss of membrane integrity, and escape of 
cellular components into the intercellular space (Festjens et al., 2006; Kroemer et al., 
2009). In contrast to necrosis, apoptosis does not lead to the release of intracellular 
enzymes (Festjens et al., 2006). 
Apoptosis occurs in response to either extrinsic or intrinsic signals. Extrinsic signals, 
which may be induced by immune cells, result from activation of the tumour necrosis factor 
(TNF) superfamily receptor leading to the recruitment of Fas-associated death domain 
(FADD) which in turn results in recruitment and subsequently autocatalytic activation of 
initiator caspase-8. Intrinsic signals, which result from DNA damage, ER stress, or other 
stresses that alter mitochondria membrane permeability, lead to the release of cytochrome C 
and other death factors with subsequent activation of initiator caspase-9. The intrinsic and 
extrinsic pathways ultimately merge with activation of the downstream executioner 
caspase-3 that targets specific proteins (Barnhart et al., 2003).  
As a result of extrinsic or intrinsic pro-death signalling, apoptosis occurs as 
signalling cascades in which caspases (a group of aspartate-specific cysteine proteases) are 
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essential signal transducers and their activation is regulated by the Bcl-2 family. Based on 
the difference in Bcl-2 homology (BH) domains, Bcl-2 family proteins are divided into 
anti- and pro-apoptotic proteins. The anti-apoptotic Bcl-2 family proteins [which include 
BCL-2, BCL-w, BCL-xL (BCL-2 related gene, long isoform), A1 and MCL-1 (Myeloid 
cell leukaemia 1)] contain BH domains 1–4 and are usually integrated within the outer 
mitochondrial membrane.  In the apoptotic pathway, these proteins directly bind and inhibit 
the pro-apoptotic BCL-2 proteins and prevent caspase activation resulting in  preservation 
of mitochondrion integrity (Chipuk & Green, 2008; Youle & Strasser, 2008). Members of 
the pro-apoptotic family proteins are functionally divided into two classes; the effector 
molecules and the BH3-only proteins. The effector molecules [BAK (BCL-2 antagonist 
killer 1) and BAX (BCL-2 associated x protein)], contain BH1-3 domains and create the 
proteolipid pore in the outer mitochondrial membrane that increases its permeability and 
results in the release of cytochrome C (Leber et al., 2007).  The BH3-only proteins [which 
include BAD (BCL-2 antagonist of cell death), BID (BCL-2 interacting domain death 
agonist), BIK (BCL-2 interacting killer), BIM (BCL-2 interacting mediator of cell death), 
BMF (BCL-2 modifying factor), bNIP3 (BCL-2/adenovirus E1B 19-KD protein-interacting 
protein 3), HRK (Harakiri), Noxa and PUMA (p53-upregulated modulator of apoptosis)] 
act in different cellular stress pathways and, by protein–protein interactions with other 
BCL-2 family members (i.e. anti-apoptotic BCL-2 proteins and/or the effector molecules), 
signal that a cellular stress has occurred. The collective signalling within the BCL-2 family 
determine whether or not to permeabilize the mitochondrial outer membrane and 
consequently the fate of the affected cell (Chipuk & Green, 2008). Many cellular organelles 
such as the nucleus, Golgi apparatus, endoplasmic reticulum, and the lysosome have 
sensors that can promote death through apoptosis (Ferri & Kroemer, 2001).  
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Cytomegalovirus has many genes that encode pro-survival or anti-apoptotic factors 
that function by different mechanisms at different levels to prevent apoptosis and ensure 
that the cell remains alive and metabolically active (Figure 1.6). The HCMV UL36 protein 
blocks the extrinsic apoptotic pathway by binding to procaspase-8 [called viral inhibitor of 
caspase-8-induced apoptosis (vICA)] and a recent study has shown that UL36 can also 
block a caspase-independent cell death pathway. Although, viral replication of vICA-
deficient viruses (HCMV and MCMV) was not affected, the ability of the virus to replicate 
in macrophages was massively impaired and apoptosis was induced (McCormick et al., 
2010).  In MCMV, deletion of M36, the homologue of UL36, resulted in attenuation of 
virus growth in macrophages in-vitro and replication of the mutant was severely impaired 
in mice and produced more apoptotic cells (Cicin-Sain et al., 2008; Menard et al., 2003). 
The UL37×1 gene encodes a viral mitochondria-localized inhibitor of apoptosis (vMIA) 
that is analogous to cellular Bcl2 proteins and is effective against many extrinsic and 
intrinsic stimuli (Goldmacher, 2005).  Furthermore, the HCMV UL38 protein suppresses 
apoptosis, and prevents premature death of host cells to promote efficient virus replication 
(Terhune et al., 2007). 
In MCMV beside M36, there are products of at least three genes, M45, m38.5, and 
m41.1, that are essential in prevention of infection-induced cell death in macrophages 
(Brune et al., 2001; Cam et al., 2010; Manzur et al., 2009). The MCMV M45 protein plays 
a role in preventing premature death of endothelial cells during murine cytomegalovirus 
infection by inhibiting receptor-interacting protein (RIP) activation and RIP1/RIP3-
dependent programmed necrosis (Upton et al., 2008). The M38.5 ORF encodes a Bax-
specific vMIA and protects virally infected leukocytes from apoptosis, whereas the m41.1 
ORF encodes a small mitochondrion-localized protein that functions as a viral inhibitor of 
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Bak oligomerization (vIBO). It prevents Bak-mediated cytochrome C release and Bak-
dependent induction of apoptosis (Cam et al., 2010; Manzur et al., 2009).  
 
 
 
 
 
 
Figure  1.6: HCMV and MCMV cell death inhibitors, and their cellular target proteins 
(Brune, 2011) 
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1.8 Latency and reactivation: 
CMVs, like other herpesviruses are able to establish a lifelong persistent infection 
where the viral genome is maintained in the host cells with limited gene expression and no 
infectious virions are produced. The viral genome is able to reactivate from latency, which 
occurs routinely in healthy virus carriers and is usually contained by the healthy immune 
system. In immunosuppressed patients, HCMV reactivation from latency is very serious 
and can result in morbidity and mortality (Rubin, 1990). Clinical studies revealed that using 
leukocyte depleted blood drastically reduced HCMV transmission from seropositive blood 
donor to healthy recipients, and leads to the suggestion that latent HCMV can be carried in 
peripheral blood leukocytes of healthy carriers (de Graan-Hentzen et al., 1989). Using 
highly sensitive techniques like PCR has unveiled that peripheral blood monocytes are sites 
for virus latency (Taylor-Wiedeman et al., 1991). Later studies showed that progenitor 
CD34
+
 cells in bone marrow carry the virus (Mendelson et al., 1996). CD34
+
 cells are 
progenitors of many cell lineages such as T and B lymphocytes, polymorphonuclear 
phagocytes and monocytes. Use of reverse transcription PCR (RT-PCR) showed that 
among these cell types, only CD34
+
 progenitor cells and their derivatives, monocytes, are 
the naturally latent cells which are not associated with lytic infection (Mendelson et al., 
1996; Taylor-Wiedeman et al., 1994). In vitro studies showed that induction of 
differentiation of naturally latent peripheral blood monocytes (PBMs) using granulocyte 
colony stimulating factor and hydrocortisone resulted in reactivation of viral IE and E gene 
expression (Taylor-Wiedeman et al., 1994). Later studies showed that monocytes are true 
latent cells and non-permissive for lytic infection; differentiation of CD34
+
 cells and 
monocytes to mature dendritic cells reactivated viral lytic gene expression and resulted in 
infectious virus production (Reeves et al., 2005).  
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Recent studies suggest that HCMV latency results from an intrinsic cellular anti-
viral response in which viral gene expression of the incoming genome is silenced via 
chromatinisation. Histone proteins are recruited to the MIEP of the HCMV genome and are 
then subjected to post-translational modifications to form a repressive chromatin structure 
preventing transcriptional activity (Reeves & Sinclair, 2010; Sinclair, 2010). Inflammatory 
and/or differentiation signals encourage chromatin remodelling of the MIEP to a 
transcriptionally active state that results in reactivation of viral lytic IE gene expression and 
production of infectious virus (Reeves & Sinclair, 2010; Sinclair, 2010). 
1.9 Antiviral treatment of CMV 
For the treatment of HCMV disease, five drugs, ganciclovir/valganciclovir, 
cidofovir, foscarnet and fomivirsen have been approved so far (Schreiber et al., 2009). 
Apart from fomivirsen, all of the above mentioned drugs share the same target molecule, 
the viral DNA polymerase. For prevention and control of CMV disease in 
immunocompromised patients, the use of these drugs has been shown to reduce or 
eliminate viraemia. 
In solid organ transplant recipients, ganciclovir (GCV) is the first-line treatment for 
HCMV infection and disease (Razonable & Emery, 2004). GCV is a purine analogue which 
is phosphorylated first by a viral protein (protein kinase encoded by the HCMV UL97 
gene) and then cellular enzymes to ganciclovir triphosphate, the chemically active form 
(Sullivan et al., 1992). During DNA synthesis, which is catalysed by the viral DNA 
polymerase (encoded by the UL54 gene), the ganciclovir triphosphate competes with 
deoxyguanosine triphosphate (dGTP) and consequently terminates viral DNA elongation 
(Gilbert & Boivin, 2005). Prolonged HCMV antiviral therapy of AIDS patients using GCV 
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lead to the emergence of resistance to ganciclovir due to UL97 and UL54 gene mutations 
(Foulongne et al., 2004). The side effects of GCV treatment include haematological 
disorders and it can result in reproductive toxicity (Markham & Faulds, 1994). 
Valganciclovir is the L-valyl ester of ganciclovir.  Following oral administration, it is 
rapidly metabolised to the active form (GCV) in the intestinal wall and liver. Initially 
valganciclovir was approved for treatment of HCMV retinitis in AIDS patients then later 
for HCMV prophylactic treatment of solid organ transplant recipients (Cvetkovic & 
Wellington, 2005). 
Cidofovir is an acyclic nucleoside phosphonate that has a broad antiviral spectrum 
with high potency against herpesviruses as well as other DNA viruses. After administration, 
host kinases convert cidofovir to the active diphosphoryl form which is a competitive 
inhibitor of the viral DNA polymerase and results in termination of elongation of viral 
DNA during DNA synthesis (De Clercq E., 2001). In 1996, cidofovir was approved for 
treatment of HCMV retinitis in AIDS patients. The side effect of the use of cidofovir is 
renal toxicity and neutropenia (Ho et al., 2000). 
Foscarnet sodium (trisodium salt of phosphormophonic acid) is an inhibitor of DNA 
polymerase (UL54) activity via binding to the pyrophosphate binding site and blocking 
cleavage of pyrophosphate from the terminal nucleoside triphosphate added to the 
extending DNA chain (De Clercq E., 2001). Resistance to foscarnet emerged due to UL54 
mutations. Foscarnet‟s major side effects are the renal impairment that can lead to cardiac 
and neurological disorders due to electrolyte imbalance.  
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Fomivirsen is a 21 nucleotide anti-sense RNA targeted against the HCMV IE2 
mRNA. It was approved for clinical use in 1998 as a second-line therapy for local treatment 
of HCMV retinitis administered by intraocular injection (De Clercq E., 2001). 
1.10  Vaccination against HCMV 
All HCMV antiviral drugs available for clinical use suffer from complications with 
prolonged use, including drug toxicity, carcinogenicity and teratogenicity as well as drug 
resistant strain emergence. Because of limitations of use and side effects of HCMV 
antiviral drugs, many HCMV vaccines have been evaluated in clinical studies. A variety of 
approaches has been used to produce HCMV vaccines, which can be divided into two 
major groups: live attenuated vaccines and subunit vaccines that target specific proteins 
(Adler et al., 1995; Pass, 2009; Pass et al., 2009). 
1.10.1 Live attenuated HCMV vaccine 
For more than 40 years, scientists and researchers have attempted to develop a live 
attenuated HCMV vaccine.  The laboratory adapted HCMV AD169 strain was the first 
HCMV vaccine tested in humans followed by another laboratory-adapted clinical isolate, 
the HCMV Towne strain. Live attenuated vaccines were able to stimulate both humoral and 
cellular immune responses.  HCMV Towne vaccination of renal transplant recipients failed 
to prevent HCMV infection after transplantation, but it protected against the development 
of HCMV disease (Plotkin et al., 1994). Also, the Towne vaccine failed to protect 
seronegative mothers from acquiring HCMV infection from their HCMV-infected children, 
but the vaccine protected seropositive women against acquiring a new strain of HCMV 
from their children (Adler et al., 1995). The relative failure of the Towne vaccine was 
attributed to inadequate antigen-specific IFN- responses by CD4+ and CD8+ cells post 
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vaccination. Co-administration of recombinant IL-12 with the Towne vaccine improved its 
immunogenicity, revealed by the elevated levels of both HCMV-specific humoral and 
cellular responses after vaccination (Jacobson et al., 2006).  
Another strategy to improve the immunogenicity of the Towne vaccine was to 
generate a series of genetic recombinant viruses from the genomes of the Towne strain and 
the un-attenuated Toledo strain.  Four chimaeric vaccine viruses were produced and tested 
in a double-blinded, placebo-controlled study. Post vaccination assessment revealed that the 
vaccines were well tolerated and no virus shedding was detected by viral and PCR analyses 
of blood and body fluids (Heineman et al., 2006). 
1.10.2 HCMV subunit vaccines 
In this approach, one or combinations of immunogenic viral proteins are used as a 
subunit vaccine to protect against HCMV infection. The envelope glycoprotein gB, pp65 
and IE1 vaccines are in clinical or preclinical trials. A recombinant gB molecule expressed 
in Chinese hamster ovary cell culture was used as a subunit vaccine combined with MF59 
adjuvant was shown to be safe, immunogenic, and produced high levels of gB-specific 
antibodies and total virus-neutralising activity in several clinical trials. This vaccine trial 
showed that the gB vaccine had the potential to reduce the incidence of cases of maternal 
and congenital HCMV infection (Pass, 2009; Pass et al., 2009).  
In another approach the extracellular domain of gB was covalently linked to 
multiple Human leukocyte antigen (HLA) class I and class II-restricted T- cell epitopes 
from multiple HCMV antigens as a contiguous polypeptide in a replication deficient 
adenoviral vector Ad5/F35. Immunisation using this vaccine produced strong gB- specific 
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neutralizing antibody and a wide range of HCMV- specific pluripotent CD8
+
 and CD4
+
 
cells (Zhong & Khanna, 2009).   
Similar strategies were used for generation of pp65 and IE1-based vaccines. A 
combination of three immunodominant viral proteins [Soluble (s) UL55 (surface 
glycoprotein), UL83 (tegument protein) and UL123/e4 (nuclear protein)] were also used as 
a subunit vaccine (Wang et al., 2006).  
Other vaccine strategies include DNA immunisation with viral glycoproteins (gN, 
gM, gH, gO, gL), non-structural proteins [DNA polymerase (UL54) or helicase (UL105)] 
(Morello et al., 2007) or structural, early/late proteins (pp28, pp50, US2, US3, US6 and 
UL18) and using dense bodies and peptide vaccines. Bacterial artificial chromosome 
(BAC) cloned CMV viral genomes allowed the generation of genetically modified viruses 
which have been shown to induce protective immunity in mouse and guinea pig models 
(Redwood et al., 2005).   
1.10.3 Murine Cytomegalovirus: 
Studies of the pathogenesis of human cytomegalovirus are limited because of its 
restricted host specificity and the fact that there are no suitable animal models for studying 
HCMV infection in vivo for growth and disease characteristics. Studies of HCMV have 
therefore been limited to tissue culture cells of human origin. Thus, murine 
cytomegalovirus in the mouse, as well other rodent cytomegaloviruses in their respective 
hosts, have been used as models for studying pathogenesis, tissue tropism, persistent 
infection, and latency (Abenes et al., 2001). The high similarity of HCMV and MCMV in 
genome organization, temporal regulation of gene expression, and amino acid sequence of 
the predicted protein products of many genes makes the latter an ideal model (Rawlinson et 
Chapter 1: Introduction 
51 
al., 1996).  Therefore, understanding of the biology of MCMV and the function of its genes 
is a key to understanding the pathogenesis of HCMV.  
Infection of mice with MCMV is similar to HCMV infection where there are three 
stages in MCMV infection. Acute infection of central visceral organs is rapidly controlled 
but is followed by persistent infection of the salivary gland for several weeks. Lastly, it 
enters the latent phase for the life of the host (Lu et al., 2006). In the immunocompromised 
or immunologically immature mouse, MCMV can result in severe infections whereas in 
immunocompetent mice it can be re-activated from latency by immunosuppression, which 
results in similar clinical syndromes (Sweet, 1999). Furthermore, MCMV has been widely 
used for experimental vaccine development (Morley et al., 2002) and used as a model for 
CMV antiviral resistance studies (Scott et al., 2005). 
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1.11 Mutagenesis: 
To understand the role of virus genes in pathogenesis and replication many 
researchers have used the mutagenesis approach in which the effect of gene mutation on 
virus phenotype is studied (Abenes et al., 2001).  Reliable and rapid mutagenesis methods 
are required for analysing CMV gene functions during the disease course in vivo. CMV 
replicates slowly and since mutagenesis approaches depend on rare recombination events in 
eukaryotic cells, many mutagenesis approaches are considered to be difficult, laborious, 
and time-consuming (Kemble et al., 1996). Chemical mutagenesis was used in herpesvirus 
studies more than thirty years ago for the generation of temperature-sensitive mutants  
resulting from random point mutations, insertions or deletions. Despite the large number of 
mutants generated by this technique (from a single treatment), identification of the 
mutation(s) responsible for an observed phenotype was difficult (Sweet et al., 2007). 
Creation of mutated virus with mutations in specific (targeted) genes, followed by 
studying their phenotype in tissue culture and in animal models has greatly improved our 
understanding of CMV pathogenesis. This approach has helped in mapping the genome of 
herpesvirus in relation to specific functions, such as the genes concerned in replication, 
tropism, virulence, and other biological phenomena such as viral immune evasion.  
Generation of herpesvirus mutants was first reported using site-directed homologous 
recombination and transposon-mediated insertional mutagenesis. Transposon mutant 
libraries helped to classify all known genes of HCMV with regards to their impact on the 
in-vitro growth of virus (Yu et al., 2003). Other approaches have used overlapping cosmid 
DNA fragments to generate mutants of HCMV and other herpesviruses (Kemble et al., 
1996). The main advantage of this approach is that only recombinant virus is produced 
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obviating selection against non-recombinant wild type virus. Nevertheless, it remains that 
the produced mutant is the product of many recombination events in eukaryotic cells that 
are not easy to control. Confirmation of correct reconstitution of the viral genome can be 
achieved after growth and isolation of the generated mutant virus (Ruzsics & Koszinowski, 
2008). 
1.11.1 BAC Technology: 
A recent advance in molecular microbiology allowed the cloning of foreign DNA 
larger than 300 kbp in size, in a fertility factor (F-factor) replicon based bacterial artificial 
chromosome (BAC) that can maintain the cloned DNA with an incredible sequence 
stability if propagated in suitable strains of E.coli such as DH10B and its derivatives 
(Shizuya et al., 1992). Since then most herpesvirus (including HCMV and MCMV) 
genomes have been cloned as BACs (Messerle et al., 1997; Redwood et al., 2005). 
The CMV BAC is generated using a recombinant plasmid containing the BAC 
cassette flanked by viral DNA sequences homologous to the target insertion site in the viral 
genome that is transfected (or electroporated) into eukaryotic cells previously infected (~2 
hrs) with virus. Homologous recombination (HR) between the BAC cassette and virus 
DNA results in insertion of the BAC vector (~8 kbp) into the CMV genome (Redwood et 
al., 2005). Since herpesviruses can tolerate only up to ~5 kbp of extra DNA in their 
genomes, insertion of the BAC vector requires deletion of part of the herpesvirus genome 
but this can be repaired later (Messerle et al., 1997; Redwood et al., 2005). The BAC vector 
contains gpt (guanosine phosphoribosyl transferase) and gfp (green fluorescent protein) 
gene, which serve as selection and screening markers respectively. In the presence of 
mycophenolic acid and xanthine in the medium, the gpt gene allows the selection of 
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recombinant viruses containing the BAC. While mycophenolic acid blocks the synthesis of 
purine by cells, replication of recombinant BAC-containing viruses is supported by the E. 
coli gpt enzyme that is able to utilize xanthine to synthesize and provide purine. In the 
infected cell, the linear, double-stranded DNA genome of herpesviruses circularises during 
replication, this circular viral DNA can be isolated and transferred to a suitable E. coli 
strain by DNA transformation. Once the BAC is transferred to bacteria, it can be repaired 
and the segment lost during insertion of the BAC can be reintroduced into the genome; this 
results in flanking of the BAC cassette by repeat sequences. Transfection of the virus BAC 
into permissive eukaryotic cells allows homologous recombination between the repeat 
sequences, which leads to reconstitution of viral progeny and excision of the BAC cassette 
from the herpesvirus genome (Adler et al., 2003; Wagner et al., 1999).  
Use of the CMV-BAC containing the whole sequence of the wild-type virus in E. 
coli facilitates the manipulation and introduction of any kind of mutation (including 
deletions, insertions, and point mutations) into the genome in a manner independent of the 
biological properties of the mutant virus and the recombinant genome can be characterized 
and controlled prior to reconstitution of viral progeny. Mutated virus progeny are then 
generated after transfection of permissive cells that support virus production with the 
MCMV BAC plasmid. The BAC-based mutagenesis approach allows detailed studies of 
viral gene functions both in vitro and in vivo because it provides a powerful and handy 
approach to generate viral mutants (Wagner et al., 1999). 
1.11.2 BAC targeted mutagenesis by Red-mediated recombination:  
Homologous recombination is important for many cellular processes, such as 
maintenance of genomic integrity, appropriate segregation of chromosomes in meiosis, and 
the rescue of stalled replication forks. It provides a means for repair of DNA double-
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stranded breaks, which occur during DNA replication, or DNA damage caused by external 
factors such as irradiation (Muyrers et al., 2000). 
Researchers have utilized homologous recombination as an insertional mutagenesis 
technique for disruption and deletion of CMV genes (Spaete & Mocarski, 1987). In 
eukaryotic cells, the frequency of homologous recombination is low, and to some extent, 
this reduces the effectiveness of this approach in eukaryotic cells. Also, unwanted deletions 
or the creation of undesired recombinant viruses has been detected (Spaete & Mocarski, 
1987; Vieira et al., 1994). Even though selection procedures have been used to develop the 
original technique, generation of CMV mutants remains a laborious, time-consuming, and 
often unsuccessful task (Messerle et al., 1997).  
Homologous recombination in prokaryotic cells presents another way to manipulate 
DNA, and many approaches have been used in E. coli including recombination between 
independent replicons, for example, between a plasmid with a conditional replication origin 
and the E. coli genome, or a BAC (Yang et al., 1997).  
Recombination-mediated genetic engineering (recombineering) using the three  
Red-encoded genes, allowed the introduction of mutations into the cloned BAC genome. 
The use of this powerful recombination reaction has encouraged the development of the 
BAC-based mutagenesis approach for studying viral gene functions in tissue culture and in 
laboratory animal models (Brune et al., 2001). The  Red-encoded genes; exo, bet, and 
gam can mediate recombination of 30-50 nucleotide homologous regions therefore 
allowing insertion of a linear DNA fragment carrying the desired mutation at any site of the 
BAC plasmid (Ruzsics & Koszinowski, 2008). Exo (redα) encodes a 5‟-3‟exonuclease that 
produces 3‟overhangs from introduced double stranded DNA targeting cassettes (dsDNA). 
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Bet (redβ), is a pairing protein that binds to the 3‟overhangs and facilitates its annealing and 
homologous recombination with complementary DNA present on the BAC (Figure 1.7). At 
the same time, gam (the inhibitor of E. coli RecBCD exonuclease) protects the linear DNA-
targeting cassette from degradation by RecBCD.  Red (or the corresponding RecE and 
RecT genes of the prophage Rac) can be expressed from a multicopy plasmid via an 
inducible promoter (such as pKD46 where RecA/T are expressed under the control of L-
arabinose) (Muyrers et al., 2000).  
An alternative method has been used recently (as in E. coli SW102) in which exo, 
bet and gam are expressed from a stably integrated defective  prophage, and controlled by 
the strong phage promoter pL, under strict control of the temperature-sensitive repressor, 
cI857 (Lee et al., 2001; Yu et al., 2000a). In this system, when the bacteria are grown at 
32ºC,  exo, bet and gam are not expressed, but they are rapidly induced to very high levels 
when the incubation temperature is shifted to 42ºC  for as little as 15 min with a very 
efficient homologous recombination (Warming et al., 2005).  
In the first step of this technique, a linear DNA fragment comprising a selectable 
marker (such as an antibiotic resistance marker or using galK positive/negative selection) 
flanked by an homologous sequence of the target site in the BAC, is introduced into the 
BAC. In the second step, a linear DNA fragment containing the desired mutation replaces 
the selection marker (Figure 2.4). Suitable permissive cells are then transfected with the 
viral BAC to yield the recombinant virus containing the desired mutation (Muyrers et al., 
2000).  
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Figure  1.7: Mechanism of Red/ET recombination. During the process of BAC replication, 
recombinase protein pairs (RecE/RecT or Redα/Redβ) starts double-stranded break repair. 
In this process RecE (Redα) digests one strand of the DNA from the double-stranded break, 
leaving the other strand as a 3` hanging strand. RecT (Redβ) recognises and coats the DNA 
overhang to form the protein-nucleic acid filament aligning with homologous DNA. Then 
the 3` end acts as primer for DNA replication. 
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1.12 Background of the study: 
MCMV is used as a model for HCMV in studying genes involved in pathogenicity. 
Generation of MCMV with mutations in genes allows the analysis of the phenotype of 
generated mutant viruses in vitro and in vivo to help in identification of virulence 
determinants (Akel et al., 1993). 
In our laboratory, 31 temperature-sensitive mutants of the MCMV-K181 
(Birmingham) strain were generated  using chemical mutagenesis (N-methyl-N-nitro-N-
nitrosoguanidine) and selection for mutants restricted in their growth at the non-permissive 
temperature for replication at 39°C and above (Akel et al., 1993; Akel & Sweet, 1993; 
Sammons & Sweet, 1989). One of these temperature sensitive mutants, tsm5, demonstrated 
an interesting phenotype, where it was able to express immediate-early, early and late phase 
genes in the tissues of infected BALB/c mice, but failed to produce infectious progeny virus 
at any time point from 1–21 days post infection and was not reactivated from latency 
following immunosuppression with cortisone acetate and anti-lymphocyte serum (Bevan et 
al., 1996). Tsm5 was able to protect mice against subsequent sublethal wild-type challenge 
when inoculated with as little as 4 pfu of tsm5 where no virus could be isolated from any 
tissue at 3-42 days after challenge (Morley et al., 2002). This suggested that tsm5 was 
replicating at undetectable levels, which can be reflected by induction of high titre 
neutralizing antibody and a CD8
+
 CTL response. In addition, an electron microscope 
investigation of tsm5 infected MEF cells grown at the non-permissive temperature revealed 
an accumulation of tsm5 virus capsids devoid of DNA, which suggests an inability of tsm5 
to package viral DNA into pre-formed capsids (Morley et al., 2002). To investigate the 
regions of tsm5 contributing to this phenotype, recombinant chimaeric viruses were 
generated using a tsm5 cosmid library and a Smith MCMV cosmid library. One of the 
Chapter 1: Introduction 
59 
recombinant viruses (Smith/tsm5DGIK) was designed to contain the central part of tsm5 
and the 3' and 5' ends of Smith virus genome. This virus was temperature sensitive although 
not to the same extent as tsm5 suggesting that a temperature sensitive gene (s) is located in 
the central region of the chimaeric virus encoded by tsm5 genes. This region contains 
herpes virus conserved genes involved in DNA synthesis, packaging and cleavage. These 
genes were sequenced in tsm5 and mutations found in M56 (G439R), M70 (C890Y) and 
M98 (P324S). The recombinant virus now replicated in the salivary glands of 
immunocompetent adult mice at levels similar to those of the wt Smith virus. From this 
observation it was concluded that mutations in the tsm5 genomic region that had been 
replaced by the Smith genome (i.e. ORFs m01 to M54 and/or m145 to m170), were 
important in the inability of tsm5 to replicate in immunocompetent mice. Some of these 
genes (m04, m06, m144, m152, m157) are known to interfere with MHC peptide 
presentation, NK cell killing or recognition and thus are called immune-evasion proteins 
(Reddehase et al., 2004).  
Other genes such as M27 and M33 interfere with cell signalling, while genes M36, 
M37 and m38.5 inhibit apoptosis.  These genes were also sequenced in tsm5 and revealed 
that there were no mutations present in ORFs m04, m06, M33, M37, m38.5, m144, m152, 
or m157 but genes M27 and M36 each contained a single point mutation resulting in amino 
acid changes (Sweet et al., 2007). 
1.12.1 Aim of the Study: 
In this study, the aim is to investigate the role of the mutations identified in ORFs 
M27 and M36 of tsm5 in the observed in vitro and in vivo phenotype of tsm5. The mutation 
in the tsm5 M27 gene was characterized at nucleotide position 32,324, where an adenosine 
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substitution for cytosine results in replacement of an alanine with a serine at residue 658 
(A658S). The mutation in the M36 ORF resulted in an isoleucine substitution for valine at 
residue 54 (V54I) resulting from a cytosine mutation to a thymine, at nucleotide position 
49,108 (Sweet et al., 2007). These mutations will be introduced into the wild type K181 
virus BAC-DNA, both individually and together, using RecE/RecT homologous 
recombination. Such mutations and their revertants, in which the mutations have been 
repaired, will subsequently be used to study of the role of each mutation in vitro.  
Furthermore, in this study, a comparative genome sequencing (CGS) approach will 
be used to analyze both the MCMV-K181 (Birmingham) strain and tsm5 genome to 
identify all possible differences of MCMV-K181 (Birmingham) from the published MCMV 
K181 (Perth) sequence and any further mutations in tsm5 that may be involved in 
generation of the tsm5 phenotype.  
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Chapter 2:  Materials and methods 
2.1 Maintenance of cell lines 
All in vitro cell culture work was carried out in sterile conditions in a Class II 
biological safety cabinet. The cells were incubated at either the permissive (37°C) or non-
permissive (40°C) temperature using a Sanyo CO2 Incubator in a humid atmosphere 
supplemented with 6% CO2. 
2.1.1 Mouse embryo fibroblasts 
2.1.1.1 NIH 3T3 cells 
The immortalized mouse embryo fibroblast cell line, NIH 3T3 (ATCC CRL-1658), 
was cultured in growth medium (GM1) comprising Dulbecco‟s Modified Eagle‟s Medium 
(DMEM) (Sigma-Aldrich, Dorset, UK) supplemented with 10% (v/v) newborn calf serum 
(NCS) (Sigma-Aldrich), 4mM L-glutamine (Invitrogen, Paisley, UK) and 200 U/ml  
penicillin and  200 g/ml streptomycin (Invitrogen). 
2.1.1.2 Primary mouse embryo fibroblasts  
Primary mouse embryo fibroblasts (MEF) were isolated from the foetuses of 14-day-
old BALB/c mice. Between 10 and 24 embryonic sacs were removed from the uterine horns 
of the mouse and placed in a Petri dish in 10 ml of phosphate buffered saline (PBS) (Oxoid, 
Hampshire, England). Each embryonic sac was opened and the embryos were released into 
the Petri dish. The placenta, membranes and foetal visceral tissues were discarded and the 
embryos placed in a clean Petri dish and washed with 10 ml of PBS. The embryos were 
subsequently forced through a 20 ml syringe and 10 ml of trypsin: EDTA (0.5% v/v 
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trypsin; 5.3 mM EDTA) (Invitrogen) was added to the cells which were then well shaken. 
The mixture was then incubated for 10 minutes at 37°C. The cell suspension was 
vigorously shaken and filtered through a fine metal sieve to extract cellular debris. The 
sieving should take only a couple of minutes as prolonged sieving time reduces viability 
and attachment of the cells due to over-exposure to trypsin. Two ml NCS and 10 ml GM1 
were added and all the homogenate transferred to a centrifuge tube. After centrifugation at 
720 x g for 10 minutes at room temperature (RT), the pellet was re-suspended in 10 ml 
GM1. The cells from the equivalent of three embryos were seeded into a 162 cm
2 
tissue 
culture flask containing 15 ml GM1 and incubated at 37°C in 94% air/6% CO2 until 
confluent. Cells were then passaged as described in section  2.1.1.3 or seeded as required for 
the experiments. MEF cells were used within 3 passages, after which time the attachment 
and growth properties of the cells were poor. 
2.1.1.3 Subculturing of cells 
Cells were subcultured when 80-95% confluent. Growth medium was removed from 
the 162 cm
2
 tissue culture flask, the cells washed with 10 ml of phosphate buffered saline 
(PBS) followed by a rinse with 2ml of 10x trypsin:EDTA (TE). Incubation of the flask 
proceeded at 37°C for 1 minute. Detachment of the cells from the flask surface was 
monitored using an inverted microscope, after that the cells were resuspended in 10 ml of 
GM1. The cells were seeded into a 162 cm
2
 tissue culture flask containing 20-40 ml GM1 
at a split ratio of 1:10, cultured at 37°C until 80-90% confluent and passaged further as 
required.  
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2.1.1.4 Long term storage of NIH 3T3 cells (Cryopreservation)    
Healthy cell cultures, free from contamination, were used for preparation for stock 
cells. Cells were maintained in log phase growth, in 162 cm
2
 tissue culture flasks, for 
several days. Cell were then trypsinised as described above (section 2.1.1.3) and harvested 
by centrifugation at 850 x g for 10 minutes at room temperature. The cell pellet was 
resuspended in GM1 supplemented with 10% (v/v) dimethyl sulphoxide (DMSO) (Sigma-
Aldrich). The cell concentration was adjusted to be 2×10
5
-5×10
6
 cells/ ml/cryovial. 
Cryovials were placed in a freezing vessel containing isopropanol and subsequently cooled 
in a -80°C freezer. Twenty four hours later, the cryovials were moved to a liquid nitrogen-
filled storage vessel for long-term storage. 
2.1.1.5 Resuscitation of NIH 3T3 cells 
A cryovial containing the NIH3T3 cells stored in liquid nitrogen was thawed in a 
37°C water bath with constant moderate agitation until ice in the cryovial was no longer 
visible. The cryovial was then warmed in the water bath for 30 seconds with gentle 
agitation and disinfected with 70% ethanol. Working in a class II safety cabinet, thawed 
cells were transferred to 1.5 ml pre-warmed GM1 (37°C) and allowed to stand at room 
temperature for five minutes. Three ml of pre-warmed GM1 were added and allowed to 
stand for another five minutes at room temperature. Six ml of pre-warmed GM1 were then 
added to the cells and allowed to stand for a further five minutes. The cells were 
centrifuged at 200 x g for 10 minutes at room temperature. The supernatant was discarded 
and the cell pellet resuspended in 25 ml fresh GM1 and seeded into a 75 cm
2
 tissue culture 
flask. The cells were then incubated in a 37°C incubator (94% air /6% CO2) for several 
days and monitored daily until 80-90% confluent. Cells were then passaged into a 162 cm
2
 
tissue culture flask.  
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2.1.2 Mouse (Raw 264.7) Macrophage cell line 
Raw 264.7 macrophages (ECACC 91062702) are mouse monocyte macrophages  
established from ascites of a tumour induced in a male mouse by intraperitoneal injection of 
Abelson Murine Leukaemia Virus (A-MuLV) (Ralph & Nakoinz, 1977; Raschke et al., 
1978). Raw cells were cultured in growth medium (GM2), comprising RPMI-1640 (Sigma-
Aldrich) supplemented with 10% (v/v) NCS, 4mM L-glutamine, 200 U/ml penicillin and 
200 g/ml streptomycin. For virus growth curves, Raw 264.7 cells were seeded at 3.5 × 105 
per well in 24 well plates and infected at an MOI = 0.1. 
2.1.2.1 Subculturing of Raw 264.7 cells 
Cells were subcultured when 80-90% confluent (i.e. every 3 days). GM2 was 
removed from the 75 cm
2
 tissue culture flask, the cells were rinsed with 10 ml of PBS, 
followed by addition of 15 ml of ice-cooled PBS and incubation at room temperature for 15 
minutes. Cells then were scraped gently from the flask surface using a rubber scraper. After 
that the cells were resuspended in PBS by gentle pipetting and collected in a 50 ml 
centrifuge tube. The cells were harvested by centrifugation at 200 x g for 10 minutes at 4°C 
and resuspended in 10 ml GM2.  The cells were then seeded into a 75 cm
2
 tissue culture 
flask containing 20 ml GM2 at a split ratio of 1:3 -1:5, cultured at 37°C and 94% air/6% 
CO2 in a humidified atmosphere until they reached 80-90% confluency (usually 3 days) 
and passaged further as required. Harvested Raw 264.7 macrophages were prepared for 
long-term storage as described for NIH 3T3 cells in sections 2.1.1.4 whereas, resuscitation 
of cryopreserved macrophages was performed as described in section 2.1.1.5  
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2.1.3 Cell counting 
Cell number was determined by counting cells in a Neubauer haemocytometer. One 
hundred µl of cell suspension was mixed with 100 µl of Trypan Blue (Sigma-Aldrich) and 
the mixture was introduced into the counting chamber. The haemocytometer consists of 
nine 1 mm
2
 squares divided into smaller squares. One of the 1 mm
2
 squares represents a 
volume of 0.1 mm
3 
or 10
-4 
ml. Cells were counted using an inverted microscope in the four 
corner 1 mm
2
 squares and the total number of cells recorded was divided by 4 giving the 
average number of cells per 1 mm
2 
square. The obtained number was multiplied by 2 taking 
into consideration the dilution 1:2 with Trypan Blue. To calculate the concentration of the 
cells the following formula was applied:  c = n/v  
Where   
c = cell concentration in cells/ml;  
 n = average number of cells per mm
2
;  
 v = volume counted = 10
-4
 ml  
 Thus c = n x 10
4 
cells/ml. 
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2.2 Viruses 
2.2.1 The MCMV K181 (Birmingham) variant: 
The K181 strain of MCMV was obtained from Professor C. A. Mims (Department 
of Microbiology, United Medical and Dental Schools of Guy's and St. Thomas' Hospitals, 
Guy's Campus, London Bridge, UK). The parent K181 strain of MCMV was originally 
received from Dr J. Osborn (Department of Medical Microbiology, University of 
Wisconsin, Madison, Wis., USA) who had isolated it and described it as a virulent variant 
of the Smith strain after many passages in mouse salivary glands (Mims & Gould, 1979; 
Smith et al., 2008). The parental Osborn strain of virus has been designated K181 
(Birmingham) in this laboratory. The K181 (Birmingham) virus was further passaged in 
mice and isolated from salivary glands to produce a seed stock. Working stocks were 
produced from propagation of K181 (Birmingham) virus (from seed stock) in vitro either 
on NIH 3T3 cells or MEF cells as described in sections 2.3.3 and 2.3.4.  
2.2.2 Tsm5 virus 
Temperature-sensitive mutant viruses were previously produced in our laboratory 
from K181 (Birmingham) MCMV by chemical mutagenesis using N-methyl-N'-nitro-N-
nitrosoguanidine. These viruses were defined on the basis of their restricted growth at non-
permissive high temperature (>39°C) (Sammons and Sweet, 1989). Among these viruses, 
one temperature sensitive virus, tsm5, was not able to produce detectable infectious virus in 
the salivary glands of mice 2-3 weeks after inoculation with 10
2
 plaque forming units 
(PFU), and so tsm5 was grown on MEF cells to produce working stocks (Akel et al., 1993; 
Akel & Sweet, 1993; Sammons & Sweet, 1989). In this study tsm5 virus was propagated 
either on NIH 3T3 cells or MEF cells to produce seed and working stocks (Sections 2.3.3 
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and 2.3.4) from virus working stocks produced previously on 21/11/1990, 4/02/1991, 
16/12/1995, 22/09/1998, 22/08/2002 and 27/07/2004. 
2.2.3 The MCMV K181 (Perth) Variant: 
The K181 (Perth) variant of MCMV was kindly provided by Dr Alec Redwood 
(University of Western Australia, Australia).  It was cloned and propagated as a BAC 
plasmid (pARK25) in the DH10B strain of E. coli (Redwood et al., 2005). It was originally 
obtained from Dr D. Lang (Duke University, Durham, N.C., U.S.A.) and designated as the 
Smith strain. Later, restriction enzyme digestion analysis of the viral DNA revealed that it 
had a pattern identical to that of the K181 strain (Hudson et al., 1988; Shellam et al., 2007; 
Xu et al., 1992). 
Because mutant tsm5 was originally derived from the K181 (Birmingham) strain of 
MCMV, the K181 (Perth) strain was used in this study to construct mutant as well as 
revertant BACs (Table 2.1) using homologous recombination as the Birmingham variant is 
not yet available as a BAC. The K181 (Perth) variant, mutant and revertant MCMV were 
reconstituted by transfection of the corresponding BAC DNA into permissive NIH 3T3 
cells (Section 2.3.1).  
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Table  2.1 MCMV BAC plasmids and reconstituted viruses used in this study. 
 Name Description 
1- K181 (Perth) Wt K181 (Perth) variant of MCMV. 
2- Mt[M27
A658S
] Mutant virus with C:T point mutation creating A658S amino acid 
change in M27 protein. 
3- Rv[M27
S658A
] Revertant virus with wt M27 gene. 
4- Mt[M36 
V54I
] Mutant virus with C:T point mutation creating V54I amino acid 
change in M36 protein. 
5- Rv[M36 
I54V
] Revertant virus with wt M36 gene. 
6- Mt[M27
A658S
 M36
 V54I
] Mutant virus with point mutations creating amino acid changes 
A658S in M27 protein and V54I in M36 protein. 
7- Rv[M27
S658A
 M36
 I54V
] Revertant virus with wt M27 and wt M36 genes. 
8- Mt[m139
Y565X
] Mutant virus with C:T point mutation resulting in a stop codon 
insertion Y565X, creating a truncated m139 protein. 
9- Rv[m139
X565Y
] Revertant virus with wt m139 gene. 
10- Mt[m141
V195M
] Mutant virus with C:T point mutation creating V195M amino acid 
change in m141 protein.  
11- Rv[m141
M195V
] Revertant virus with wt m141 genes. 
12- Mt[m143
M232I
] Mutant virus with C:T point mutation creating V195M amino acid 
change in m143 protein. 
13- Rv[m143
I890M
] Revertant virus with wt m143 genes. 
14- 
Mt[M70
C890Y
] * 
Mutant virus with C:T point mutation creating C890Y amino acid 
change in M70 protein. 
15- Mt[M70
 403Cys
] The M70 mutant virus with whole M70 gene codons converted to 
sub-optimal codons but containing wt cytosine at residue 890. 
16- Rv[M70
 403Cys
] Revertant virus with wt M70 gene sequence. 
17- Mt[M70
 403Tyr
] The M70 mutant virus with whole M70 gene codons converted to 
sub-optimal codons but containing mt tyrosine at residue 890. 
18- Mt[[M70
 155Cys
] The M70 mutant virus with the carboxyl terminal of M70 gene 
codons converted to sub-optimal codons but containing wt 
cytosine at residue 890. 
19- Rev[M70
 155Cys
] Revertant virus  of Mt[[M70
 155Cys
] with wt M70 gene codons 
20- Mt[M70
 155Tyr
] The M70 mutant virus with the carboxyl terminal of  M70 gene 
codons converted to sub-optimal codons but containing mt 
tyrosine at residue 890. 
* Mt[M70
C890Y
] construct was designed by Dr. Olga Timoshenko (Timoshenko et al., 2009b).  
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2.2.4 HCMV Merlin BAC 
The HCMV Merlin BAC was kindly provided by Professor Gavin Wilkinson 
(Department of Infection, Immunity and Biochemistry, School of Medicine, Cardiff 
University) and designated as PAL1111 in E. coli SW102 strain (Stanton et al., 2010). 
Unlike its parent strain E. coli DH10B, SW102 does not need transformation with a 
plasmid containing  Red-encoded genes: exo, bet and gam.  It contains a stably integrated 
defective  prophage and exo, bet and gam are expressed under the influence of the strong 
phage promoter pL under the control of the temperature sensitive repressor, c1857. Exo, bet 
and gam genes are not expressed at 32ºC but they are expressed efficiently by shifting the 
incubation temperature  to 42ºC for 15 minutes (Warming et al., 2005). 
2.3 Virology methods 
All virus work and cell infection was carried out under sterile conditions in a Class 
II biological safety cabinet. The infected cells were incubated in a Sanyo CO2 Incubator in a 
humid atmosphere supplemented with 94% air/6% CO2. 
2.3.1 Transfection of MCMV BAC plasmids into NIH 3T3 cells 
MCMV BAC plasmid DNA was isolated using mini preps (alkaline lysis method) as 
described in section (Section 2.5.3.1) or maxi preps [BACMAX
TM
 DNA purification kit 
(EPICENTRE
®
 Biotechnologies)] (Section 2.5.3.2). NIH 3T3 cells were seeded at a 
concentration of 4x10
5
 cells per well of a 6-well plate (Corning Incorporated, USA) in 3 ml 
of GM1 24 hours before transfection. At the time of transfection the cell monolayers were 
80-90% confluent. ExGen500 in vitro transfection reagent (Fermentas, York, UK) was used 
according to the manufacturer‟s instructions with modifications. ExGen500 is a sterile 
Chapter 2: Materials and methods 
70 
apyrogenic solution of linear 22 kDa polyethylenimine in water, which belongs to an 
efficient new class of non-viral, non-liposomal gene delivery reagents. BAC DNA (20-80 
µl), isolated by the alkaline lysis method, or 5 µg of BAC DNA, isolated with the 
BACMAX
TM
 DNA purification kit, was added to a tube containing 150 mM NaCl to make 
a final volume of 300 µl. The mixture was gently mixed by tapping for 10 seconds and spun 
down briefly. Fifteen µl of ExGen500 reagent was added to the tube, the solution gently 
mixed by tapping for 10 seconds and then left to stand for 10 minutes. Three hundred µl of 
the ExGen500/DNA mixture was added slowly to the monolayer in each well. The plate 
was gently rocked back and forth and from side to side to achieve even distribution of the 
transfection mixture. The cells were incubated at 37°C in a humid 94% air/6% CO2 
atmosphere for 24-48 hours and then transferred to a 75 cm
2
 tissue culture flask (Section 
2.1.1.3). Plaque formation was monitored for up to 10 days using an inverted microscope. 
As the BAC contains the gfp gene it was possible to monitor plaque formation using a 
fluorescence microscope. When 100% CPE was observed the supernatant containing virus 
was harvested as described in section 2.3.3. 
2.3.2 Plaque purification of BAC-derived virus 
 BAC-derived virus was plaque purified in order to isolate the viral clone and to 
excise the BAC cassette from the viral genome. Either NIH 3T3 or MEF cells were seeded 
as 4x10
5
 cells in 3 ml of GM1 into each well of a 6-well flat bottomed plate and cultured 
overnight at 37°C. A 10 fold dilution series of each harvested supernatant containing 
virions was prepared in 1 ml of maintenance medium (MM) comprising DMEM, 2% (v/v) 
NCS, 4 mM L-glutamine, 200 U/ml penicillin and 200 µg/ml streptomycin. When cell 
confluence was about 80-90% the GM1 was removed from each well and 500 µl of viral 
dilution was added. The cells were incubated at 37°C for 1 hour and then 2 ml of MM was 
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added. Plaque formation was monitored using an inverted fluorescence microscope. Three-
to-four days p.i., plaques that did not show green fluorescence, and thus may have excised 
their BAC cassette, were picked by scraping the area of cells containing the plaque using a 
sterile tip. An inverted microscope was used to aid the accuracy of scraping. Each isolated 
plaque was transferred to 0.5 ml of MM. The virus-infected cells were harvested (Section 
2.3.3) and viral DNA extracted (Section 2.5.2). Virus-containing supernatants were 
prepared for long term storage (Section 2.3.3) and labelled as 1
st
 passage. A 6-well plate 
with 4x10
5
 cells in 3 ml of GM1 in each well was prepared the day before and 1 ml of MM 
containing the isolated plaque was added to the cells in a well. Cells were incubated at 
37°C for 1 hour and a further 2 ml of MM was added to the cells. The cells were incubated 
at 37°C until formation of new plaques was observed. The plaques were picked and used to 
inoculate new cell monolayers in 6-well plates as described above.    
2.3.3 Virus propagation and harvesting 
 NIH 3T3 or MEF cells were seeded in a 162 cm
2
 tissue culture flask in 25 ml of 
GM1 and cultured at 37°C until 80-90% confluent. The GM1 was removed from the flask 
and 0.5-1.0 ml of virus stock, or virus-containing supernatant harvested after virus 
passaging (Section 2.3.2), in 5 ml of MM was added. The flasks were incubated at 37°C for 
1 hour to allow virus attachment to the cells. A further 15 ml MM was then added and the 
flasks incubated at 37°C until the cell monolayer showed 100% CPE. At this point the 
medium from the flask was transferred to a centrifuge tube. The cells left in the flask were 
detached using a cell scraper and transferred to the same centrifuge tube. The contents of 
the tube were then centrifuged at 850 x g for 10 minutes at room temperature. After 
centrifugation, the supernatant, containing virus, was supplemented with 10% DMSO and 
stored at -80°C. The cell pellet was kept at -20°C for DNA extraction (Section 2.5.2). 
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2.3.4 Production of seed and working stocks of virus 
Viral seed stocks were produced on NIH 3T3 or MEF cells as described in section 
2.3.7. Infection of cells with virus was carried out as described in section 2.3.3 with the 
exception that only 15 ml of MM was used per flask to yield higher titres of virus. When all 
cells showed 100% CPE, the virus-containing supernatant was harvested and centrifuged at 
850 x g for 10 minutes at RT to remove cellular debris. The virus-containing supernatant 
was supplemented with 10% DMSO, aliquoted in 2 ml cryogenic vials and stored at -80°C. 
In order to produce stocks with a higher virus concentration, the supernatant was filtered 
through a Whatman filter paper directly into Oakridge-style centrifuge tubes and 
centrifuged at 29,000 x g for 40 minutes at 4°C. The viral pellet was re-suspended in MM 
supplemented with 10% DMSO. The viral stock was aliquoted and stored at -80°C. The cell 
pellet was kept at -20°C for DNA extraction (Section 2.5.2).  
2.3.5 Virus titration using a plaque assay 
Based on the ability of MCMV to form plaques in a close-to confluent monolayer of 
permissive cells, viral stocks were assayed on MEF cells to determine viral titres. The 
amount of virus present in viral stocks (Section 2.3.4), and tissue culture supernatants 
(Sections 2.3.6 and 2.3.7) are expressed in PFU per ml.  
MEF cells were seeded at 1x10
5
 cells in 0.5ml of GM1 in each well of a 24 well 
tissue culture plate. Cells were allowed to adhere during overnight incubation at 37ºC, this 
density of cells being established to provide a confluent monolayer after attachment. The 
GM1 was replaced by 200l of serially diluted virus samples diluted in MM. The control 
well only contained MM. After 1 hour incubation at 37C, 1ml of overlay medium [2/3 
carboxymethylcellulose (CMC) and 1/3 GM1] was added to each well and the plates 
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returned to the incubator. Medium containing CMC was used to limit the spread of virus 
from distinct virus replicating loci to distant uninfected cells. After 5 days for viral plaques 
to form the cells were fixed and stained.  At room temperature, 0.5ml of formal saline 
fixative (4% formaldehyde in PBS) was added directly to each well. After 10 minutes, the 
overlay was replaced by another 0.5 ml of fixative. The plates were incubated at room 
temperature for 30 minutes and then the fixative was replaced by 0.5-1.0 ml of 0.3% crystal 
violet solution [0.3% (w/v) crystal violet dissolved in 10% (v/v) methanol in water] in each 
well. The plates were left for 1 hour at room temperature, when the wells were washed 
gently with running tap water and the plates left on the bench to air dry. The plaques were 
counted using a light microscope. 
2.3.6 In vitro growth curves of viruses on MEF cells 
To study the growth properties of viruses used in this study, MEF cells from the 
second culture passage were seeded at a density of 1x10
5
 cells in 0.5ml of GM1 per well of 
24 well tissue culture plates; three wells were infected for each virus. Cells were allowed to 
adhere during overnight incubation at 37ºC, this density of cells being established to 
provide a confluent monolayer after attachment. GM1 was removed and the cells were 
infected at an MOI of either 0.05 plaque forming units (PFU) per cell in 200 l. After one 
hour incubation at 37 ºC, the culture medium was removed and the cells washed with PBS. 
To each well, 1000l of GM1 was added and the cells incubated at 37ºC. At different time 
points, two 500l aliquots were collected from each well and stored at -80C; the medium 
being replaced by a further 1 ml of GM1. The samples were thawed and viral titres were 
determined by plaque assay (Section 2.3.5). 
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2.3.7 In vitro growth curves of viruses on Macrophage cell-lines 
Raw 264.7 macrophage cells were seeded at 3.5x10
5
 cells in 0.5ml of GM2 into each 
well of a 24 well tissue culture plate. Cells were allowed to adhere during overnight 
incubation at 37ºC, this density of cells being established to provide a confluent monolayer 
after attachment. Raw 264.7 cells were infected at an MOI of 0.1 PFU per cell in 200 l. 
After one hour incubation at 37 ºC, the culture medium was removed and the cells washed 
with PBS. To each well, 1000 l of GM1 was added and the cells incubated at 37ºC.  At 
different time points, three 500 l aliquots were collected from each well and stored at -
80C; the medium being replaced by a further 1 ml of GM1. The samples were thawed and 
viral titres were determined by plaque assay (section 2.3.5). 
2.3.8 Statistical analysis 
Virus titres and genome copy numbers were log10-transformed and processed using 
the computer program GraphPad Prism (GraphPad Prism Software, Inc.). Results were 
considered to be significantly different when P<0.05 was achieved. Values reported 
represent mean ± standard deviation (SD). 
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2.4 Bacteriology methods 
2.4.1 Bacterial hosts and plasmids 
 E. coli strain DH10B (recA
-
), containing the MCMV K181 (Perth) BAC and 
designated as pARK25, was kindly provided by Professor G. R. Shellam (University of 
Western Australia, Australia) (Redwood et al., 2005). The pRpsL-neo plasmid carrying a 
kanamycin resistance and a streptomycin susceptibility gene and the RecE/RecT protein 
expression plasmid pKD46 (Datsenko & Wanner, 2000) were originally obtained from 
Gene Bridges (Dresden, Germany).  
A stab culture of SW102 (developed from the E. coli DH10 B strain) containing the 
HCMV Merlin BAC was kindly provided by Professor Gavin Wilkinson (Department of 
Infection, Immunity and Biochemistry, School of Medicine, Cardiff University) and 
designated as PAL1111. Hosts  and plasmids used in this study are shown in Table 2.2. 
Table  2.2: Bacterial hosts and plasmids used in this study. 
Plasmid name Host Antibiotic selection 
Growth 
Temp. 
Source or reference 
pARK-25 [wt MCMV 
K181 (Perth) BAC ] 
DH10B 
12 µg/ml Cm
1
, 
80 µg/ml Sm
2 37°C (Redwood et al., 2005) 
pKD46 TOP10 50 µg/ml Carb
3
 30°C (Datsenko & Wanner, 2000) 
pRpsL-neo DH10B 20 µg/ml Kan
4
 30°C Gene Bridges, Germany 
PL1111 (HCMV Merlin 
BAC) 
SW102 12 µg/ml Cm 30°C 
Prof. Gavin Wilkinson, 
Cardiff University 
pGEM®-T Easy vector XL1-Blue 
100 µg/ml Amp
5
, 
0.1 mM IPTG
6
, 
20 µg/ml X-Gal
7
, 
37°C Promega, USA 
pPCR-Script Amp SK(+) 
plasmid 
XL1-Blue 100 µg/ml Amp 37°C 
ShineGene Molecular 
Biotech, Inc., Shangai, 
China 
1- Cm, Chloramphenicol. 
2- Sm, Streptomycin 
3- Carb, Carbenicillin  
4- Kan, Kanamycin  
5- Amp, Ampicillin 
 
6- IPTG, isopropyl-beta-D-thiogalactopyranoside 
7- X-Gal 5-bromo-4-chloro-3-indolyl-beta-D-galacto-     
pyranoside 
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2.4.2 Media for bacterial cultures 
Bacterial cultures were grown in Luria-Bertani (LB) medium prepared by dissolving 
10 g tryptone, 5 g yeast extract and 10 g NaCl in 800 ml distilled water. All culture media 
were autoclaved for 15 minutes at 121°C and, where required, mixed with appropriate 
antibiotics. For making agar plates, 100 to 200 ml aliquots of LB medium supplemented 
with 15g/l bacto-agar (L-Agar) were autoclaved, cooled and stored at 4C. The L-Agar was 
dissolved by boiling, cooled down to 50C and supplemented with appropriate antibiotics 
(Table 2.2).  In a laminar flow hood, 20-25 ml of L-Agar was poured into each Petri dish 
(agar plate) and left to solidify for 20 to 30 minutes. 
2.4.3 Cultivation and long term storage of bacteria 
Single colonies isolated from agar plates were transferred aseptically into 5 or 10 ml 
of LB medium supplemented with appropriate antibiotics. Bacteria were then grown 
overnight at a suitable temperature (Table 2.2) on a shaker at 200 rpm. For long term 
preservation of bacteria, 500 l of overnight culture were transferred to 2 ml cryovials 
followed by addition of 500 l 80% (w/v) glycerol, mixed by pipetting, and stored at -
80C. 
2.4.4 Preparation and transformation of electrocompetent cells 
A single colony was picked from an LB agar (LBA) plate and grown in 5 ml LB 
medium (supplemented with appropriate antibiotics) for overnight incubation with shaking 
at 37C. A 500 l aliquot of the overnight culture was added to 25 ml of pre-warmed LB 
medium supplemented with appropriate antibiotics. Cells were grown at 37°C with shaking 
until growth reached an absorbance OD600 of 0.6. The culture was then transferred to a 50 
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ml centrifuge tube and placed on ice for 10 minutes.  The cells were harvested by spinning 
down for 10 minutes at 4,000 x g in a pre-cooled centrifuge (4°C). The cells were washed 
by resuspension in 10 ml of 10% (w/v) glycerol followed by centrifugation for 10 minutes 
at 4,000 x g. The supernatant was discarded and the washing step was repeated twice. The 
supernatant from the final wash was discarded and the cells resuspended in the remaining 
liquid (about 250 l). For long term storage, the cells were then aliquoted into 0.5 ml 
centrifuge tubes and snap-frozen in liquid nitrogen prior to storage at -80°C. 
2.4.4.1 Transformation of pKD46 into Electrocompetent cells: 
pARK-25 (E.coli DH10B) containing the K181 (Perth) BAC was used for 
manipulation of the virus and construction of the mutated and reverted constructs by 
homologous recombination. In order for these cells to be ready for homologous 
recombination they have to contain the red recombinase plasmid, pKD46 (GenBank Acc. 
No: AY048746.1, size = 6329 bp) (Figure 2.1) (Yu et al., 2000b). pKD46 is a temperature 
sensitive plasmid that can be maintained in bacteria at 30° C but is lost if the cells are 
grown for 24 hours at 37-40° C. It encodes the lambda Red genes (exo, bet, gam) that are 
required for recombination with the native terminator (tL3) after the exo gene. The 
expression of these genes is under the control of an arabinose-inducible promoter, ParaB. It 
also encodes araC for repression of the ParaB promoter. Bacteria containing pKD46 can be 
selected on ampicillin or its derivatives. 
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Figure  2.1: Plasmid pKD46 expresses lambda red under Para (the arabinose-inducible 
promoter) control. Expression is regulated by L-arabinose. The plasmid carries bla [the 
beta-lactamase gene (ampicillin resistance gene)]and can be maintained under ampicillin 
selection. The plasmid origin of replication is temperature sensitive, and the plasmid will be 
lost on temperature shift from 30°C to 37-40°C on overnight incubation. 
 
For transformation of pARK-25, electrocompetent cells, prepared as described in 
section 2.4.4, were thawed on ice. Up to 5 l (100-300 ng) of pKD46 plasmid solution were 
added to the thawed cells, mixed by gentle pipeting and placed on ice for 5 minutes. The 
cells and plasmid mixture was then transferred to an ice-cold 1mm gap cuvette and 
electroporation was performed using a Bio-Rad Gene Pulser set to 25F, 1.85 KV with 
pulse controller set at 200 ohm. One ml of SOC medium (2.0g tryptane, 0.5g yeast extract, 
1ml 1M MgCl2, 1ml 1M MgSO4, 1ml 1M NaCl, 250l 1M KCl and 1.8l 20% glucose in 
100ml distilled water) was added to the cells in the cuvette immediately after 
electroporation. The cells were transferred to a 1.5 ml centrifuge tube and incubated at 
30C for 70 minutes with shaking spread on a plate containing 12 µg/ml chloramphenicol 
and 50 µg/ml carbenicillin and then incubated for 24-48 hours at 30C. 
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2.4.4.2 Electrocompetent cell preparation and transformation with linear DNA: 
A single colony of pARK-25 containing the pKD46 plasmid was picked and grown 
in 5 ml LB medium containing 12 g/ml choramphenicol and 50g/ml carbanacillin 
overnight with shaking at 30C. An aliquot of the 440 l overnight culture was added to 20 
ml of pre-warmed LB broth supplemented with 12 g/ml choramphenicol and 50g/ml 
carbanacillin (Table 2.2). Cells were grown at 30°C with shaking until the absorbance at an 
OD 600 reached 0.3. 10 ml of the culture were then transferred to a 25 ml Universal tube. 
300-500 l of 10% L-arabinose was added to the culture to induce the recombinase proteins 
expression. Cells were further grown at 37°C for one hour (to induce production of proteins 
necessary for recombination). The cells were then placed on ice for 10 minutes and 
electrocompetent cells prepared as described in section 2.4.4. Electrocompetent cells were 
then transformed with 100-300 ng linear DNA as described in section 2.4.4.1. 100 l of the 
cells were spread onto a plate (supplemented with appropriate antibiotics) and incubated for 
24-48 hours at 30C in order not to lose the temperature sensitive pKD46 plasmid needed 
for all steps of BAC mutagenesis. 
2.4.5 Transformation of XL-1 Blue competant cells 
XL-1 Blue competent cells (Stratagene, UK) was used as a host for cloning of 
pGEM®-T Easy plasmid containing UL70 gene DNA frament insert (Section 2.6.1). XL1-
Blue cells were thawed on ice, mixed gently and then 100 l of the cells were transferred 
into a pre-chilled 14 ml Falcon polypropylene round-bottom tubes. A 1.7µl sample of β 
mercaptoethanol was then added to cells and incubated one ice for 10 minutes, whilst being 
swirled gently. A 2µl sample of the mutated pGEM T Easy plasmid was then added to the 
cell and incubated on ice for a further 30 minutes. The cells were then heat shocked for 45 
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seconds in a 42
o
C water bath, after which they were incubated on ice for a further 2 minutes 
followed by addition of 900 µl of preheated (42
o
C) SOC medium. The cells were then 
incubated at 37
o
C for 1 hour, on a shaking plate at 225 rpm and then streaked directly onto 
a previously prepared LB agar plate containing 100µg/ml ampicillin, 80µg/ml X-Gal and 
0.5mM of IPGT. Plates were incubated at 37
o
C overnight. Successfully transformed cells 
(white colonies) were grown in LB medium containing 100µl/ml ampicillin at 32
o
C for 24 
hours.  
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2.5 Molecular biology methods: 
2.5.1 Isolation of DNA from viral particles: 
Five 162 cm
2
 flasks of NIH 3T3 cells were infected with MCMV and, when the CPE 
had reached 100%, the cells were harvested by scraping. Cell debris was pelleted at 850 x g 
for 10 minutes at 4°C, and the supernatant filtered through a Whatman filter paper directly 
into a sterile Oakridge-style centrifuge tube and the cell pellet stored at -20 for viral DNA 
extraction as described in section 2.5.2. Virus in the supernatant was centrifuged at 29,000 
x g for 30 minutes at 4°C and the pellet resuspended in 500 l of DNase I buffer [50 mM 
Tris HCl (pH 8.0), 5 mM MgCl2, 0.1 M sodium acetate, 100 g of bovine serum albumin 
per ml]. Extra-virion DNA was digested for 1 hour in 0.2 U of DNase I (Sigma-Aldrich, 
DN25) at room temperature, and the reaction was stopped with 20 l of 500 mM EDTA 
(pH 8.0). Virus was treated with 500 l of 1% sodium dodecyl sulphate (SDS) and 40 l of 
20 mg/ml proteinase K (Sigma-Aldrich) for 16 hours at 56°C. The liberated viral DNA was 
purified twice by phenol-chloroform extraction and 0.1 volume 3M sodium acetate was 
added to the collected aqueous phase. Ethanol (2.5 x volume) was added and the viral DNA 
precipitated at 15,000 x g for 15 minutes at 4°C. The pellet was washed twice with 5 ml 
70% ethanol at RT and centrifuged at 15,000 x g for 10 minutes at 4°C. The supernatant 
was carefully poured out and the tube was centrifuged for a short time and the remaining 
ethanol removed using a 1ml pipette. The pellet was air-dried at RT for 5 minutes and then 
resuspended in 250-500 l TE [1 mM Tris HCl (pH 7.6) and 10 mM Tris EDTA (pH 8.0)] 
elution buffer. 
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2.5.2 Isolation of viral DNA from infected tissue culture cells 
Isolation of total DNA from virus-infected tissue culture cells was performed using a 
DNeasy Tissue Kit (Qiagen, Crawley, UK), according to the manufacturer‟s instructions. 
Virus infected and virus lysed cells were harvested from 162 cm
2
 tissue culture flasks using 
a cell scraper and pelleted by centrifugation at 850 x g for 10 minutes at  RT. Alternatively, 
cell debris stored at -20ºC was thawed at RT. The pellet was resuspended in 200 l PBS, 20 
l proteinase K and 200 l buffer Al was added to the sample, which was vortex-mixed 
thoroughly and incubated at 56C for 10 min. To this homogeneous solution, 200 l of 
100% ethanol was added and mixed thoroughly by vortexing. The mixture was then 
pipetted into the DNeasy mini spin column placed in a 2 ml collection tube followed by 
centrifugation at 6,000 x g for 1 minute in a bench top centrifuge at RT. The flow-through 
and collection tube was discarded and the column was placed in a new 2 ml collection tube. 
500 l buffer AW1 was added to the column and the column was centrifuged for 1min at 
6,000 x g at RT. The flow-through and collection tube were again discarded and the column 
placed in a new 2 ml collection tube. 500 l buffer AW2 was added to the column, 
followed by centrifugation for 3 min at 20,000 x g at RT to dry the DNeasy membrane. 
After discarding the flow-through and collection tube, the column was placed in a clean 1.5 
ml microcentrifuge tube and 200 l buffer AE was pipetted onto the DNeasy membrane.  
The column was incubated at RT for 1 minute and then centrifuged for 1 minute at 6,000 xg 
RT to collect the eluate. The eluted DNA was stored at 4C. 
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2.5.3 Plasmid DNA isolation 
2.5.3.1 Small scale preparation of plasmid DNA 
BAC DNA used for PCR screening (Section 2.5.7) and transfection of eukaryotic 
cells (Section 2.3.1) was isolated from 1.5-5 ml of overnight bacterial cultures using an 
alkaline lysis method. The culture was centrifuged at 5,000 x g for 8 minutes at 4ºC. The 
supernatant was discarded and the pellet re-suspended in 300 µl of re-suspension buffer (15 
mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 µg/ml RNase). After resuspension, 300l of 
freshly prepared solution-II (0.2M NaOH; 1% SDS) was added to lyse the cells and the 
tube was inverted gently several times. The lysis reaction was allowed to proceed for a 
maximum of 5 minutes at RT. To stop the reaction, 300l of solution-III (117.78 g 
potassium acetate; 46 ml glacial acetic acid in 400ml distilled water) was added and 
incubated on ice for 15 minutes before centrifugation at 15,000 x g for 15 minutes at RT. 
The supernatant was then transferred to a fresh Eppendorf tube containing 700 l 
isopropanol which was then centrifuged at 15,000 x g for 10 minutes at RT. The 
supernatant was discarded and the pellet, containing DNA, was washed by adding 500 µl of 
70% ethanol to the tube, and then the tube was centrifuged 15,000 x g for 5 minutes at RT. 
The supernatant was then fully removed and the pellet air dried for 5-10 minutes. DNA was 
re-suspended in 50 µl TE buffer and stored at 4°C for use or at -20 for long-term storage. 
2.5.3.2 Isolation of high quality BAC plasmid DNA 
The BACMAX
TM
 DNA purification kit (EPICENTRE
®
 Biotechnologies, Cat. No. 
BMAX04) was used for isolation of MCMV BAC DNA for transfection and RFLP study 
purposes. 50 ml of LB medium, containing 15 µg/ml of chloramphenicol and 50 µg/ml 
streptomycin, in a 250 ml flask was inoculated with a single bacterial colony from a freshly 
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streaked plate and incubated at 37°C with vigorous shaking for 14-16 hours (~ 250 rpm). 
When the culture reached an OD600 of 3-4, the cells were transferred into centrifuge tubes. 
The cells were pelletted by centrifugation at 5,000 x g for 8 minutes at 4ºC and the 
supernatant was discarded. Three ml of chilled BACMAX solution 1 were added to the 
pellet and vortexed vigorously until completely resuspended. Six ml of BACMAX solution 
2 were added and mixed very gently by inverting the tube 2-3 times; the suspension was 
incubated at RT for not more than 5 minutes. Chilled BACMAX solution 3 (4.5 ml) was 
added and the tube mixed gently by inversion 2-3 times and then incubated on ice for 15 
minutes prior to  centrifugation  at 15,000 x g for 15 minutes at 4ºC to pellet cellular debris. 
The supernatant was transferred carefully to a 40 ml Oakridge-style centrifuge tube using a 
10 ml pipette, avoiding aspiration of the white precipitate. Room temperature isopropanol 
(0.6 volumes) was added and mixed thoroughly by inverting the tube 4-6 times. Nucleic 
acid was precipitated by centrifugation at 15,000 x g for 15 minutes at 4ºC. Isopropanol 
was carefully decanted and the tube was briefly centrifuged then excess isopropanol was 
pipetted off without disrupting the pellet. The pellet was air-dried at RT for 3-5 minutes and 
then resuspended in 500 l of TE buffer by tapping and swirling. Eighteen l of 
RiboShreder RNase Blend were added to the tube and incubated at 37ºC for 30 minutes. An 
additional 500 l of TE buffer were added and mixed by tapping the tube. One ml of chilled 
BACMAX solution 4 was added, the tube mixed gently by tapping and then incubated on 
ice for 15 minutes followed by centrifugation at 15,000 x g for 15 minutes at 4ºC. The 
supernatant was carefully transferred to a 40 ml Oakridge-style centrifuge tube without 
disrupting the pellet. Four ml of absolute ethanol were added to the recovered supernatant 
and mixed gently by inverting the tube 4-6 times. The DNA was precipitated by 
centrifugation at 15,000 x g for 15 minutes at 4ºC and the supernatant discarded. The pellet 
was air-dried at RT for 5 minutes and resuspended in 200 l of TE buffer.  
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2.5.3.3 Quick method for BAC DNA preparation for PCR screening 
 For fast and efficient BAC preparation for PCR screening, 200 µl of overnight 
bacterial culture was centrifuged at 6,000 x g for 5 minutes at RT, the supernatant removed 
and the cell pellet re-suspended in 200 µl of sterile distilled water. The cell suspension was 
boiled for 10 minutes and then centrifuged at 15,000 x g for 5 minutes at RT to remove cell 
debris. 1-2 µl of supernatant containing DNA was used in 25 µl of PCR reaction.    
2.5.3.4 Isolation of plasmid DNA (mini preps) 
Small plasmid DNA (up to 10 kb) was isolated from 1-5 ml of overnight bacterial 
culture using a QIAprep Spin Miniprep Kit (Qiagen). The bacterial cells were harvested by 
centrifugation at 6,800 x g for 3 minutes at RT and then re-suspended in 250 µl of buffer P1 
containing RNase A. The cells were lysed by adding 250 µl of buffer P2 (contains NaOH, 
SDS). The mixture was incubated for a maximum of 5 minutes and 350 µl of buffer N3 was 
added to neutralise the lysate and precipitate cellular debris, denatured proteins and 
chromosomal DNA. The mixture was then centrifuged at 17,900 x g for 10 minutes at RT 
and the supernatant applied to a QIAprep spin column. The column was centrifuged at 
17,900 x g for 30 seconds at RT and the flow-through was discarded. The column was 
washed by adding 750 µl of buffer PE and centrifuged at 17,900 x g for 30 seconds at RT. 
The flow-through was discarded and the column was centrifuged for an additional 1 
minute. To elute plasmid DNA, 50 µl of buffer EB (10 mM Tris-HCl, pH 8.5) was added to 
the centre of the QIAprep spin column, left to stand for 1 minute, and centrifuged at 17,900 
x g for 30 seconds at RT.   
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2.5.4 DNA quantification 
DNA was quantified using the NanoDrop
TM
 ND-1000 Spectrophotometer (Labtech 
International Ltd., UK). Two µl of sample was used and the concentration of the sample 
was presented as ng/µl based on absorbance at 260 nm. Ratios 260/280 and 260/230 were 
also obtained to indicate the purity of DNA. A 260/280 ratio of 1.8 and 260/230 ratio of 
1.8-2.2 is accepted as pure for DNA. If the 260/280 ratio is lower than 1.8 it may indicate 
the presence of contaminants such as proteins, phenol, salts or other contaminants that 
absorb at or near 280 nm. A lower ratio for 260/230 also indicates the presence of 
contaminants. 
2.5.5 Primer design and preparation  
Most of the primers used in this study were designed using the Primer-BLAST 
computer program, available at http://www.ncbi.nlm.nih.gov/tools/primer-blast/. The 
program identified all possible primer pair combinations within the proximities of the 
screened sequence of interest. The best primer combinations were selected and the 
sequences underwent any modification, before being sent to Eurogentec S.A, for primer 
synthesis.   
 Primers used for amplification of the RpsL-neo cassette containing DNA fragments 
and for insertion of the RpsL-neo cassette into the gene of interest, were designed to 
contain 50 bases homologous (homology arm) to the 5‟end of the wild-type gene sequence 
and 20-22 bases from the pRpsL-sequence at the 3‟ end. Primers used for „QuikChangeTM‟ 
site directed mutagenesis (Stratagene, UK) of the Merlin strain of HCMV were designed to 
contain a single base alteration in the middle of the 30 base primer (Table 2.10). 
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2.5.6 Preparation of Primers 
All primers received from Eurogentec S.A were in solution at a concentration of 
100µM. Primers used in PCR reactions were diluted to a 10µM concentration by combining 
20µl of the primer solution to 180µl dH20. All primers used within the sequencing reactions 
were diluted to a 3µM concentration by combining 3µl of the primer solution into 97µl 
dH20.  
 
Table  2.3: Primers used for the M27 gene mutagenesis and sequencing.  
 
Primer name Forward sequence 
Tm 
(°C) 
M27FA CGGAAGTTATCGCCAAAACC 65.2 
M27FB CAAGAGGTCCATGAACTTGG 62.1 
M27FC CGCGTAGCCCAGATCGATGT 61.3 
M27FD ATCGTAGATGACCTCCATGG 56.5 
M27F5 CGACCTCTATTCCCCTGAGT 62.0 
M27F6 AGGTGAAGACCTGGCCCAC 62.0 
M27RA TGGCTGCTTGCTGTGTAGG 69.6 
M27RB ATCGAGTTCGTCCCCTTCGC 69.6 
M27RC ACATCGATCTGGGCTACGCG 69.5 
M27RD ACACCTTCTTCATCAAGAG 58.3 
M27R5 GCATGCGGCTGCGCTACTAC 70.1 
ET M27 F* 
TCCGCAACTCATCCCCTTGGAACCGCCGGCGACCGCGAC
CGCCTCCGAGGCCCTGGTGATGATGGCGGGATC 
82.2 
ET M27 R* 
ACAGGCTCATCCCCTACTACATGTTTGTCGGCGGATACCG
CCGGCGCGACGGTCAGAAGAACTCGTCAAGAAGGA 
96.7 
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Table  2.4: Primers used for the M236 gene mutagenesis and sequencing. 
 
Primer name Forward sequence 
Tm 
(°C) 
M36F1 CCCGGCGTCGCCCGTGAGGC 83.3 
M36F2 ATCGATGATGAGGATGAGCC 64.0 
M36F3 TCCTTTTAGGGAGGACGTCG 65.2 
M36F4 CCTTGATCACGGGGTCAGAG 64.0 
M36F5 CCTGATTCTCCGCGACGATG 64.0 
M36R1 AACGCGAGTCGCTGTTCAAA 68.0 
M36R2 GAGATCGTCCCTTACCAGGA 63.0 
M36R3 CAGCACCTTTGACATCTTCG 63.4 
M36R4 TCTGCATGTCGCGGATGACC 64.0 
M36R5 GGAAACTGGTCCACCGTCTG 64.0 
ET M36 F* GAAGAGCATCACGAACCTCGTGGTGTCCAGGTCCCGTCC
ACGCAGCCGGCCGCCTGGTGATGATGGCGGGATC 
80.6 
ET M36 R* ATAAAGTTGCTGCTTGCCTCAAAATGCTCGAATGCGGTCT
TGTTTTTCGCGTTCAGAAGAACTCGTCAAGAAGGA 
93.2 
 
Table  2.5: Primers used for the m139 gene mutagenesis and sequencing. 
 
Primer name Forward sequence 
Tm 
(°C) 
m139 F1 TAGCGATCGGAGCCGGTTTC 64 
m139 F2 CCCTCGGTAGCATTGCCTTC 64 
m139 F3 AGGAGGCAGAGTGCGATCAG 64 
m139 F4 TCCTCGGCGATCCTGAAGAC 64 
m139 F5 CGGGATCAGGTACCAGTTCTC 66 
m139 R1 GGCTTCGTCTTCGAGGTGTC 64 
m139 R2 GAAGAGGCAGCTGACCCATC 64 
m139 R3 TGCGCGACTTCAAGAGCTTCC 66 
m139 R4 CGAGAGCGTGCTAACGACAC 64 
ET m139  F* GATGCGGCACGGCTTTTATAGACTGATGGTTGCTGCGCG
CCCCCCCGCGAGCGGCCTGGTGATGATGGCGGGATC 
 
ET m139 R* CCGCCGCTCTGTCCCCACAGGGACGAAGACCGGCCGCC
GATCGCCACGTCGCTCAGAAGAACTCGTCAAGAAGG 
 
Chapter 2: Materials and methods 
89 
Table  2.6: Primers used for the m141 gene mutagenesis and sequencing. 
 
Primer name Forward sequence 
Tm 
(°C) 
m141 F1 GAAGAATTCGGCCACGCTGTC 66 
m141 F2 GTGGCGATGTTGACAGGCAG 64 
m141 F3 AACGACCACGAGCAGTGCAAC 66 
m141 R1 ATCGGGCAAGAGTTGCTGGTC 66 
m141 R2 ATGTGCGACCCCGAGTTCAAG 66 
m141 R3 CGTTTCGGGATCTCCCGAC 62 
m141 R4 CACTTCTGGCTCTGGTCTCTC 66 
ET m141 F* GAACTTGTCGGCCACGATCACGTGGTCGGCCCTGAACTC
CGCGTCCGGCAGGGGCCTGGTGATGATGGCGGGATC 
 
ET m141 R* GATACGGGGTGTCCCTCGTGCTGTCGGGCGAGTACGGAC
GGGTGTACGTGTATCAGAAGAACTCGTCAAGAAGG 
 
 
 
Table  2.7: Primers used for the m143 gene mutagenesis and sequencing. 
 
Primer name Forward sequence 
Tm 
(°C) 
m143 F1 ACGTGAGATCCACGCGAACTG 66 
m143 F2 TCGCCCAAGTGTGAGAGAGG 64 
m143 F3 TCTTCAGCAGTCCCATGCGAC 66 
m143 F4 AGTTCGAGCCGGTCCAGTAG 64 
m143 R1 ATGGGCAAGGAGTCGAGGATG 66 
m143 R2 TATCGCTGATCAGCGGCGAG 64 
m143 R3 TGACCGGCTACGACCTGAAC 64 
m143 R4 TCCCGGATCCCAGCATTTGAG 64 
ET m143 F* TCGGGAGTGGAACCACAGCTCCTGGTCGGGTGGGGGCT
CGAGCCGGACGCTCGGCCTGGTGATGATGGCGGGATC 
 
ET m143 R* CTACAGGGTGCCGCTGTCGATACCGTTGAAGAAAGACCC
GGTCTGGGACGCCTCAGAAGAACTCGTCAAGAAGG 
 
 
  
Chapter 2: Materials and methods 
90 
Table  2.8: Primers used for the M70 gene mutagenesis and sequencing. 
 
Primer name Forward sequence Tm (°C) 
M70ExtLargeF TTTCCAGTTGGGATGAGAGG 60 
M70ExtSmallF CGGAAATGTGGCTAGGTGTT 60 
M70F ACGTTAGTTAGGGCCGGGTG 57.5 
M70F3 TCAAGCATTCCAGGTCGTCGG 67.3 
M70F4 CGGTAGTGGTTACGCGTGTG 61.5 
M70F6 GTCCGCAGCATGGTTTCGCC 60.5 
M70F7 CACCGTCTCCTGGCGAGTGT 63.0 
M70R1 ACTCCCACCCCGTCTTCTTC 66.5 
M70R3 CGTCGAGCGATTACGAGGAG 70.3 
M70R4 CTGCTGCCCAAGGACCTGAT 70.8 
M70R7 GCCGGCATCCTCGATCACAC 74.2 
M70ExtSmall Rev CTTCCGGTCTATAAGCGCTGC 62 
M70ExtLarge Rev AAATCCAAACGTGTCATGCA 56 
ETM70F* GTGCGCTGCCGGAACGGGGGTCGTCGTCGCCCACGCGC
TCGTCGACGCGTCCTGGTGATGATGGCGGGATC 
 
ETM70R* GATGATGACCGACTTCGGCGGTGGCGGGACTGGCACTA
GTAATGCTTCAGAAGAACTCGTCAAGAAGG 
 
M70HA-RpsL-
Rev1* 
AGAACGCCGCGGGGGCGGCGGACGAGGCGATGCTGTAC
GGCGGCGGCGGCTCAGAAGAACTCGTCAAGAAGG 
 
M70HAwt-Rev1 ● AGAACGCCGCGGGGGCGGCGGACGAGGCGATGCTGTAC
GGCGGCGGCGGCTACGACGAAGACGACGACCC * 
 
M70 Suboptimal Primers 
M70ExtLargeF TTTCCAGTTGGGATGAGAGG 60 
M70ExtSmallF CGGAAATGTGGCTAGGTGTT 60 
M70SubOpt For2 GCTCCTCCTCGTAATCCGACG 64 
M70SubOpt For3 AGGGAATAATGACCCGGAG 60 
M70SubOpt For4 CGCGTCTCGTCTTCTTTTTC 60 
M70SubOpt For5 AACATTTCGTGTAATCCCGC 58 
M70SubOpt Rev1 CGTAATGTGGAGGACGACCT 59.9 
M70SubOpt Rev2 TCTCGTTGAACATCTCGTGC 60 
M70SubOpt Rev3 ATCTTGGCGTCGACGTATTC 60.1 
M70SubOpt Rev4 TTGAGATACCGGAGAATGGC 60 
● The common sequence between wt and the suboptimal synthesised sequence is shown in bold and 
underlined.  
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Table  2.9 : Other primers used in the study 
 
Primer name Forward sequence 
Tm 
(°C) 
RpsL-For GGGTGGAGAGGCTATTCGG 69.0 
RpsL-Rev GCCGAATAGCCTCTCCACCC 69.0 
6530R TCCGTTAGCCTTAGATTCCACCG 68.7 
m06F TTGGAGCGATACGTTGACAATG 66.8 
ARK25 15204 R AATACATCGTCACCTGGGACA 64.1 
ARK25 14832 F CATATCCCACGGCTGTTCAAT 65.7 
Other ORFs sequencing primers 
m20 F1 TCGACGGCCATCTGTTCCTC 64 
M20 R1 GCACGGATGTTCGGAATCGAC 66 
m21 F1 AGGGCGTGCGACTTTAAGCC 64 
m21 R1 AGGGTGTCGGGACTCTTCTC 64 
m132.1 F1 CCCATAGGCAGTAACGACACC 66 
m132.1 R1 TGCCTGCTGAAGACGGACAAC 66 
 
Table  2.10: HCMV Merlin strain primers 
Primer name Forward sequence 
Tm 
(°C) 
UL70 Fwd GTAATCCAGACAGAAGCGCC 62oC 
UL70 Rev ATCTACCACCATGGACGCTC 62oC 
UL70 inter Fwd GCGTGTAGTTGAGACAGCGA 62oC 
UL70 inter Rev ATCTACCACCATGGACGCTC 62oC 
External UL70 Fwd TCTTCCGCGAGATGGTATTC 60oC 
External UL70 Rev GTACACCCCAGCGTTTTACG 60oC 
UL70mut Fwd ■ CGCTTGACGGCCACGTAGCAGGCGCCGTGGG 50 
UL70mut Rev ■ CCCACGGCGCCTGCTACGTGGCCGTCAAGCG 50 
UL70 RpsL-Fwd* TTTATCGAGACGCGCTCGCTTAACGTGACGCGTTATCG 
ACGCCGCGGTCTCCTGGTGATGATGGCGGGATC 
 
UL70 RpsL-Rev* TCAGACGGCGGTCGCCGGCGGCATGGGCGCGTCGGG 
CGGTCTGATTTTGATCAGAAGAACTCGTCAAGAAGG 
 
■ The 30 base primers used in the site-direected mutagenesis containing one base 
substation in the middle of the pirmer. 
* 3‟ end of the primer annealing to the RpsL-neo cassette is shown in bold and italics.  
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2.5.7 Polymerase chain reaction (PCR)  
PCR for screening of bacterial recombinants, checking the excision of the BAC 
cassette from BAC-derived virus DNA or amplifying viral sequences for sequencing, was 
performed using the 2 x ReddyMix
TM
 PCR Master Mix (Abgene, Surrey, UK). The PCR 
reaction was performed in a 25 µl final volume comprising 12.5 µl 2x ReddyMix PCR 
Master Mix [1.25 units of Thermus aquaticus (Taq) Thermoprime Plus DNA polymerase, 
75 mM Tris-HCl (pH 8.8), 20 mM (NH4)2SO4, 1.5 mM MgCl2, 0.01% (v/v) Tween 20, 0.2 
mM each of dATP, dCTP, dGTP and dTTP, precipitant and red dye for electrophoresis], 
10-300 ng of DNA template or 0.5-2 µl of DNA prepared from bacterial overnight culture 
as described in section 2.5.3.3, 0.6 µM of each forward and reverse primer (Sigma-
Genosys, Suffolk, UK or Eurogentec, Southampton, UK), and the appropriate volume of 
sterile distilled water. Standard PCR conditions were as follows:  
 Temperature Duration Number of cycles 
Initial denaturation  95ºC 2 minutes 1 cycle 
Denaturation  95ºC 30 seconds 
    
 
29 cycles Annealing XºC1 30 seconds 
Extension  72ºC Y minutes2 
Final extension  72ºC 7 minutes 1 cycle 
 
1- The annealing temperature depends on the melting temperatures (Tm) of the primers (Tables 2.3 
– 2.10); in this case it is 3-5°C below the lowest primer Tm.  
2- Extension time depends on the length of sequence to be amplified; in this case it is 45-60 
seconds per 1kb. 
Linear DNA fragments used for mutagenesis (Section 2.4.4.2) were amplified using 
the Extensor Hi-Fidelity PCR Master Mix (Abgene). The PCR reaction was carried out in a 
total volume of 50 µl, and contained 100-300 ng of DNA template, 0.3 µM of each forward 
and reverse primer and 25 µl Extensor Hi-Fidelity PCR Master Mix [1.25 units total DNA 
polymerase (Taq Thermoprime Plus DNA polymerase with proprietary thermostable 
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proofreading enzyme), 2.25 mM MgCl2, 350 µM of each dNTP, and red dye for 
electrophoresis] in distilled autoclaved water to a final volume of 50 µl. The PCR protocol 
was as described above.     
2.5.8 Restriction enzyme digestion  
For restriction fragment length polymorphism (RFLP) analysis , BAC DNA isolated 
as described in section 2.5.3.2,  was digested with EcoRI, AseI, DraI, HpaI (Fermentas, 
York, UK) fast digest enzymes. The BAC DNA (1.5-3.5 µg) was digested with 1 µl of 
enzyme in a final volume of 50 µl containing 5 µl of appropriate buffer. The reaction 
mixture was incubated at 37°C for 10-20 minutes. Loading buffer [0.25% bromophenol 
blue, 0.25% xylene cyanol FF, 15% ficoll type 400 (Pharmacia) in water] was added and 
the digest visualised by agarose gel electrophoresis as described in section 2.5.9. 
Samples of linear PCR products, amplified from plasmid DNA (e.g. pRPSL-neo 
plasmid) for the purpose of mutagenesis, were treated with the restriction enzyme DpnI to 
destroy any residual parental plasmid DNA. The digestion reaction was carried out in a 
final volume of 50 μl with 1 μl of DpnI enzyme (New England Biolab, Hitchin, UK), 5 μl 
of 10 x NE Buffer (New England Biolab) added to 40 μl of PCR product. The reaction was 
left to proceed at 37°C for one hour. The product was then purified (Section 2.5.10) and 
used for electroporation of electrocompetent cells (Section 2.4.4.2). 
2.5.9 Agarose gel electrophoresis  
Products of PCR and plasmid digests were separated and visualised on 0.8% agarose 
gels. Agarose gels were prepared by dissolving an appropriate amount of agarose (Sigma-
Aldrich) by heating in 0.5 x TBE buffer (45 mM Tris base, 45 mM boric acid, 1 mM 
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EDTA, pH 8.0). GelRed
TM
 (Biotium, Heyward, USA) was added to the agarose gel solution 
at a final dilution of 1:10,000 (i.e. 10 µl of the GelRed
TM
 10,000 x stock reagent added to 
100 ml of the gel solution). Gels were run in horizontal tanks containing 0.5 x TBE buffer. 
3-10 µl of the DNA sample was mixed with 6 x loading buffer before loading onto the gel 
and a voltage of 100 volts was applied to separate DNA samples. A 1kb DNA ladder 
(Fermentas) was used as a marker.  
To get an enhanced separation of RFLP digest fragments, the digest products were 
run on 0.4% agarose gels dissolved in 1% TAE (40 mM Tris acetate and 1 mM EDTA, pH 
8.0). GelRed
TM
 was added to the agarose gel solution at a final dilution of 1:10,000 (50 μl 
in 500 ml gel). 50 μl of digest samples were mixed with 6 x loading buffer and loaded onto 
a 30 cm length gel.  2.5 μl of a 1 kb DNA ladder was used as a marker. Electrophoresis was 
carried out in 1% TAE buffer at a voltage of 40 volts for 16-20 hours. DNA bands were 
visualized under UV light in a transilluminator, and gel images were recorded using a UVP 
digital camera. 
2.5.10 PCR product purification from PCR reactions and agarose gels 
A QIAquick PCR Purification Kit (Qiagen) was used to purify DNA from PCR 
samples and QIAquick Gel Extraction Kit (Qiagen) was use to extract DNA from bands in 
the agarose. All centrifuging steps were carried out in an Eppendorf bench centrifuge at 
17,900 x g at RT. One volume of PCR sample was mixed with 5 volumes of Buffer PBI 
and loaded onto the QIAquick spin column. The column was centrifuged for 30 seconds 
and the flow-through was discarded. 0.75 ml of Buffer PE was added to the column for 
washing and centrifuged for 30 seconds. The flow-through was discarded and the column 
centrifuged for 1 more minute to ensure removal of all residues of washing buffer. The 
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PCR product was eluted form the column with 50 µl of TE applied to the centre of the 
QIAquick membrane and incubation for 1 minute. Then the column was centrifuged for 1 
minute to collect the eluted DNA.   
For extraction of DNA from agarose gels, the gel slice (containing the DNA band) 
was weighed and 3 volumes of Buffer QG were added to 1 volume of gel (100 mg ~ 100 
µl). The sample was incubated at 56°C until the gel slice had completely dissolved (~ 10 
minutes). One volume of isopropanol was added to the sample and the mixture was applied 
to the QIAquick column and centrifuged for 1 minute. The column was washed and DNA 
was eluted as described above. After purification DNA was stored at 4°C for use or at -
20°C for long-term storage. 
2.5.11 Sequencing 
PCR and plasmid DNA were sequenced using the ABI PRISM
TM
 BigDye
TM
 
Terminator Cycle Ready reaction Kit (Perkin Elmer Applied Biosystems Division, Foster 
City, CA) on an automated ABI 377 sequencer in the University of Birmingham Functional 
Genomics Laboratory, Plasmid to Profile sequencing (Birmingham, UK). The sequencing 
reaction was carried out in a 10 µl reaction volume, consisting of 0.6 µmole primer and 
template DNA in concentrations as shown below. 
 Size in bp Quantity in ng 
PCR product  
100-200 1-3 
200-500 3-10 
500-1000 5-20 
1000-2000 10-40 
> 2000 40-100 
Plasmid DNA - 200-500 
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The sequences obtained from the ABI Prism 377 DNA Analyser were analysed with 
Chromas software (version 1.45, Griffith University, Queensland, Australia). The NCBI 
BLAST network service was used to compare obtained sequences with that of the published 
MCMV K181 (Perth) genome sequence (accession number AM886412).  
2.6 Cloning 
2.6.1 Preparation of UL70 insert and vector 
HCMV Merlin was cloned as a BAC in E. coli SW102 and designated as PAL1111 
(Stanton et al., 2010). UL70 gene fragment was synthesised from the wt Merlin BAC 
genome using the UL70 Fwd and UL70 Rev primers (Table 2.10). The PCR was performed 
using the high fidelity polymerase (Section 2.5.4) and the product was quantified using the 
NanoDrop (Section 2.5.4).  
The UL70 gene fragment was clonec into pGEM®-T Easy Vector (Promega, 
Madison, USA). pGEM –T Easy vector and the insert  were combined in a 0.5 ml 
centrifuge tube at a ratio of 1:3. 5 µl of 2x rapid ligation buffer and 1 ml of T4 DNA ligase 
were added and scaled up to 10 µl using distilled water. The ligation reaction was carried 
out at RT for 1 hour. 
Two µl of ligation reaction was transformed into 100 µl of XL1-blue competent cells 
(Stratagene, La Jolla, California, USA) (Section 2.4.5). Fifty µl of cells were plated on an 
agar plate containing 20 µg/ml X-Gal, 0.1mM IPTG and 100 µg/ml Ampicillin (Table 2.2) 
and incubated at 37°C overnight. White colonies (carrying recombinant plasmids) were 
screened by PCR and the presence of the inserted gene was confirmed by sequencing. 
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2.6.2 Site-directed mutagenesis 
The QuikChange Site-directed Mutagenesis Kit (Stratagene, Cambridge, UK) was 
used to generate a nucleotide substitution in UL70 gene of HCMV Merlin strain at nt 
positions 102,094 of leading to the amino acid change cysteine to tyrosine at the position 
890 of the UL70 encoded primase. The UL70 gene fragment was cloned in the pGEM –T 
Easy vector (Section 2.6.1) and two synthetic oligonucleotide primers containing a base 
substitution (Table 2.10) were designed, according to Stratagene‟s guidelines and obtained 
from Eurogentec. The strategy used for site-directed mutagenesis is shown in Figure 2.2. 
The mutant strands synthesis reaction was set as follows: 5 µl of 10 x reaction 
buffer, 60 ng of dsDNA template, 125 ng of each of oligonucleotide primer, 1 µl of dNTP 
mix, 1 µl of PfuTurbo DNA polymerase (2.5 U/µl) and sterile water to a final volume of 50 
µl. Cycling conditions were as follows:  
 Temperature Duration Number of cycles 
Initial denaturation  95ºC 30 seconds 1 cycle 
Denaturation  95ºC 30 seconds 
    
 
18 cycles Annealing 55ºC 1 minute 
Extension  68ºC X minutes* 
Final extension  68ºC 7 minutes 1 cycle 
* Extension time depends on the length of sequence to be amplified (1 minute per 1 kb of plasmid 
length). 
The oligonucleotide primers, each complementary to opposite strands of the vector, 
were extended during temperature cycling generating a mutated plasmid with staggered 
nicks. The parent wt DNA was digested with DpnI (Section 2.5.7) and the mutated plasmid 
was purified (Section 2.5.10) and transformed into XL1-blue competent cells (Section 
2.4.5). Plasmids were extracted from XL1-blue and sequenced to confirm the presence of 
the mutation. 
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Figure  2.2: Strategy used for the site-directed mutagenesis. Two primers containing the 
desired mutation anneal to the opposite strands of the vector and are extended by DNA 
polymerase to produce a mutated plasmid. Parent plasmid is digested with DpnI and 
mutated plasmids were used for transformation of XL-1 Blue cells. 
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2.7 BAC mutagenesis using ET homologous recombination 
To introduce a mutation into the K181 (Perth variant) of MCMV cloned as a BAC 
(Redwood et al., 2005), a two-step mutagenesis strategy involving homologous 
recombination  was used  as shown in Figure 2.4. 
2.7.1 Insertion of the RpsL-neo cassette into the MCMV BAC 
A linear RpsL-neo PCR product flanked by homology arms was used in the first 
step. Using the pRpsL-neo plasmid (Figure 2.3) as template, the RpsL-neo cassette was 
amplified by PCR (Section 2.5.7) using a primer designed to contain a 51-54 nucleotide 
homology arm from the 5‟ end of the gene of interest plus 21-24 nucleotides homologous to 
the 5‟ end of the pRpsL-neo plasmid and a similar primer designed to contain 21-24 
nucleotides and 51-54 nucleotides of the 3‟ end of pRpsL-neo plasmid and gene of interest 
resepectively (Table 2.3). After amplification, the PCR products were run on an agarose gel 
to confirm that the products had been amplified. To remove any residual template, PCR 
samples were purified (Section 2.5.10) and digested for one hour with the DpnI restriction 
enzyme to digest the methylated RpsL-neo plasmid. The PCR products were purified once 
again and used to transform pARK25 electrocompetent cells (300 ng DNA). 100l of 
culture were spread on an LB agar plate containing 12 g/ml chloramphenicol, 20 g/ml 
kanamycin and 50 g/ml carbanacillin. After an overnight incubation at 30C, colonies 
grown on the kanamycin/chloramphenicol plate were streaked on an LB agar plate 
containing kanamycin (20 g/ml), streptomycin (80g/ml) plus chloramphenicol 
(12g/ml). The plates were incubated at 30C overnight to confirm that the RpsL-neo 
cassette had been inserted. The plate was examined and the colonies which didn‟t grow on 
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this plate were identified. The recombinant BAC plasmid DNA was isolated (Section 
2.5.3.1) and used for PCR screening to confirm MCMV BAC-RpsL-neo clones. 
2.7.2 Replacing the RpsL-neo cassette by linear DNA of the gene of interest carrying 
the point mutation 
A linear DNA fragment derived by PCR from the gene of interest and containing the 
desired point mutation was prepared by PCR as described above. The product was 
visualized on an agarose gel, purified and then used to transform cells containing the 
MCMV K181(Perth) BAC in which the  region of interest had been replaced by the RpsL-
neo cassette. Electroporated cells were then incubated for at least one hour at 37C without 
any antibiotic pressure to give time for cells to recover and allow time for homologous 
recombination to occur. One hundred l of culture were spread on an LB agar plate 
containing streptomycin (80g/ml), carbanacillin (50 g/ml) plus chloramphenicol 
(12g/ml). After overnight incubation at 30C, colonies grown were streaked on an LB 
agar plate containing kanamycin (20g/ml), streptomycin (80g/ml) plus chloramphenicol 
(12g/ml). The plates were incubated at 30C overnight. The kanamycin plate was checked 
and the colonies which didn‟t grow on this plate were identified. The recombinant BAC 
plasmid DNA was isolated and used for PCR screening and sequencing in order to confirm 
that the RpsL-neo cassette had been replaced with the mutated MCMV gene. Revertants 
were producend by the same two-step process, initially replacing the mutated region of 
ORF with the RpsL-neo cassette then the cassette was replaced with the wild type linear 
DNA. 
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Figure  2.3. Diagram showing: A: pRpsL-neo plasmid containing both the wild-type RpsL 
gene (green colour) and neomycin resistance gene (orange colour). B: Use of primers with 
50 base homology arms (HA of wt K181 (Perth) BAC sequence) at the 5‟ends and 20 bases 
of RpsL-neo sequence to generate the RpsL-neo cassette to replace the wild-type sequence 
of the gene of interest in K181 (Perth) BAC. 
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B
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Figure  2.4 Schematic representation of the two steps BAC mutagenesis.  
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2.8 Comparative genome sequencing 
 Comparative genome sequencing (CGS) provided by Nimblegen Systems Inc. is a 
hybridisation-based method of screening whole genomes for changes against a reference 
genome (Wong et al., 2004; Albert et al., 2005; Waldmuller et al., 2008). In this method, 
putative mutations are first mapped approximately within the genome. Then, to identify the 
mutation precisely, each base within the mutated loci is exhaustively screened. Apart from 
the production of viral DNA, this procedure was essentially performed by Roche 
NimbleGen as described below. 
2.8.1 DNA labelling  
MCMV K181 (Birmingham), K181 (Perth), and tsm5 DNA was extracted from viral 
particles as described in section 2.5.1. Viral genomic DNA was cleaved to pools of low 
molecular weight fragments by sonication and labelled with a random prime reaction. One 
g of DNA was mixed with 1 O.D. of 5‟-Cy5 or 5‟-Cy3 labelled random nonamer (TriLink 
Biotechnologies) in 62.5 mM Tris-HCl, 6.25 mM MgCl2 and 0.0875%  mercaptoethanol, 
denatured at 98°C for 5 min, chilled on ice and incubated with 100 units of Klenow 
fragment and dNTP mix (6 mM each in TE buffer) for 2 h at 37°C. Reactions were 
terminated with 0.5 M EDTA (pH 8.0), precipitated with isopropanol and re-suspended in 
water.  
2.8.2 Mutation mapping microarray design 
Based on the published annotated sequence of the K181 (Perth) MCMV variant 
(Smith et al., 2008); EMBL accession number AM886412), mutation mapping microarrays 
were designed and produced by NimbleGen (Albert et al., 2005). The microarrays 
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contained 385,000 29-mer “tiled” oligonucleotides spaced every 7 bases on each strand of 
the genome sequence (Figure 2.5. A). All oligonucleotides were synthesised in parallel on a 
two-array set using a Digital Light Processor (Texas Instruments, Plano, Texas, USA) and 
photoprotected phosphoramidite chemistry (markless array synthesis) (NimbleGen 
Systems, Madison, WI, USA) in a random probe layout. 
2.8.3 Microarray hybridisation 
Labelled genomic DNA from the reference virus (labelled with Cy5) and from test 
virus (labelled with Cy3) were hybridised in parallel to arrays in 1 x NimbleGen 
Hybridization Buffer (NimbleGen) for 16 hours at 42°C and washed with non-stringent 
buffer, centrifuged in a NimbleGen custom centrifuge to remove buffer and then stored 
until scanned.  
2.8.4 Analysis of mapping array data and hybridisation of re-sequencing arrays 
Microarrays were scanned at 5 m resolution using a Genepix® 4000b scanner 
(Axon Instruments, Union City, CA, USA) and pixel intensities were extracted using 
NimbleScan™ software (NimbleGen). Hybridisation intensity ratios (reference/test) plotted 
versus genome position mapped possible mutations sites. 
Probes that spanned potential mutations were selected for re-sequencing. Each 
nucleotide of both the sense and anti-sense DNA strands was interrogated with eight probes 
(29-39 bases, depending on sequence and calculated Tm), four for each strand of DNA, that 
differed only with respect to the central position (A, C, G and T) (Figure 2.5B). When 
target DNA was hybridised to these arrays the perfect match probe will hybridise more 
strongly than the three corresponding mismatch probes for each strand. This differential 
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signal intensity between the perfect probe and mismatch probes allows the base to be 
determined precisely.  
These re-sequencing arrays were synthesised, hybridised with labelled genomic 
DNA from each test line and scanned as above.  Sequence base assignments were made 
using a machine-learning algorithm (Albert et al., 2005). Segments containing mutations in 
tsm5 identified by CGS were PCR amplified and verified by conventional sequencing 
(Sections 2.5.7 and 2.5.11). 
 
Figure  2.5: Diagram of the CGS process. A. Labelled reference (red) and test (green) 
genomic DNA were hybridised in parallel to microarrays composed of 29-base-long 
oligonucleotides (blue) tiled with 7-base spacing. B. Re-sequencing probes are short 
oligonucleotides in which every possible variant is represented at the central position of the 
probe (coloured font). Four probes for each strand are used to interrogate each nucleotide 
position. Hybridisation of the sample with perfect match probe will result in the highest 
intensity (yellow coloured box) (Modified from Albert et al., 2005 and Gresham et al., 
2008). 
Reference genome
Test genome
Tiling array probes Mutations
A
- - -TGCTACGATCGTGCGTCGAGTAGTGTCAAT- - -
ACGATGCTAGCACGCAGCTCATCACAGTTA
ACGATGCTAGCACGCCGCTCATCACAGTTA
ACGATGCTAGCACGCGGCTCATCACAGTTA 
ACGATGCTAGCACGCTGCTCATCACAGTTA
Re-sequencing 
probes
Sample
Probe 
intensity
Perfect match probe
Mismatch 
probes
Called base T
B
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Chapter 3:  Results 
3.1 Sequence analysis of M27 and M36 Mutations in tsm5 
Tsm5 was generated in our laboratory from the MCMV K181 (Birmingham) variant 
by chemical mutagenesis (Sammons & Sweet, 1989). Partial sequencing of the tsm5 
genome revealed point mutations in several genes (Sweet et al., 2007). Among them there 
were two mutations in immune evasion genes: a C to A mutation in the M27 gene (the IFN 
signalling inhibitor) and a C to T mutation in the M36 gene (the apoptosis inhibitor) 
resulting in A658S and V54I residue changes in the two genes respectively. Other 
mutations were also identified in genes involved in DNA replication, processing and 
packaging; a C to T mutation (G439R) in the large terminase subunit (M56), a C to T 
mutation (C890Y) in the primase component (M70) of the helicase-primase complex and a 
C to T mutation (P324S) in the alkaline nuclease (M98) (Sweet et al., 2007; Timoshenko et 
al., 2009b). 
The aim of this study is firstly to introduce the mutations identified in the M27 and 
M36 genes, individually and together, into the wt virus using the BAC containing the 
MCMV genome and RecE/T homologous recombination to study their potential role in the 
phenotype of tsm5. The second aim is to identify any other possible mutations in the tsm5 
genome that might be contributing to its phenotype using CGS in which its genome will be 
compared to its parent K181 (Birmingham) variant and the published MCMV K181 (Perth) 
variant sequence. 
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3.1.1 Confirmation of the M27 and M36 mutations in tsm5 virus stocks 
To study the role of the M27 (A658S) and M36 (V54I) mutations identified in tsm5 
in its phenotype they need to be introduced into the wt virus and the phenotype of the 
mutated viruses assessed in vitro. Since tsm5 was to be used as the template for generating 
PCR products containing the mutations it was important to confirm that stocks of tsm5 still 
contained the mutations. As described below it was necessary to sequence the M27 and 
M36 ORFs in all currently available stocks of tsm5. 
3.1.1.1 Sequencing of the M27 gene  
The M27 gene mutation in tsm5 is a C to A nucleotide change at base position 
32,302 compared to the parent K181 (Birmingham) and the published K181 (Perth) 
(accession number AM886412) variants of MCMV. The mutation results in an amino acid 
alanine substitution for serine at position 658 (Sweet et al., 2007). The region spanning the 
M27 mutation was sequenced in all available stocks (Figure 3.1).  
As with tsm5 virus stock  prepared on the 27/07/2004, the sequence of all other 
available tsm5 virus stocks prepared at various dates from 21/11/1990, 04/02/1991, 
16/12/1995, 22/09/1998 to 22/08/2002 were heterogeneous at base position 32,302  
revealing double peaks showing both the mutant A and the wt C nucleotides (Figure 3.1). 
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Figure  3.1:   Virus stocks produce in 1990, 1991, 1995, 1998, 2002 and 2004 were 
examined and showed double peaks for the mutated (A) and wt (C) nucleotides. 
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3.1.1.2 Sequencing of the M36 gene  
In tsm5, the M36 gene mutation is a C to T change at base position 49,108 compared 
to the parent K181 (Birmingham) and the published K181 (Perth) variants of MCMV. This 
mutation result in an amino acid valine substitution for isoleucine at residue 54 of the M36 
gene (Sweet et al., 2007).  
As with the M27 gene, the M36 gene was sequenced in all available tsm5 stocks 
21/11/1990, 04/02/1991, 16/12/1995, 22.09/1998, 22/08/2002 and 27/07/2004. Again the 
M36 gene showed double peaks at base position 49,108 in most stocks but the 1990 and 
2004 stocks contained the mutated nucleotide only (Figure 3.2). The 1990 stock thus was 
passaged for production of seed and working stocks. DNA extracted from cells infected 
with this virus stock was re-sequenced, but unfortunately contained a mixed population 
showing a double peak for M36.  
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Figure  3.2: Sequence profile of the M36 ORF region of tsm5 containing the mutation at 
nucleotide position 49,108 compared to the wt K181 (Perth) published sequence. Tsm5 
virus stocks produced in1990, 1991, 1995, 1998, and 2002 were examined and showed 
double peaks for the mutated (T) and wt (C) nucleotides, whereas the stock produced in 
2004 contains the mutated (T) only. 
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Sequence analysis of other genes including M56, M70 and M98 in tsm5 stocks 
carried out by Dr. Olga Timoshenko showed that these were also heterogeneous in some 
stocks while other stocks contained only the mutant or wt nucleotide.  Tsm5 contains a C to 
T nucleotide change in its M56 gene at base position 86,783. This was confirmed in tsm5 
stocks produced in 1990, 1991, and 2004 whereas in the 1995, 1998 and 2002 stocks the 
sequence showed double peaks.   
A nucleotide substitution (C to T) at base position 99,286 of the M70 gene of tsm5 
was initially confirmed in the 1990, 1991 and 2004 stocks but later, after only one passage 
for preparation of working stocks, showed a mixture of mutant (T) and wt (C) nucleotides 
(Table 3.1). A C to T nucleotide change at base position 143,114 of the M98 gene of tsm5 
was wt in stocks prepared in 1990 and 1991 but all other examined stocks were a mixed 
population of mutant and wt nucleotides. 
Table  3.1: Summary of sequencing results obtained for tsm5 virus stocks. 
 
Gene M27 M36 M56* M70* M98* 
Base position 32,302 49,108 86,783 99,286 143,114 
tsm5 21/11/90 Hetero** Hetero Mutant Hetero Wild type 
tsm5 04/02/91 Hetero Hetero Mutant Hetero Wild type 
tsm5 16/12/95 Hetero Hetero Hetero Hetero Hetero 
tsm5 22/09/98 Hetero Hetero Hetero Hetero Hetero 
tsm5 22/08/02 Hetero Hetero Hetero Hetero Hetero 
tsm5 27/07/04 Hetero Mutant Mutant Hetero Hetero 
 
*  The M56, M70 and M98 genes of the tsm5 stocks produced in 1990, 1991, 1995, 1998, 
2002 and 2004 were sequenced by Dr. Olga Timoshenko. 
** Hetero – heterogeneous population of viruses containing mutant and wt copies of the 
gene 
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3.2  Sequence analysis of K181 (Birmingham) and tsm5 using 
comparative genome sequencing  
Sequencing of some targeted tsm5 genes identified single point mutations in some of 
the genes involved in DNA packaging and cleavage (M98, the alkaline nuclease,  [P324S]; 
M56, the large terminase subunit [G439R]; and M70, the primase [C890Y]) as well as 
some immune evasion genes (M27 [A658S] and M36 [V54I]) (Sweet et al., 2007). To 
determine if mutations in other genes may also be involved in the attenuation of virus 
growth at 40
o
C and in vivo, the whole genome (≈ 230kb) of tsm5 has to be sequenced.  
Sequencing technology at the time of this work was too expensive as it required sequencing 
of both tsm5 and the parent virus K181 (Birmingham) variant to detect any variation of 
both genomes from the published K181 (Perth) sequence. Instead we considered another 
comparatively inexpensive and rapid method in which the genomes are screened against a 
reference sequence [the published K181 (Perth) sequence] called Comparative Genome 
Sequencing (CGS) provided as a service by NimbleGen Systems Inc (Albert et al., 2005). 
This technique is a microarray method in which sequence variations are detected as 
hybridisation signal intensities. It enables the screening of the whole genome and detects 
any single nucleotide polymorphisms (SNPs) including mutations, insertions or deletions. 
In this method the SNP loci are first identified then the bases within the identified loci are 
carefully analysed for any base changes. Recent publication of the K181 (Perth) MCMV 
genomic sequence (Smith et al., 2008) made this method suitable to be used for re-
sequencing of K181 (Birmingham) and tsm5, because CGS requires synthesis of a reference 
oligonucleotide array based on an already established genome sequence.  
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K181 (Perth), K181 (Birmingham) and tsm5 (27/07/2004 stock) viruses were 
provided by Dr. Olga Timoshenko. Viral genomic DNA was prepared by Abdulaziz Alali.  
Viral genomic DNA was then submitted to NimbleGen Systems Inc. 
3.2.1 MCMV K181 (Birmingham) mutation mapping  
CGS is a two-step approach in which mutations are mapped approximately as 
Regions of Interest (ROIs) followed by determination of mutations precisely (Albert et al., 
2005). Based on the K181 (Perth) variant published sequence, microarrays containing 
385,000 29-mer “tiled” oligonucleotides spaced every 7 nucleotides along the genome on 
both strands were synthesized by NimbleGen Systems Inc. 
  DNA from MCMV K181 (Perth), the reference strain, and K181 (Birmingham), 
the tested strain, was fragmented by sonication then labelled with Cy5 and Cy3 
respectively. Both reference and tested labelled DNAs were hybridised in parallel to the 
designed microarrays. Microarrays were scanned at 5 m resolution using a Genepix 4000b 
scanner (Axon Instrument, Union City, CA) and the pixel intensities were extracted using 
NimbleGen
TM
 software (NimbleGen Systems Inc.). The software is very sensitive and can 
detect the slightest reduction in hybridisation intensity. The hybridisation intensity ratio 
(reference/test) for each pair of probes was plotted versus genome position. ROIs were 
determined by a significant difference in the probe signal intensity. 
Based on the determined ROIs, a re-sequencing microarray was designed to 
investigate all possible sequence differences at single-base pair resolution.  Eight probes per 
base position (four for each strand) were designed to contain all the possible nucleotides at 
a centrally located position. One of the four probes hybridises with the genomic DNA more 
strongly than the other corresponding mismatch probes for each strand that allows the 
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precise determination of the base difference as single nucleotide polymorphisms (SNPs). 
CGS identified three SNPs in the K181 (Birmingham) at base positions 10,078 (T to G), 
40,250 (A to G) and 45,607 (C to G) compared to the published K181 (Perth) sequence 
(Table 3.2).  
PCR products of regions containing these SNPs were sequenced by conventional 
ABI3799 capillary sequencing and confirmed two of the putative SNPs, the T to G at the 
base position 10,078 (m10 gene), and the A to G at the base position  40,250 (M32 gene) 
whereas the third SNP,  C to G at the base position 45,607 was not confirmed. 
Other genes of the K181 (Birmingham) variant of MCMV had been sequenced in 
this laboratory previously (Sweet et al., 2007). Eleven mutations were identified in the 
K181 (Birmingham) variant compared to the published K181 (Perth) variant of MCMV, not 
all of which were detected by the CGS analysis. The mutations are an A to C polymorphism 
at position 41,958 (M107L) in the M33 gene; a G to A at position 76,843 (D123D) in M51; 
a T to C at position 82,062 (D309G) in M54; a G to A at position 89,124 (A919V) in M57; 
a C to A at 202,998 (Q314H), a C to T at 203,055 (R295R), an A to G at 203,070 (G290G), 
a TT to CC at 203,182 and 203,183 (K253G), a G to A at 203,238 (Y234Y) and a C to G at 
position 203,515 (S142T), all in m144 (Table 3.3).   
3.2.2 Tsm5 mutation mapping 
For identification of tsm5 mutations, MCMV K181 (Birmingham), the reference 
strain, was labelled with Cy5 and tsm5, the tested strain, was labelled with Cy3 then both 
labelled DNAs were hybridised in parallel to the K181 (Perth) designed microarrays. CGS 
was able to identify fifteen ROIs in tsm5, which revealed a total of 10 synonymous and 15 
non-synonymous SNPs and 1 mutation characterized as intergenic (Table  3.2). Identified 
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non-synonymous changes were then examined by conventional ABI3700 capillary 
sequencing.  
Conventional sequencing confirmed 14 out of the 15 non-synonymous SNPs in 
tsm5, while the T to G base change at position 44,715 leading to the amino acid substitution 
V548G in the M34 ORF is considered false positive. Importantly, three previously 
observed tsm5 mutations from sequencing were confirmed by CGS:  the C to T mutations 
at positions 49,108 (V54I) in M36, 99,286 (C890Y) in M70 and 143,114 (P324S) in M98 
(Sweet et al., 2007). However, previous sequencing studies of tsm5 in the laboratory 
revealed five mutations that were not detected by CGS. Two false negative non-
synonymous mutations were observed, the C to A mutation at position 32,302 (A658S) in 
M27 and the A to G mutation at position 86,783 (G439R) in M56 and three synonymous 
mutations were not confirmed by CGS: an A to G at position 76,843 (D123D) in M51; an A 
to G at positions 77,752 (R281R) and 77,791 (L294L) in M52. 
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Table  3.2: Polymorphisms identified in the K181 (Birmingham) variant compared to the 
K181 (Perth) variant and mutations identified in tsm5 by CGS. 
 
Gene 
ORF position (nt)
a
  Position 
of 
mutation
 
Nucleotide 
change 
Amino acid 
change
b
 
From: To: 
K181 Birmingham polymorphisms (also present in tsm5) 
m10 9,624 10,499 10,078 T to G V152G 
M32 39,261 41,426 40,250 A to G F393L 
M34 43,073 45,646 45,607 C to G A846A
c
 
m34.2 45,512 45,844 45,607 C to G G80R
c
 
tsm5 mutations
e
 
m20 20,575 23,028 
20,949 C to T A694T 
22,698 C to T E111K 
m21 22,628 23,317 22,698 C to T S24F 
M25 25,995 28,793 
27,523 G to A R510K 
28,697 G to A Q920Q
d
 
M34 43,073 45,646 
44,687 C to T P539S 
44,715 T to G V548G
c
 
m34.2 45,512 45,844 45,740 G to A P35P
d
 
M36 exon 1 49,031 49,267 49,108 C to T V54I 
M45 59,515 63,039 61,705 G to A I445I
d
 
M47 63,924 67,046 
65,612 G to A Q563Q
d
 
66,658 C to T A912V 
M53 78,456 79,454 79,272 G to A V273M
f
 
M54 79,694 82,987 82,379 G to A S203S
d
 
M69 96,243 98,771 98,442 C to T R110R
d
 
M70 99,060 101,954 99,286 C to T C890Y
f
 
M82 115,757 117,556 115,946 C to T G537G
d
 
M87 127,433 130,213 127,756 C to T V108V
d
 
M97 140,185 142,116 141,258 C to T G358G
d
 
intergenic   142,121 C to T 
Promoter of 
M98? 
M98 142,145 143,830 143,114 C to T P324S 
m127 185,267 185,668 185,594 C to T R25R
d
 
m132.1 188,672 189,499 188,683 C to A G273C 
m139 194,162 196,096 194,402 G to T Y565X
f
 
m141 197,787 199,313 198,731 C to T V195M 
m143 201,008 202,639 201,944 C to T M232I 
 
a
 Gene positions are based on the K181 (Perth) sequence (EMBL Acc. No. AM886412)  
b 
Non-synonymous mutations in red font 
c
 These mutations were not confirmed by conventional capillary sequencing 
d
 These synonymous mutations were not sequenced 
e
 The K181 (Birmingham) SNPs were also present in tsm5 
f
 Conventional capillary sequencing revealed heterogeneous nucleotide  
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Table  3.3 K181 (Birmingham) variant polymorphisms compared to K181 (Perth) and 
mutations in tsm5 compared to K181 (Birmingham) not identified by CGS. 
   
Gene 
ORF position (nt)
a
  Position 
of 
mutation
 
Nucleotide 
change 
Amino acid 
change
b
 From: To: 
K181 Birmingham polymorphisms 
M33 41,476 42,770 41,958 A to C M107L 
M51 76,510 77,211 76,843 G to A D123D 
M54 79,694 82,987 82,062 T to C D309G 
M57 88,304 91,879 89,124 G to A A919V 
m144 202,788 203,939 202,998 C to A Q314H 
m144 202,788 203,939 203,055 C to T R295R 
m144 202,788 203,939 203,070 A to G G290G 
m144 202,788 203,939 
203,182-
203,183 
TT to CC K253G 
m144 202,788 203,939 203,238 G to A Y234Y 
m144 202,788 203,939 203,515 C to G S142T 
tsm5 mutations
c
 
M27 32,225 34,273 32,302 C to A A658S 
M52 76,910 78,463 
77,752 A to G R281R 
77,791 A to G L294L 
M56 85,701 88,097 86,783 C to T G439R 
 
a
 ORF positions are based on the K181 (Perth) sequence (EMBL Acc. No. AM886412)  
b Non-synonymous mutations highlighted in red 
c 
The K181 (Birmingham) SNPs were also present in tsm5 
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3.3 Construction of recombinant viruses 
The BAC cloned MCMV K181 Perth variant genome was used for construction of 
recombinant MCMVs by targeted mutagenesis (Redwood et al., 2005). The homologous 
recombination technique was used for introduction of mutations into the MCMV K181 
(Perth) BAC (Figure 2.3) (Lee et al., 2001; Yu et al., 2000a). The recombinant viruses were 
then reconstituted by transfection of the corresponding BAC plasmids into mouse 
fibroblasts as described (Section 2.3.1). The recombination-deficient E. coli DH10B strain 
was used for propagation of the MCMV K181 Perth variant genome BAC used for 
homologous recombination following transformation with the plasmid pKD46 that 
expresses lambda Red recombination proteins that are induced by an L-arabinose-inducible 
promoter (Datsenko & Wanner, 2000). Because of a mutation in the RpsL gene, E. coli 
strain DH10B is resistant to streptomycin, so it can be grown selectively on media 
containing streptomycin. However, the effect of the mutated RpsL gene can be overridden 
by the wild-type RpsL gene (introduced on a plasmid) resulting in susceptibility of the 
bacteria to streptomycin. 
In the beginning of this study our intention was to study the role of the identified 
tsm5 M27 (C to A at nt 32,302) and M36 (C to T at nt 49,108) mutations in its phenotype 
by introducing these two mutations separately and together into the wild-type MCMV 
K181 (Perth) BAC and reconstitution of the mutated recombinant viruses (Figure 2.4 & 
Figure 3.3) (Sweet et al., 2007). However, following the determination of other mutations 
present in the tsm5 using CGS, we decided to include three other immunoevasion genes 
m139, m141 and m143, in our study. A G to T substitution at base position 194,402 in 
m139 results in the introduction of a stop codon instead of tyrosine that lead to a truncation 
of the m139 protein product at residue 565. In m141, a C to T base change at base position 
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198,731 resulted in a valine substitution with methionine at residue 195. Whereas in the 
m143 gene a C to T mutation at base position 201,944 resulted in a methionine substitution 
with isoleucine at residue 232 (Timoshenko et al., 2009a). 
 
Figure  3.3 : Flowchart showing the strategy followed for construction and analysis of 
MCMV mutants starting with pARK25 E.coli containing the MCMV BAC. Mutants and 
revertants were constructed in a similar manner starting with the constructed mutants. 
1-  CM: chloramphenicol.               3-  Carb: Carbenicillin.          5-  SM: Streptomycin. 
2-  EC: Electrocompetent.                4-  Kan: Kanamycin. 
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3.3.1 Construction of mutant and revertant BACs  
To overcome the problem of heterogeneity of the M27 and M36 ORFs in all 
examined tsm5 stocks and the presence of both mutant and wt bases represented with 
double peaks at base position 32,302 and 49,108 respectively, a cosmid library of tsm5 that 
had been generated previously in our labo (Sweet et al., 2007) was examined. Sequencing 
of cosmid H that represents the region nt 29970-nt71089 confirmed that both mutations of 
interest for the M27 and M36 ORFs were present (Figure 3.4 & Figure 3.5). Cosmid H was 
then used as a template for generation of mutated linear DNA for each of these two genes to 
be used for construction of Mt[M27
A658S
], Mt[M36
V54I
]  and Mt[M27
A658S
 M36
V54I
] 
mutant BACs. 
 
 
Figure  3.4: The sequence profile of region of interest in the M27 gene in Cosmid H 
showing the presence of the mutation.  
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Figure  3.5: The sequence profile of region of interest in the M36 gene in Cosmid H 
showing the presence of the mutation.  
Mutated linear DNA fragments for the m139, m141, and m143 genes were 
generated from the  tsm5 (27/07/2004) stock as the stock contained the mutated nucleotide 
for all 3 genes (Figure 3.6).  The generated mutated linear DNA for each of these three 
genes was then used to construct Mt[m139
Y565X
], Mt[m141
V195M
]  and Mt[m143
M232I
] 
mutant BACs. 
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Figure  3.6 Sequence profile of A; m139, B; m141and C; m143 mutations in the tsm5 
(27/07/2004) stock showing: a G to T; base substitution in m139 and a C to T base 
substitution in both the m141 and m143 genes. 
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In the first mutagenesis step, a fragment of about 500 bp of the gene of interest 
spanning the position of the potential mutation was replaced with a linear DNA fragment 
(1,320 bp) derived from the RpsL-neo cassette by PCR; this fragment contains a kanamycin 
resistance and streptomycin sensitivity cassette flanked with sequences of 51-52 
nucleotides homologous to each end of the target gene locus of the K181 (Perth) BAC 
(Section 2.7). This cassette was PCR amplified using ET M27F+R, ET M36F+R, ET 
m139F+R, ET m141F+R and ET m143F+R primers with the flanking 52 bases (Table 3.4) 
for M27, M36, m139, m141 and m143 respectively.  
Table  3.4: Primers used for amplification of RpsL-neo cassette. 
 
ORF 
RpsL-neo cassette amplification 
primers (1,320 bp) 
RpsL-neo cassette 
replacing the 
segment at position 
Replaced 
segment 
size (bp) 
Construct 
designated name 
Forward primer Reverse primer Start End 
M27* ET M27F ET M27R 31989 32559 570 M27 RpsL-neo 
M36* ET M36F ET M36R 48819 49359 540 M36 RpsL-neo 
m139 ET m139F ET m139R 194089 194641 552 m139 RpsL-neo 
m141 ET m141F ET m141R 198459 198961 502 m141 RpsL-neo 
m143 ET m143F ET m143R 201671 202151 480 m143 RpsL-neo 
* M27 and M36 mutations were introduced into constructs both individually and together. 
Following insertion of RpsL-neo cassette into the target genes of the wild type 
BACs, bacterial isolates with BACs containing the RpsL-neo cassette were then selected 
based on their resistance to kanamycin and streptomycin sensitivity phenotype. The isolates 
were then PCR screened for RpsL-neo cassette presence using viral genome primers just 
outside the flanking arms at both ends. Because the RpsL-neo cassette is ~800 bp bigger 
than the replaced viral gene fragment, a larger PCR product obtained using primers 
flanking the insertion site would indicate an RpsL-neo cassette insertion (Figure 3.7).  
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Figure  3.7 PCR screening of the rpsL-neo cassette insertion into the MCMV BAC using 
primers outside the recombination region.  A. schematic diagram showing the difference in 
the expected product size before and after insertion or replacement of RpsL-neo cassette 
using primers outside the recombination region.  B; PCR screening of 12 different isolates 
for replacement of the wild-type region of m141 gene segment with the RpsL-neo cassette 
in the gene of interest giving PCR products that are about 800 bp larger than the PCR 
products from the wt K181 BAC [(-)ve]. Isolates in which the RpsL-neo cassette insertion 
was unsuccessful are indicated by the stars. Lane (+)ve is the RpsL-neo positive control. 
Molecular size markers (lanes M), in kilobases are included. 
 
A thorough PCR examination was then performed for isolates with apparent 
successful RpsL-neo cassette insertion (showing larger bands in the screening PCR) in the 
target gene using four pairs of primers. To confirm the insertion of the RpsL-neo cassette 
into the target gene, two pairs of primers are used where in each pair one primer binds to 
the RpsL-neo cassette and the other to the viral DNA sequence outside the recombination 
region. Another two pairs of primers are used to confirm the absence of the wt K181 BAC 
sequence where in each pair one primer binds to the replaced wt segment sequence and the 
other to the viral DNA sequence outside the recombination region. Positive and negative 
controls were routinely used for each PCR (Figure 3.9 – Figure 3.14). 
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In the second round of mutant construction, the rpsL-neo cassette was replaced with 
a PCR amplified linear fragment containing the desired mutation. The M27 and M36 gene 
linear fragments were amplified from the tsm5 virus cosmid H DNA whereas m139, m141 
and m143 gene fragments were amplified from tsm5 virus stock 27/07/2004 DNA. 
Bacterial isolates showing a streptomycin resistant and kanamycin sensitive phenotype (as a 
result of losing the RpsL-neo cassette) were selected and BACs extracted for PCR 
screening and analysis. Constructs with the desired mutations were designated as 
mt[M27
A658S
], mt[M36
V54I
] , mt[M27
A658S
M36
V54I
]  mt[m139
Y565X
], mt[m141
V195M
]  and 
mt[m143
M232I
] BACs.     
3.3.2 PCR analysis and sequence confirmation of mutant constructs 
PCR screening of recombinant BACs with the rpsL-neo cassette replaced by the 
M27, M36, m139, m141, or m143 mutated gene fragments, respectively, was performed 
using primer sets outside the flanking arm of the RpsL-neo cassette (Figure 3.8A). Primers 
M27F5+RD, M36F2+R, m139F3+R1, m141 F1+R1 and m143 F1+R1 were used for 
generation of the linear mutated segments of viral DNA giving a PCR products of 819, 
1153, 904, 761, and 727 bp respectively. Following proper recombination, the sizes of the 
PCR products indicated the replacement of the rpsL-neo cassette (~1500 bp) with the 
correct viral sequence (Figure 3.8B). 
To confirm the replacement of the RpsL-neo cassette in the target gene with the 
linear mutated segments of viral DNA, two pairs of primers are used where one primer of  
each pair binds to the inserted linear mutated viral DNA segment  and the other to the viral 
DNA sequence outside the recombination region. Another two pairs of primers are used to 
confirm the absence of the RpsL-neo cassette sequence where one primer of each pair binds 
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to the replaced RpsL-neo cassette sequence and the other to the viral DNA sequence 
outside the recombination region. Positive and negative controls were routinely used for 
each PCR (Figure 3.9 - Figure 3.14). 
Furthermore, each gene manipulated by mutagenesis of these BACs was sequenced 
to ensure the presence of the desire mutation in each manipulated gene. Sequence studies of 
mt[M27
A658S
], mt[M36
V54I
], mt[m139
Y565X
], mt[m141
V195M
]  and mt[m143
M232I
] BACs 
confirmed the presence of mutations at base position 32,302 (C to A), 49,108 (C to T), 
194,402 (G to T), 198,731 (C to T) and 201,944 (C to T) respectively (Figure 3.10 – Figure 
3.14). 
 
 
Figure  3.8. PCR screening for the RpsL-neo cassette replacement with the mutated linear 
DNA segment in the MCMV BAC using primers outside the recombination region.  A. 
Schematic representation of the primer binding sites. ha – homology arms. B; PCR 
screening of 7 different isolates for replacement of RpsL-neo cassette in the  m141 gene 
segment with MCMV sequence containing the desired mutation which gives PCR products 
that are about 800 bp smaller than the PCR products from the RpsL-neo cassette [(-)ve]. 
Lane (+)ve is MCMV segment positive control and (C) is a negative control (PCR with no 
DNA). Lanes M contain molecular size markers (in kilobases).  
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Figure  3.9 Schematic representation of the detailed PCR analysis and the primer binding 
sites in the manipulated gene. K181 Perth sequence primers (a+b and c+d) are used in the 
1
st
 and 2
nd
 PCR reaction that will give products in the presence of wt K181 (Perth) or 
mutated sequence in the region of the gene of interest,  whereas after replacement of the wt 
K181 (Perth) sequence with the RpsL-neo cassette these combinations of primers do not 
give any products. Primer combinations (a+e and f+d) are used in the 3
rd
 and 4
th
 PCR to 
verify the successful insertion of RpsL-neo cassette in the gene of interest (agarose gel 
images are shown in the subsequent figures). 
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Figure  3.10 Mt[M27
A658S
] construction. A. Shows the detailed PCR analysis (Figure 3.9) 
and the steps for the M27 mutant construction starting with the wt K181 (Perth) BAC, M27 
RpsL-neo cassette (insertion of the RpsL-neo cassette), Mt[M27
A658S
] (replacement of the 
RpsL-neo cassette with the mutated M27 ORF) using M27 specific primers in the 1
st
 and 
2
nd
 PCR reactions, and RpsL-neo specific primers in the 3
rd
 and 4
th
 PCR reactions. Lanes 
M contain molecular size markers (in kilobases). B. The sequence profile of the M27 gene 
in Mt[M27
A658S
]showing that the mutation of interest (C to A) has been inserted at base 
position 32,302 of the K181 (Perth) BAC. 
 
 
 
Chapter 3: Results (Section III) 
131 
 
 
 
 
 
 
 
 
 
 
Figure  3.11 Mt[M36
V54I
]  construction. A. Shows the detailed PCR analysis (Figure 3.9) 
and the steps for the M36 mutant construction starting with the wt K181 (Perth) BAC, M36 
RpsL-neo cassette (insertion of the RpsL-neo cassette), Mt[M36
V54I
]  (replacement of the 
RpsL-neo cassette with the mutated M36 ORF) using M36 specific primers in the 1
st
 and 
2
nd
 PCR reactions, and RpsL-neo specific primers in the 3
rd
 and 4
th
 PCR reactions. Lanes 
M contain molecular size markers (in kilobases). B. The sequence profile of the M36 gene 
in Mt[M36
V54I
]  showing that the mutation of interest (C to T) has been inserted at base 
position 49,108 of the K181 (Perth) BAC. 
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Figure  3.12 Mt[m139
Y565X
] construction. A. Shows the detailed PCR analysis (Figure 3.9) 
and the steps for the m139 mutant construction starting with the wt K181 (Perth) BAC, 
m139 RpsL-neo cassette (insertion of the RpsL-neo cassette), Mt[m139
Y565X
] (replacement 
of the RpsL-neo cassette with the mutated m139 ORF) using m139 specific primers in the 
1
st
 and 2
nd
 PCR reactions, and RpsL-neo specific primers in the 3
rd
 and 4
th
 PCR reactions. 
Lanes M contain molecular size markers (in kilobases). B. The sequence profile of the 
m139 gene in Mt[m139
Y565X
] showing that the mutation of interest (G to T) has been 
inserted at base position 194,402 of the K181 (Perth) BAC.  
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Figure  3.13 Mt[m141
V195M
] construction. A. Shows the detailed PCR analysis (Figure 3.9) 
and the steps for the m141 mutant construction starting with the wt K181 (Perth) BAC, 
m141 RpsL-neo cassette (insertion of the RpsL-neo cassette), Mt[m141
V195M
] (replacement 
of the RpsL-neo cassette with the mutated m141 ORF) using m141 specific primers in the 
1
st
 and 2
nd
 PCR reactions, and RpsL-neo specific primers in the 3
rd
 and 4
th
 PCR reactions. 
Lanes M contain molecular size markers (in kilobases). B. The sequence profile of the 
m141 gene in Mt[m141
V195M
] showing that the mutation of interest (C to T) has been 
inserted at base position 198,731 of the K181 (Perth) BAC. 
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Figure  3.14 Mt[m143
M232I
]  construction. A. Shows the detailed PCR analysis (Figure 3.9) 
and the steps for the m143 mutant construction starting with the wt K181 (Perth) BAC, 
m143 RpsL-neo cassette (insertion of the RpsL-neo cassette), Mt[m143
M232I
] (replacement 
of the RpsL-neo cassette with the mutated m143 ORF) using m143 specific primers in the 
1
st
 and 2
nd
 PCR reactions, and RpsL-neo specific primers in the 3
rd
 and 4
th
 PCR reactions. 
Lanes M contain molecular size markers (in kilobases). B. The sequence profile of the 
m143 gene in Mt[m143
M232I
]  showing that the mutation of interest (C to T) has been 
inserted at base position 201,944 of the K181 (Perth) BAC.  
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3.3.3 Double mutant construction 
Early in our study, we decided to study the impact of the presence of two mutations 
present in tsm5 in two immune evasion genes M27
A658S
 and M36
V54I
, in one construct. 
Starting from the construct in which the single mutation (C to A at nt 32,302) had been 
introduced into the M27 gene (mt[M27
A658S
]), a C to T mutation  at position 49,108 of the 
wt K181 (Perth)  BAC was then introduced into the M36 gene by two-step homologous 
recombination as described above. The resultant double mutant BAC construct was 
designated as mt[M27
A658S
M36
V54I
].  The BAC construct was carefully checked by PCR 
and sequencing as described above (data not shown). 
3.3.4 Revertants construction 
Revertants of the MCMV mutants were constructed to ensure that the phenotypic 
properties of the constructed mutants were attributed to the mutations not to other factors or 
mistakes during their construction. In a similar way, the revertants were constructed using 
the two-step homologous recombination technique as described above, starting with the 
mutant construct in which the mutated segment was replaced with the RpsL-neo cassette 
which was in turn replaced with the wt linear DNA amplified form the wt K181(Perth) 
BAC. Revertants for each single mutation underwent four rounds of homologous 
recombination whereas the double revertant for the double mutant underwent six rounds. 
The BAC constructs of each stage of mutagenesis were thoroughly checked and analysed 
by PCR and sequencing as described above (data not shown). The revertant constructs were 
designated as Rv[M27
S658A
], Rv[M36
I54V
], Rv[M27
S658A
M36
I54V
] Rv[m139
X565Y
], 
Rv[m141
M195V
]  and Rv[m143
I232M
]. 
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3.3.5 Restriction fragment length polymorphism (RFLP) analysis 
During the construction of the mutants and their revertants it is possible that 
deletions, insertions or gene re-arrangements may occur. RFLP is widely used to exclude 
these possibilities during the recombineering process (Redwood et al., 2005; Yu et al., 
2002). 
Due to the difficulties in separating big fragments (>10 kbp) and visualisation of 
small fragments (<1 kbp) on the gel, a complete picture of the whole genome restriction 
fragment digestion pattern is not usually achievable using one restriction enzyme only. 
Thus, using several restriction enzymes gives a better coverage of the genome. In the 
present study, RFLP analyses were performed on the wt K181 (Perth) BAC as well as the 
constructed mutant and revertant BACs using two or more of six different restriction 
enzymes (HpaI, EcoRI, AseI DraI, HindIII and BamHI) to ensure that no rearrangements 
had occurred anywhere in the whole BAC. 
 BAC DNA of wt K181 (Perth), mutants and revertants were purified from bacterial 
cultures (Section 2.5.3.2) and digested with HpaI, EcoRI, AseI and DraI restriction 
enzymes (Section 2.5.8). The digests were then separated on a 0.4% agarose gel and 
analysed (Section 2.5.9). The K181 Perth BAC RFLP pattern was first compared to the 
theoretical RFLP pattern of the K181 Perth BAC (sequence provided by Dr Alec Redwood, 
University of Western Australia, Australia) generated by the Vector NTI Advance™ 11 
programme (Invitrogen, Paisley, UK). The analysis showed that the size and number of the 
restriction fragments distinguishable on the gels were consistent with the theoretical 
digestion patterns (Figure 3.15- Figure 3.18).  
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Recombinant  mutants and revertants RFLPs were then compared to that of the K181 
(Perth) BAC where results showed that there were no genome rearrangements in either of 
the recombinant BACs compared to the wt BAC digested with HpaI, AseI, DraI, BamHI or 
EcoRI enzyme (Figure 3.19- Figure 3.26).  Therefore, the RFLP patterns obtained in this 
study for the constructed BACs were indistinguishable from that of both the experimental 
and theoretical RFLP patterns of the wt K181 (Perth) BAC. 
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Figure  3.15 Comparison of the experimental and the expected theoretical RFLP patterns of 
the K181 Perth BAC digested with DraI. The experimental RFLP pattern was compared to 
the theoretical RFLP pattern generated by the Vector NTI Advance™ 11 programme. The 
exact coordinates of the fragments according to the K181 BAC genome sequence provided 
by Dr Alec Redwood and the fragment sizes are shown in the Figure. The restriction 
fragments present on the gel and the corresponding range of the theoretical restriction 
fragments are enclosed by the red boxes. Molecular size markers (lanes M), in kilobases, 
are indicated. 
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Figure  3.16 Comparison of the experimental and the expected theoretical RFLP patterns of 
the K181 Perth BAC digested with AseI. The experimental RFLP pattern was compared to 
the theoretical RFLP pattern generated by the Vector NTI Advance™ 11 programme. The 
exact coordinates of the fragments according to the K181 BAC genome sequence provided 
by Dr Alec Redwood and the fragment sizes are shown in the Figure. The restriction 
fragments present on the gel and the corresponding range of the theoretical restriction 
fragments are enclosed by the red boxes. Molecular size markers (lanes M), in kilobases, 
are indicated. 
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Figure  3.17 Comparison of the experimental and the expected theoretical RFLP patterns of 
the K181 Perth BAC digested with HpaI. The experimental RFLP pattern was compared to 
the theoretical RFLP pattern generated by the Vector NTI Advance™ 11 programme. The 
exact coordinates of the fragments according to the K181 BAC genome sequence provided 
by Dr Alec Redwood and the fragment sizes are shown in the Figure. The restriction 
fragments present on the gel and the corresponding range of the theoretical restriction 
fragments are enclosed by the red boxes. Molecular size markers (lanes M), in kilobases, 
are indicated. 
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Figure  3.18 Comparison of the experimental and the expected theoretical RFLP patterns of 
the K181 Perth BAC digested with EcoRI. The experimental RFLP pattern was compared 
to the theoretical RFLP pattern generated by the Vector NTI Advance™ 11 programme. 
The exact coordinates of the fragments according to the K181 BAC genome sequence 
provided by Dr Alec Redwood and the fragment sizes are shown in the Figure. The 
restriction fragments present on the gel and the corresponding range of the theoretical 
restriction fragments are enclosed by the red boxes. Molecular size markers (lanes M), in 
kilobases, are indicated. 
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Figure  3.19: RFLP analysis of recombinant MCMV BAC genomes using DraI and AseI 
restriction enzyme digestion. wt K181 (Perth) and M27 and M36 mutant and revertant BAC 
DNA (~2 µg) was digested with 1 µl of DraI or AseI restriction enzyme and the resulting 
fragments were separated on a 0.4% agarose gel for ~19 hours at 2 V/cm. Molecular size 
markers (lanes M), in kilobases, are indicated. 
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Figure  3.20: RFLP analysis of recombinant MCMV BAC genomes using HpaI restriction 
enzyme digestion. wt K181 (Perth) and M27 and M36 mutant and revertant BAC DNA (~2 
µg) was digested with 1 µl of  HpaI restriction enzyme and the resulting fragments were 
separated on a 0.4% agarose gel for ~19 hours at 2 V/cm. Molecular size markers (lanes 
M), in kilobases, are indicated. 
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Figure  3.21: RFLP analysis of recombinant MCMV BAC genomes using EcoRI and DraI 
restriction enzyme digestion. wt K181 (Perth) and m139 mutant and revertant BAC DNA 
(~2 µg) was digested with 1 µl of EcoRI or DraI restriction enzyme and the resulting 
fragments were separated on a 0.4% agarose gel for ~19 hours at 2 V/cm. Molecular size 
markers (lanes M), in kilobases, are indicated. 
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Figure  3.22: RFLP analysis of recombinant MCMV BAC genomes using AseI and HpaI 
restriction enzymes digestion. wt K181 (Perth) and m139 mutant and revertant BAC DNA (~2 
µg) was digested with 1 µl of AseI or HpaI restriction enzyme and the resulting fragments were 
separated on a 0.4% agarose gel for ~19 hours at 2 V/cm. Molecular size markers (lanes M), in 
kilobases, are indicated. 
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Figure  3.23: RFLP analysis of recombinant MCMV BAC genomes using EcoRI restriction 
enzyme digestion. wt K181 (Perth) and m141 and m143 mutant and revertant BAC DNA 
(~2 µg) was digested with 1 µl of EcoRI restriction enzyme and the resulting fragments 
were separated on a 0.4% agarose gel for ~19 hours at 2 V/cm. Molecular size markers 
(lanes M), in kilobases, are indicated. 
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Figure  3.24: RFLP analysis of recombinant MCMV BAC genomes using DraI restriction 
enzyme digestion. wt K181 (Perth) and mm141 and m143 mutant and revertant BAC DNA 
(~2 µg) was digested with 1 µl of DraI restriction enzyme and the resulting fragments were 
separated on a 0.4% agarose gel for ~19 hours at 2 V/cm. Molecular size markers (lanes 
M), in kilobases, are indicated. 
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Figure  3.25: RFLP analysis of recombinant MCMV BAC genomes using AseI restriction enzyme 
digestion. wt K181 (Perth) and m141 and m143 mutant and revertant BAC DNA (~2 µg) was 
digested with 1 µl of AseI restriction enzyme and the resulting fragments were separated on 
a 0.4% agarose gel for ~19 hours at 2 V/cm. Molecular size markers (lanes M), in 
kilobases, are indicated. 
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Figure  3.26: RFLP analysis of recombinant MCMV BAC genomes using HpaI restriction enzyme 
digestion. wt K181 (Perth) and m141 and m143 mutant and revertant BAC DNA (~2 µg) was 
digested with 1 µl of HpaI  restriction enzyme and the resulting fragments were separated 
on a 0.4% agarose gel for ~19 hours at 2 V/cm. Molecular size markers (lanes M), in 
kilobases, are indicated. 
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3.3.6 Virus reconstitution  
Recombinant (mutant and revertant) as well as the wt MCMV viruses were 
reconstituted by transfection of the corresponding BACs into permissive eukaryotic cells 
(NIH 3T3). For BAC cassette excision, BAC-derived viruses were further passaged in cell 
culture to allow the recombination via repeated sequences flanking the BAC cassette of the 
viral genome. Excision of the BACs was confirmed by PCR. The mutations introduced into 
the targeted genes of the recombinant viruses were sequenced to confirm the presence of 
mutations by sequencing.    
3.3.6.1 Transfection of recombinant BACs 
NIH 3T3 cells were transfected with the recombinant mutants, revertants or wt BAC 
DNA [extracted as described in (Section 2.5.3.2)], using ExGen500 transfection reagent 
(Section 2.3.1). Successful transfection was detected and monitored by expression of green 
fluorescent protein (GFP) encoded by the gfp gene of the BAC cassette (Figure 3.50 on 
page 198) (Redwood et al., 2005). Viral plaques were detected under the inverted 
microscope 3-6 days post infection. A 100% CPE was observed 4-5 days after detection of 
the first plaques, at which point virus was harvested (Section 2.3.3). 
3.3.6.2 BAC cassette excision  
The K181 (Perth) BAC is flanked with repeat sequences. Following transfection of 
the BAC into permissive eukaryotic cells, viral packaging restrictions preferentially lead to 
homologous recombination between the repeat sequences resulting in the exclusion of the 
BAC cassette (Redwood et al., 2005; Wagner et al., 1999). 
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 Virus progeny obtained from the transfection were plaque purified on NIH 3T3 
and/or MEF cells. After passage of the reconstituted virus in these cells, the excision of the 
BAC which can be monitored by loss of GFP expression and confirmed by PCR. Although 
GFP expression is usually lost within 3-4 passages where the green florescence can not be 
detected under the florescence microscope, BAC excision can be confirmed only by PCR.  
BAC excision needs up to 10 passages to be achieved.   
The presence of the BAC cassette in the genome of the reconstituted viruses is 
detected using ARK2514832F and ARK2515204R primers (Table 3.2) which bind within 
the gpt gene of the BAC cassette (Figure 3.27A) to yield a PCR product of 413 bp. Primers 
m06F and 6530R bind to the viral sequence flanking the BAC cassette (Figure 3.27A). 
BAC cassette excision can be determined using m06F and 6530R primers which they will 
produce a PCR fragment of 1,245 bp. If the BAC is still preset, the PCR product of 10,391 
bp would be amplified, but the PCR conditions used did not allow the amplification of 
10,391 bp product (short extension time).  
 PCR analysis of the BAC cassette excision was performed using DNA isolated from 
cells collected after transfection and each passage of the virus. PCR analysis of the BAC 
cassette excision from the Mt[M27
A658S
] virus genome is shown as a representative 
example in Figure 3.27B. Complete BAC cassette excision was usually achieved after at 
least five passages. Although a study in our lab (thesis of Dr. Olga Timoshenko) showed 
that presence of BAC in the reconstituted virus has no impact of the presence of the BAC 
on viral replication in vitro.  In general, all viruses produced in this study were passaged 
until BAC cassette excisions were confirmed by PCR.  Seed stocks of the reconstituted 
viruses were produced from the last passages showing the excision of BACs (Section 
2.3.3).  
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Figure  3.27: PCR screening of the BAC cassette excision from the viral genome 
reconstituted from the BAC plasmid. A. Schematic representation showing the structural 
organisation of the MCMV K181 (Perth) genomes before and following BAC cassette 
excision and primer binding sites. The red arrows indicates the repeated sequences flanking 
the BAC. B. PCR analysis of the BAC cassette excision from the Mt[M27A658S] BAC-
derived virus. The PCR product of 1,245 bp (lanes 1) amplified with primers a (m06F) and 
b (6530R) indicated the excision of the BAC cassette from viral genomes apparent already 
in passage No. 1 (P1). The PCR product of 413 bp (lanes 2) amplified with primers c 
(ARK2514832F) and d (ARK2515204R) indicated the BAC cassette is still presence in 
some viral genomes up to P4. No product of 413 bp in P5 of the virus indicated the 
complete loss of the BAC cassette in all virus progeny. PCR conditions did not allow the 
amplification of a product of 10,391 bp using primers a and b from viral genome containing 
the BAC cassette. K181 Perth BAC and wt K181 (Perth) virus DNA were used as controls 
to amplify 413 and 1,245 bp products, respectively. Lanes M contain molecular size 
markers (in kilobases). 
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3.4 Characterisation of recombinant viruses phenotypes 
To determine the effects of the various mutations inserted in the wt virus on the 
growth phenotype in vitro, each of the constructed mutant and revertant virus growth 
phenotypes was studied and compared to the wild-type MCMV-K181 strain (Birmingham 
and Perth variants) at both permissive (37º C) and non-permissive (40º C) temperatures. 
The growth rates of the constructed viruses as well as the wt virus were studied on MEF 
cells (Section 2.3.6) and on mouse macrophage cell line (Section 2.3.7). For growth 
characterization on MEF cells, the cells were seeded in three wells of the 24 well plates (0.5 
x 10
5
 cell/well) then infected with one of the viruses at an MOI of 0.05 (Section 2.3.6). 
Whereas for growth characterization on murine macrophage cells, the cells were seeded in 
three wells of the 24 well plates (3.5 x 10
5
 cell/well) then infected with one of the viruses at 
an MOI of 0.1 (Section 2.3.7). One hour post infection, supernatants from each well of the 
infected MEF cells and macrophages were collected and assigned as day 0 and replaced 
with 1 ml GM1 or GM2 respectively. Every 24 hours the supernatants were collected and 
replaced with suitable fresh GM for up to seven days. Collected samples were stored at -
80°C until titrated on MEF cells by plaque assay (Section 2.3.5).  The growth rates of all 
viruses were performed and assayed in triplicate. 
3.4.1 Characterisation of virus phenotype on MEF cells 
3.4.1.1 Replication of the wt MCMV K181 strains 
The MCMV K181 strain was developed from the Smith strain by serial passages in 
mouse salivary glands by Dr J. Osborn (Department of Medical Microbiology, University 
of Wisconsin, Madison, Wis., USA) (called Osborn strain) and described as a virulent 
variant of the Smith strain which later became designated as the K181 strain (Mims & 
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Gould, 1979; Smith et al., 2008). The K181 strain of MCMV we are studying in our 
laboratory was obtained from Professor C. A. Mims (Department of Microbiology, United 
Medical and Dental Schools of Guy's and St. Thomas' Hospitals, Guy's Campus, London 
Bridge, UK) and designated as the MCMV K181 (Birmingham) variant. The K181 (Perth) 
variant was originally considered to be the Smith strain but later was shown to have a 
restriction pattern identical to that of the K181 strain (Hudson et al., 1988). Both 
Birmingham and Perth variants of K181 may have originated from the same source, the 
Osborn strain, however passaging these K181 variants in different laboratories has resulted 
in a few nucleotide variations between the two variants as described in section 3.2.1 
(Timoshenko et al., 2009a).  
The MCMV tsm5 virus was obtained following chemical mutagenesis of the wt 
MCMV K181 (Birmingham) variant which has not been cloned as a BAC to be used for 
mutant construction (Sammons & Sweet, 1989). However, both the mutants and their 
corresponding revertants were to be constructed using the BAC cloned MCMV K181 
(Perth) variant. Thus, it was important to show that their growth characteristics were 
similar. 
The growth kinetics of both viruses was very similar at 37°C (Figure 3.28 ) where 
the viruses were first detected on day 2 post infection and their yields increased rapidly 
reaching the maximum yield of ~10
5.9
 PFU/ml on day 6 and 7 post infection. No significant 
differences between K181 Perth and Birmingham virus yields were identified from 3 to 7 
days post infection (p>0.05).  
 At 40°C, the growth kinetics of both viruses was also very similar (Figure 3.28).  
Virus yields were first detected on day 1 post infection, then they increased rapidly 
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reaching the maximum level of 10
3.7 
PFU/ml (K181 Birmingham) and 10
3.9 
PFU/ml (K181 
Perth) on days 4-5 post infection. Statistical analysis showed that there were no differences 
between yields of the two viruses at any time point (p>0.05). The yields of both viruses 
were approximately 10-30 times lower at 40°C compared to those at 37°C (p<0.05).  
 
 
Figure  3.28: Replication of K181 (Birmingham) and K181 (Perth) variant viruses at the 
permissive (37°C) and non-permissive (40°C) temperatures. MEF cells were infected with 
virus at an MOI of 0.05 PFU per cell and incubated at either 37°C or 40°C. Virus titres 
(log10 pfu/ml) were determined in cell culture supernatants 1-7 days post infection by 
plaque assay. Results are the mean ± standard deviation (SD) of two separate experiments, 
each with three replicates. The limit of detection is 0.7 log10 PFU/ml. 
 
Growth curves at both permissive and non-permissive temperature revealed that the 
growth kinetics of both K181 (Perth) and K181 (Birmingham) viruses were very similar. 
Therefore, introducing the tsm5-specific mutations into the K181 (Perth) genome and 
assaying their phenotype in the K181 (Perth) background, rather than in K181 
(Birmingham) background, is justified. 
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3.4.1.2 Characterisation of tsm5 phenotype in MEF cells 
The growth kinetics of tsm5 was studied previously in our laboratory using one-step 
growth curves in which it was shown that tsm5 yields in MEFs at the permissive (33°C or 
37°C) and non-permissive (40°C) temperatures was reduced by approximately 10-fold and 
1000-fold, respectively, on day 5 post infection compared to that of the parent K181 
(Birmingham) virus (Karen Ball, PhD thesis, University of Birmingham, UK, 2005). 
Furthermore, a detailed study of the tsm5 phenotype in MEFs using multi-step growth 
curves at 33°C and 41°C showed that virus was not detectable in cell culture supernatants 
until day 4 (33°C) or day 5 (41°C) post infection (Sweet et al., 2007).  
 In the current study, replication of tsm5 was examined under multi-step growth 
conditions at 37°C, 40°C, and 40.5°C in order to confirm its temperature-sensitive (ts) 
phenotype and possibly clarify the role of the M27, M36, m139, m141, and m143 ORFs,  in 
this phenotype.  At 37°C, the replication kinetics of tsm5 virus was similar to that of K181 
(Birmingham) variant (Figure 3.29). Both viruses were first detected in cell culture 
supernatants on day 2 post infection and reached maximum levels on days 4 and 5 post 
infection. Maximum yields of the K181 (Birmingham) variant and tsm5 were ~10
6.00
 
PFU/ml and 10
5.9
 PFU/ml, respectively. No significant differences were identified between 
yields of the two viruses from days 2 to 8 post infection (p>0.05).  
 At 40°C, tsm5 produced higher overall virus yields than those observed in previous 
studies (Figure 3.29A), (Sweet et al., 2007). Virus was first detected on day 2 post infection 
(~10
1.0
 PFU/ml). It increased rapidly to reach its maximum on day 5 post infection (10
2.2
 
PFU/ml). The yields of tsm5 were about 2.6-7.5 times lower than that of wt virus from 3 to 
7 days post infection (p<0.05). 
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Replication of the Perth variant was similar to that of the Birmingham variant at 
both 37
o
C and 40.5
o
C (Figure 3.29B). Again replication of tsm5 was impaired at 40.5°C 
where the virus could not be detected until day 6 compared to the wt virus which was first 
detectable at day 2 (Figure 3.29B). Tsm5 only reached yields of ~10
1.0
 PFU/ml  by days 6 
and 7 post infection compared to the wt K181 (Perth) variant that reached its maximum 
yields on day 6 post infection of ~10
3.0
 PFU/ml. The yields of tsm5 were about 25-60 times 
lower than that of wt virus from 3 to 7 days post infection (p<0.05). Although replication of 
mutant tsm5 was not identical to that observed previously, it is still clearly ts and the 
differences probably reflect the differences between stocks in the polymorphic viruses 
present within them (Section 3.1) 
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Figure  3.29: Replication of tsm5 virus compared to wt K181 (Birmingham) and K181 
(Perth) viruses at the permissive (37°) and non-permissive (40 or 40.5°C) temperatures. 
MEF cells were infected with virus at an MOI of 0.05 PFU per cell and incubated at 37°C 
and 40oC (A) or 37oC and 40.5°C (B). Viral titres were determined in cell culture 
supernatants 1-7 days post infection by plaque assay. Results are the mean ± SD of three 
replicates at each time point for the wt K181 (Birmingham) [A] or K181 (Perth) [B] and 
tsm5 [A, B]. The limit of detection is 0.7 log10 PFU/ml. 
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3.4.1.3 Replication of mutant Mt[M70C890Y] virus 
As previously shown in Section 3.1.1, the tsm5 stock 27/07/2004 virus used in this 
study was heterogeneous in some genes including the aforementioned loci of the M27, M70 
and M98 genes (Table 3.1) In addition, from the above it was clear that tsm5 no longer 
represented a good control virus for studies of temperature-sensitivity as virus stocks 
varied.  A study in this laboratory, in which a mutation was introduced into the  M70 gene 
(Timoshenko et al., 2009b) and resulted in a temperature sensitive recombinant virus 
(Mt[M70
C890Y
]), produced a cloned ts virus and this  was used in the current study as the 
temperature sensitive control.   
At 37°C, the replication kinetics of mutant Mt[M70
C890Y
] was similar to that of 
K181 (Perth) (Figure 3.30). Both viruses were first detected in cell culture supernatants on 
day 2 post infection and reached maximum levels on day 5 post infection. Maximum yields 
of Mt[M70
C890Y
] were ~10
5.00
 PFU/ml. No significant differences were identified between 
yields of the two viruses from days 3 to 8 post infection (p>0.05).  
Mutant Mt[M70
C890Y
] produced significantly lower virus yields at 40°C (Figure 
3.30A). Virus was first detected on day 3 post infection (~10
1.0
 PFU/ml), yields increasing 
slowly to reach maximum on day 5 post infection (10
1.5
 PFU/ml). Yields of Mt[M70
C890Y
]  
were about 200-300 fold times lower than those of wt virus from 3 to 7 days post infection 
(p<0.05). The mutant Mt[M70
C890Y
] virus was even more impaired for growth at 40.5°C 
where no virus could be detected from days 1-7  post infection  compared to the wt virus, 
which was detectable at day 2 and reached maximum yields of 10
2.9 
PFU/ml by day 6 post 
infection (Figure 3.30B).  In conclusion, the M70 mutant was more affected at the non-
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permissive  temperature than tsm5, which can be attributed to the presence of wt and 
mutated forms of the genes in tsm5 virus stock populations. 
 
 
 
Figure  3.30: Replication of Mt[M70
C890Y
] virus compared to wt K181 (Perth) virus. Viral 
titres were determined in cell culture supernatants 1-7 days post infection at 37oC and 40oC 
[A] or 37oC and 40.5oC [B]. Results are the mean ± SD of three replicates for K181 (Perth) 
and mutant Mt[M70
C890Y
] viruses. The limit of detection is 0.7 log10 PFU/ml. 
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3.4.1.4 Replication of mutant Mt[M27A658S], Mt[M36V54I]  and Mt[M27A658SM36V54I]  
viruses 
The replication pattern of the mutant Mt[M27
A658S
], Mt[M36
V54I
] and 
Mt[M27
A658S
M36
V54I
] viruses at 37°C were very similar to that of their revertants Rv[M27
 
S658A
], Rv[M36
I54V
] and Rv[M27
S658A
M36
I54V
] respectively and to the wt virus (Figures 
3.31A, 3.32A, and 3.33A ). No significant differences were identified between mutant and 
wt virus yields at any day post infection (p>0.05).  
Also, at 40°C Mt[M27
A658S
] and Mt[M36
V54I
]  as well as their revertants and the wt 
viruses replicated similarly and no significant differences were identified between their 
yields on days 2 to 7 post infection (p>0.05) (Figure 3.31B and 3.33B ). Whereas the 
double mutant virus Mt[M27
A658S
M36
V54I
] was lower than those of its revertant and wt 
virus (Figure 3.33B), but they were higher than those of the ts Mt[M70
C890Y
] virus. 
Statistical analysis of mutant Mt[M27
A658S
M36
V54I
] virus yields for time points days 2 to 7 
showed that virus yields were significantly different from those of its revertant and wt virus 
at each time point (p<0.05). Although virus yields of the double mutant 
Mt[M27
A658S
M36
V54I
] on MEF cells at the permissive temperature (37°C) were similar to 
that of its revertant and wt viruses, the plaque size produced by the double mutant was very 
small compared to wt K181 (Perth), the double revertant Mt[M27
A658S
M36
V54I
] and the 2 
individual single mutants Mt[M27
A658S
], Mt[M36
V54I
] and their revertants (Figure 3.34B).  
Sequence analysis of the double mutant at the end of the growth curve studies revealed that 
there were no changes to the mutations introduced into both M27 and M36 genes at base 
position  32,302 and 49,108 respectively of the published K181 (Perth) sequence (data not 
shown). 
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At day 7 of the growth curves, infected MEF cells were collected, DNA extracted 
and sequenced for analysis of each recombinant virus. The presence of mutations in the 
mutant Mt[M27
A658S
], Mt[M36
V54I
] and Mt[M27
A658S
M36
V54I
] viruses were confirmed 
(data not shown).  
In conclusion, the presence of either M27 (M27
A658S
) or M36 (M36
V54I
) mutations 
separately do not show a phenotype different from wt at either 37°C or 40°C, but presence 
of  both mutations together in one construct Mt[M27
A658S
M36
V54I
] resulted in an attenuated 
phenotype at 40°C and could contribute to the attenuation of tsm5 virus in vitro at 40°C. 
Furthermore, these mutations decreased the ability of virus to spread to surrounding cells or 
the death of infected cells (Figure 3.34). 
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Figure  3.31: Replication of mutant Mt[M27
A658S
] virus compared to its revertant 
Rv[M27
S658A
], wt K181 (Perth) and the ts Mt[M70
C890Y
] viruses at the permissive (37°C) 
and non-permissive (40°C) temperatures. MEF cells were infected with virus at an MOI of 
0.05 PFU per cell and incubated at: [A] 37°C or [B] 40°C. Viral titres were determined in 
cell culture supernatants 1-7 days post infection by plaque assay. Results are the mean ± SD 
of two experiments, each with three replicates. The limit of detection is 0.7 log10 PFU/ml. 
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Figure  3.32: Replication of mutant Mt[M36
V54I
] virus compared to its revertant 
Rv[M36
I54V
], wt K181 (Perth) and the ts Mt[M70
C890Y
] viruses at the permissive (37°C) 
and non-permissive (40°C) temperatures. MEF cells were infected with virus at an MOI of 
0.05 PFU per cell and incubated at: [A] 37°C or [B] 40°C. Viral titres were determined in 
cell culture supernatants 1-7 days post infection by plaque assay. Results are the mean ± 
standard deviation (SD) of two experiments, each with three replicates. 
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Figure  3.33: Replication of the double mutant Mt[M27
A658S
M36
V54I
] virus compared to its 
revertant Rv[M27
S658A
M36
I54V
], wt K181 Perth and the ts Mt[M70
C890Y
] viruses at the 
permissive (37°C) and non-permissive (40°C) temperatures. MEF cells were infected with 
virus at an MOI of 0.05 PFU per cell and incubated at: [A] 37°C or [B] 40°C. Viral titres 
were determined in cell culture supernatants 1-7 days post infection by plaque assay. 
Results are the mean ± standard deviation (SD) of two experiments, each with three 
replicates. 
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Figure  3.34: Plaque size of wt (A), Mt[M27
A658S
M36
V54I
] (B),  Rv[M27
S658A
M36
I54V
] (C), 
Mt[M27
A658S
] (D),  and Mt[M36
V54I
] (E) viruses. The viruses were grown and titrated on 
MEF cells. The images were taken using an inverted microscope attached to a digital 
camera at 60x magnification. 
A B 
C D 
E 
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3.4.1.6 Replication of Mt[m139Y656X], Mt[m141V195M] and Mt[m143M232I] mutant 
viruses 
The replication kinetics of the mutant Mt[m139
Y656X
], Mt[m141
V195M
] and 
Mt[m143
M232I
] viruses at 37°C  and were very similar to that of their revertants Rv[m139
 
X656Y
],  Rv[m141
M195V
] and Rv[m143
I232M
] respectively and to the wt virus (Figures 3.35A, 
3.36A, and 3.37A ). No significant differences were identified between mutant and wt virus 
yields at any day post infection (p>0.05).  
Yields of mutant Mt[m139
 Y656X
] virus at 40°C were lower than that of its revertant 
and wt virus, but  very similar to that of tsm5 (Figure 3.35B). Mutant virus was first 
detected on day 2 post infection; on days 3 and 4 mutant Mt[m139
 Y656X
] virus yields were 
approximately one log lower than those of the revertant and wt viruses. Its yields increased 
gradually and reached the maximum level of 10
3.5 
PFU/ml by day 5 post infection. 
Statistical analysis showed that only the yields of days 3 and 4 were significantly different 
from those of its revertant and wt virus at any time point (p<0.05).  
In contrast, Mt[m141
V195M
] and Mt[m143
M232I
] growth pattern at 40°C (data not 
shown) and 40.5°C were not significantly different (p>0.05) from the revertant and wt virus 
yields (Figure 3.36B and 3.37B). 
In conclusion, the mutation Mt[m139
 Y656X
] virus has a ts phenotype at 40°C and 
therefore it is likely that this mutation also contributes to the attenuation of tsm5 virus in 
vitro at 40°C. Whereas, Mt[m141
V195M
] and Mt[m143
M232I
] appear not to pay a role in the ts 
phenotype of tsm5.   
 
Chapter 3: Results (Section IV) 
168 
 
 
 
Figure  3.35: Replication of mutant Mt[m139
Y656X
] compared to its revertant Rv[m139
 
X656Y
], wt K181 (Perth), the ts mutant Mt[M70
C890Y
] and tsm5 viruses at the permissive 
(37°C) and non-permissive (40°C) temperatures. MEF cells were infected with virus at an 
MOI of 0.05 PFU per cell and incubated at: [A] 37°C or [B] 40°C. Viral titres were 
determined in cell culture supernatants 1-7 days post infection by plaque assay. Results are 
the mean ± standard deviation (SD) of two experiments, each of three replicates. 
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Figure  3.36: Replication of mutant Mt[m141
V195M
] virus compared to its revertant 
Rv[m141
M195V
], wt K181 (Perth) and the ts Mt[M70
C890Y
] viruses at the permissive (37°C) 
and non-permissive (40.5°C) temperatures. MEF cells were infected with virus at an MOI 
of 0.05 PFU per cell and incubated at: [A] 37°C or [B] 40.5°C. Viral titres were determined 
in cell culture supernatants 1-7 days post infection by plaque assay. Results are the mean ± 
standard deviation (SD) of two experiments, each of three replicates. 
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Figure  3.37: Replication of mutant Mt[m143
M232I
] compared to its revertant Rv[m143
I232M
], 
wt K181 (Perth) and the ts Mt[M70
C890Y
] viruses at the permissive (37°C) and non-
permissive (40.5°C) temperatures. MEF cells were infected with virus at an MOI of 0.05 
PFU per cell and incubated at: [A] 37°C or [B] 40.5°C. Viral titres were determined in cell 
culture supernatants 1-7 days post infection by plaque assay. Results are the mean ± 
standard deviation (SD) of two experiments, each of three replicates. 
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3.4.2 Characterisation of virus phenotype on macrophage cell lines: 
M27, M36, m139, m141 and m143 are immunoevasion genes and studies showed 
that are important for virus growth in macrophages (Hanson et al., 1999; Hanson et al., 
2001; Menard et al., 2003). Based on that the growth kinetics of the viruses were also 
studied on the Raw 264.7 macrophage cell line but at 37
o
C only. Initial experiments 
showed that, although the macrophages were viable at 40
o
C, yields were very low or 
undetectable even for wt virus.   
3.4.2.1 Replication of wt MCMV K181 (Perth) 
Raw 264.7 macrophage cell were infected with the wt at an MOI= 0.1 to study its 
growth kinetics. K181 (Perth) virus yields were first detected on day 2 post infection and 
increased rapidly reaching the maximum yield of ~10
7.1
 PFU/ml on day 6 post infection  
(Figure 3.38).  
3.4.2.2 Replication of mutant Mt[M70C890Y] virus 
Unexpectedly mutant Mt[M70
C890Y
] virus replication in Raw  264.7 macrophages 
was impaired at 37
o
C and virus yields were 2-3 logs below those of the wt K181 (Perth) 
virus (Figure 3.38). Mutant Mt[M70
C890Y
] virus yield were first detected on day 2 post 
infection (~10
2.5
 PFU/ml) then gradually increased to reach its maximum yield of ~10
4.6
 
PFU/ml on day 6 post infection.  
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Figure  3.38: Replication of the wt K181 (Perth) and mutant Mt[M70
C890Y
] viruses in Raw 
264.7 macrophages. Macrophages were infected with virus at an MOI of 0.1 PFU per cell 
and incubated at 37°C. Viral titres were determined in cell culture supernatants 1-7 days 
post infection by plaque assay on MEF cells. Results are the mean ± standard deviation 
(SD) of two experiments, each of three replicates. 
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3.4.2.3 Replication of mutant Mt[M27A658S], Mt[M36V54I], Mt[M27A658SM36V54I] 
Mt[m139
Y656X
], Mt[m141
V195M
] and Mt[m143
M232I
] viruses 
 As in MEF cells, the replication of mutant Mt[M27
A658S
], Mt[M36
V54I
], Mt[m139
Y656X
], 
Mt[m141
V195M
] and Mt[m143
M232I
] in Raw 264.7 cells were similar to that of their revertants and the 
K181 (Perth) variant parent viruses (Figure 3.39-3.40 and Figure 3.42-3.44).  
Interestingly, replication of the double mutant Mt[M27
A658S
M36
V54I
] was attenuated in Raw 
264.7 macrophages, compared to its revertant Rv[M27
S658A
M36
 I54V
] virus and the parent wt K181 
(Perth) variant. Initially, the yield of Mt[M27
A658S
M36
V54I
] on day 2 was only slightly lower than 
that of the double revertant, but at later time points the yields  increased at a slower rate reaching a 
maximum of ~10
5.2
 PFU/ml on day 7 compared to maximums of ~10
7.1
 PFU/ml on day 6 for the wt 
virus and 10
6.3 
PFU/ml on day 5 for the revertant virus (Figure 3.41).  The yield of mutant 
Mt[M27
A658S
M36
V54I
] was more than 300 fold lower on day 4 than the wt and more than 150 fold on 
day 5. The replication of the double mutant was statistically similar to that of the M70 mutant 
[MtM70
C890Y
] and statistically lower than both the wt and revertant viruses.  
From this growth pattern, we can conclude that apart of the double mutant 
Mt[M27
A658S
M36
V54I
], all other mutant constructs do not have a phenotype in Raw 264.7 cells. 
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Figure  3.39: Replication of mutant Mt[M27
A658S
] virus compared to its revertant 
Rv[M27
S658 A
], wt K181 (Perth) and Mt[M70
C890Y
] viruses at 37°C. Raw 264.7 macrophage 
cells were infected with virus at an MOI of 0.1 PFU per cell and incubated at 37°C. Viral 
titres were determined in cell supernatants 1-7 days post infection by plaque assay on MEF 
cells. Results are the mean ± standard deviation (SD) of two experiments, each of three 
replicates. 
 
Figure  3.40: Replication of mutant Mt[M36
V54I
] virus compared to its revertant 
Rv[M36
I54V
], wt K181 (Perth) and Mt[M70
C890Y
] viruses at 37°C. Raw 264.7 macrophage 
cells were infected with virus at an MOI of 0.1 PFU per cell and incubated at 37°C. Viral 
titres were determined in cell culture supernatants 1-7 days post infection by plaque assay 
on MEF cells. Results are the mean ± standard deviation (SD) of two experiments, each of 
three replicates. 
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Figure  3.41: Replication of mutant Mt[M27
A658S
M36
V54I
] virus compared to its revertant 
Rv[M27
S658A
M36
 I54V
], wt K181 (Perth) and Mt[M70
C890Y
] viruses at 37°C. Raw 264.7 
macrophage cells were infected with virus at an MOI of 0.1 PFU per cell and incubated at 
37°C. Viral titres were determined in cell culture supernatants 1-7 days post infection by 
plaque assay on MEF cells. Results are the mean ± standard deviation (SD) of two 
experiments, each of three replicates. 
 
 
Figure  3.42: Replication of mutant Mt[m139
Y656X
]  virus compared to its revertant 
Rv[m139
X656Y
], wt K181 (Perth) and Mt[M70
C890Y
] viruses at 37°C. Raw 264.7 
macrophage cells were infected with virus at an MOI of 0.1 PFU per cell and incubated at 
37°C. Viral titres were determined in cell culture supernatants 1-7 days post infection by 
plaque assay on MEF cells. Results are the mean ± standard deviation (SD) of two 
experiments, each of three replicates. 
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Figure  3.43 Replication of Mt[m141
V195M
]   mutant virus compared to its revertant 
Rv[m141
M195V
], wt K181 Perth and Mt[M70
C890Y
] viruses at 37°C. Raw 264.7 macrophage 
cells were infected with virus at an MOI of 0.1 PFU per cell and incubated at 37°C. Viral 
titres were determined in cell supernatants 1-7 days post infection by plaque assays (on 
MEF cells). Results are the mean ± standard deviation (SD) of two experemnets three 
replicates in each. 
 
 
Figure  3.44: Replication of mutant Mt[m143
M232I
]  virus compared to its revertant 
Rv[m143
I232M
], wt K181 (Perth) and Mt[M70
C890Y
] viruses at 37°C. Raw 264.7 
macrophage cells were infected with virus at an MOI of 0.1 PFU per cell and incubated at 
37°C. Viral titres were determined in cell culture supernatants 1-7 days post infection by 
plaque assay on MEF cells. Results are the mean ± standard deviation (SD) of two 
experiments, each of three replicates. 
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3.5 Changing codon preferences in the M70 ORF 
It is believed that large DNA viruses, including herpesviruses, have low mutation 
rates as estimated by methods such as analysis of RFLP or function of individual genes 
(Sakaoka et al., 1994). The high genome stability of MCMV at the single-nucleotide level in 
the absence of obvious selection pressure was also supported by the analysis of MCMV 
using whole genome sequencing that showed that sequence of three sister plaques showed 
only two single-base-pair substitutions after in vitro passage. Furthermore, passage of 
MCMV in the mouse, revealed that mutation rates were also low (Cheng et al., 2010). 
However, other studies have shown that mutations many emerge in both HCMV and MCMV 
as a result of the presence of selective pressure (French et al., 2005; Sanchez et al., 2004). 
Ganciclovir resistance of HCMV in up to 25% of immunosuppressed patients infected with HCMV 
resulted from mutations in the UL97 ORF (Sanchez et al., 2004). 
On the other hand, MCMV has been shown to acquire de novo mutations after in vivo 
passage. Passage of MCMV in mice lacking adaptive immunity but carrying the Cmv1r 
allele, which encodes the Ly49H activation receptor on NK cells, resulted in emergence of 
viruses carrying mutations in the m157 ORF (encoding the only known ligand for Ly49H). 
These mutants were characterized by an increased virulence in naive Cmv1r mice, which 
was attributed to the presence of single amino-acid substitutions or premature stop codons 
(French et al., 2004). The adjacent ORFs (m156 and m158) showed no mutations suggesting 
that mutations emerged under selective pressure (Cheng et al., 2010). 
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A previous study in our laboratory, in which mutations were introduced into the M56, 
M70 and M98 genes by Dr. Olga Timoshenko, showed that a C to T mutation in the M70 
gene at base position 99,286 made the recombinant Mt[M70
C890Y
] virus temperature 
sensitive where virus replication was drastically reduced at 40ºC compared to the parent wt 
K181 (Perth) virus (Timoshenko et al., 2009b). In vivo, the virus was not detectable in the 
salivary glands of BALB/c mice 21 days post infection. From in vitro investigation at 40ºC, 
it was noticed in some experiments that the T mutation at base position 99,286 reverted to 
the wt C.  Astonishingly, in some experiments using a triple mutant (Mt98
324S
70
890Y
56
439R
) 
virus, the codon of the introduced mutation of M70 had mutated from the mutant UAC 
(ATG on the complementary strand) coding tyrosine to UCC (AGG on the complementary 
strand) coding for serine as early as one-day post infection, or more likely during passage of 
the virus to remove the BAC (Timoshenko et al., 2009b). Furthermore, this tyrosine to serine 
mutation was also observed at the permissive temperature (37ºC) (Timoshenko et al., 
2009b).  
According to the genetic code, all amino acids (except methionine and tryptophan) in 
the protein coding sequence can be encoded by more than one synonymous codon (Table 
3.5). The synonymous codons for each amino acid are used in unequal frequencies and might 
have developed with the cell‟s translation machinery to evade excessive use of suboptimal 
codons which often correspond to rare or less used tRNAs (Gustafsson et al., 2004). This 
phenomenon was termed as “synonymous codon bias” which varies greatly between 
evolutionarily distant species and perhaps even between different tissues in the same species 
(Plotkin et al., 2004). Analysis of codon usage bias in 43 herpesviruses showed that most of 
the herpesviruses do not have high codon bias, with the exceptions of only simplex viruses 
and some varicella viruses (Fu, 2010).  
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Codon manipulation is widely used in modern molecular microbiology, where codon 
optimization via changing the gene‟s synonymous codon into codons used most frequently 
by the host cell is used to increase the efficiency of cross-species protein expression 
(Gustafsson et al., 2004).  Whereas the opposite approach of reducing expression by 
intentional introduction of suboptimal synonymous codons has been  rarely used. Recently, 
with advances in synthetic biology, researchers were able to proceed in live attenuated 
vaccine development as it is now possible to synthesise large segments of synthetic DNA for 
poliovirus. The synthetic DNA is then used to produce the entire genome of the infectious 
agents (Cello et al., 2002). In addition, it is possible now to create viable viruses by chemical 
synthesis in which large segments of the viral genome are modified without altering the 
amino acid sequence, leading to controlled and deliberate attenuation of the virus (Burns et 
al., 2006; Mueller et al., 2006).  Replacement of natural codons used in the Sabin type 2 
(Sabin 2) oral poliovirus vaccine strain for the capsid region with synonymous non-preferred 
(minor) codons resulted in a significant reduction in the virus yield and virus plaque sizes, 
which was proportional to the number of non-preferred codons incorporated into the capsid 
region sequences. Serial passage (for 25 passages in HeLa cells) of the virus with altered 
codon compositions showed that the relative fitness of the modified viruses remained lower 
than that of the unmodified virus (Burns et al., 2006). Mice, transgenic for the poliovirus 
receptor (CD155tg mice), infected with equal amounts of virus particles of the wt virus or 
the virus with altered codons, revealed that the latter was over 100-fold neuro-attenuated 
compared to the wt virus (Mueller et al., 2006). The synthetic viruses with synonymous non-
preferred codons were stable and may prove suitable  as attenuated substrates for the 
production of poliovirus vaccines (Mueller et al., 2006). 
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In MCMV, to reduce the possibility of reversion/mutation of the tyrosine residue 890 
to cysteine or serine, a synthetic M70 gene with many synonymous mutations was 
introduced into the M70 ORF, the hypothesis being that with many mutations present it 
would be less likely that the tyrosine codon would revert. The aim was to replace M70 
codons with the least preferred or sub-optimally codons used by the mouse (Mus musculus 
domesticus) (Table 3.5). 
Several strategies were examined for changing the codon sequence of the M70 ORF 
to those used less frequently by the mouse. Initially, all codons that were not already used 
least frequently were changed to the least frequently used mouse codons. This resulted in an 
M70 ORF with a G + C content of 43% compared to the K181 (Perth) ORF of 64% (leop.all 
line in Figure 3.45). To maintain the high G + C content an alternative strategy was used in 
which the 9 amino acids that have more than 2 codons were changed to the codon used sub-
optimally by the mouse with the highest GC content (M70
SO304Cys
in Figure 3.45). This 
produced an M70 ORF with a G + C content of 66% and a CpG of 379 compared to a CpG 
content of 381 for the K181 (Perth) ORF (Figure 3.46); 403 of the 964 codons  (42%) were 
changed (Figure 3.45). The numbers of the particular codons in each construct are shown in 
Table 3.6.   
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Table  3.5:  Codon preferences for the mouse (Mus musculus domesticus). 
Source: http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=10092 
 
Amino Acid Codon 
Number/ 
1000 
Fraction Amino Acid Codon 
Number/ 
1000 
Fraction 
Alanine 
(Ala or A) 
GCG 325 6.1 
Leucine 
(Leu or L) 
CTA 665 12.6 
GCA 913 17.3 CTT 616 11.6 
GCT 705 13.3 CTC 984 18.6 
GCC 1087 20.5 Lysine 
(Lys or K) 
AAG 1701 32.1 
Arginine 
(Arg or R) 
AGG 739 14.0 AAA 237 44.8 
AGA 1016 19.2 
Methionine 
(Met or M) 
ATG 1183 22.4 
CGG 397 7.5 Phenylalanine 
(Phe or F) 
TTT 793 15.0 
CGA 291 5.5 TTC 1231 23.3 
CGT 178 3.4 
Proline 
(Pro or P) 
CCG 305 5.8 
CGC 385 7.3 CCA 995 18.8 
Asparagine 
(Asn or N) 
AAT 970 18.3 CCT 746 14.1 
AAC 1396 26.4 CCC 872 16.5 
Aspartic Acid 
(Asp or D) 
GAT 973 18.4 
Serine 
(Ser or S) 
AGT 489 9.2 
GAC 1542 29.1 AGC 847 16.0 
Cysteine 
(Cys or C) 
TGT 506 9.6 TCG 220 4.2 
TGC 616 11.6 TCA 781 14.8 
Glutamic Acid 
(Glu or E) 
GAG 1739 32.9 TCT 587 11.1 
GAA 1673 31.6 TCC 755 14.3 
Glutamine 
(Gln or Q) 
CAG 2608 49.3 
Threonine 
(Thr or T) 
ACG 244 4.6 
CAA 845 16.0 ACA 1206 22.8 
Glycine 
(Gly or G) 
GGG 618 11.7 ACT 702 13.3 
GGA 832 15.7 ACC 828 15.6 
GGT 498 9.4 
Tryptophan  
(Trp or W) 
TGG 800 15.1 
GGC 916 17.3 Tyrosine 
(Tyr or Y) 
TAT 655 12.3 
Histidine 
(His or H) 
CAT 600 11.3 TAC 933 17.6 
CAC 1135 21.5 
Valine 
(Val or V) 
GTG 988 18.7 
Isoleucine 
(Ile or I) 
ATA 905 17.1 GTA 428 8.1 
ATT 838 15.8 GTT 321 6.1 
ATC 1334 25.2 GTC 540 10.2 
Leucine 
(Leu or L) 
TTG 479 9.1 
End 
(Stop codon or  X) 
TGA 30 0.6 
TTA 333 6.3 TAG 50 1.0 
CTG 1639 31.0 TAA 30 0.6 
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atgaccgtcgtgctgttcgccaccgaatacgacaccccaaatatcgtagtcaatatgctg  K181P 
atgacggttgttttatttgcgacggaatatgatacgccgaatattgttgttaatatgtta  leop.all 
atgacggtcgtcctcttcgccacggaatacgacacgcccaatattgtcgtcaatatgctc  M70SO
403Cys
  
atgaccgtcgtgctgttcgccaccgaatacgacaccccaaatatcgtagtcaatatgctg  M70
SO155Cys
 
 M  T  V  V  L  F  A  T  E  Y  D  T  P  N  I  V  V  N  M  L   
 
tcggagacaccgacggagcaccacctgttccccctgatgattaaatacaaaccgtcgaac  K181P 
tcggaaacgccgacggaacatcatttatttccgttaatgattaagtataagccgtcgaat  leop.all 
tcggagacgcccacggagcaccacctcttccccctcatgattaaatacaaaccctcgaac  M70SO
403Cys
 
tcggagacaccgacggagcaccacctgttccccctgatgattaaatacaaaccgtcgaac  M70
SO155Cys
 
 S  E  T  P  T  E  H  H  L  F  P  L  M  I  K  Y  K  P  S  N   40  
 
cgtatagaattcgtacttcagacccagaggtgcccggattcgacccgggtccgccccgtt  K181P 
cgtattgaatttgttttacaaacgcaacgttgtccggattcgacgcgtgttcgtccggtt  leop.all 
cggattgaattcgtcctccagacgcagcggtgccccgattcgacgcgggtccggcccgtc  M70SO
403Cys
 
cgtatagaattcgtacttcagacccagaggtgcccggattcgacccgggtccgccccgtt  M70
SO155Cys
 
 R  I  E  F  V  L  Q  T  Q  R  C  P  D  S  T  R  V  R  P  V    
 
ttcatatgcgacgcgcgccgcctctccctgtccgaatacgtgtccaccaacacaccgcta  K181P 
tttatttgtgatgcgcgtcgtttatcgttatcggaatatgtttcgacgaatacgccgtta  leop.all 
ttcatttgcgacgcccggcggctctcgctctcggaatacgtctcgacgaacacgcccctc  M70SO
403Cys
 
ttcatatgcgacgcgcgccgcctctccctgtccgaatacgtgtccaccaacacaccgcta  M70
SO155Cys
 
 F  I  C  D  A  R  R  L  S  L  S  E  Y  V  S  T  N  T  P  L   80  
 
cccgcgcgcgttatctgcgccggcatagacgccgacgctactcgcgagttgtacgaacac  K181P 
ccggcgcgtgttatttgtgcgggtattgatgcggatgcgacgcgtgaattatatgaacat  leop.all 
cccgcccgggtcatttgcgccgggattgacgccgacgccacgcgggagctctacgaacac  M70SO
403Cys
 
cccgcgcgcgttatctgcgccggcatagacgccgacgctactcgcgagttgtacgaacac  M70
SO155Cys
 
 P  A  R  V  I  C  A  G  I  D  A  D  A  T  R  E  L  Y  E  H    
 
ctgttcgatcgtaaaaaagacgagacgggtcatgacgaggagaacgggtccgccggcggc  K181P 
ttatttgatcgtaagaaggatgaaacgggtcatgatgaagaaaatggttcggcgggtggt  leop.all 
ctcttcgatcggaaaaaagacgagacggggcatgacgaggagaacgggtcggccgggggg  M70SO
403Cys
 
ctgttcgatcgtaaaaaagacgagacgggtcatgacgaggagaacgggtccgccggcggc  M70
SO155Cys
 
 L  F  D  R  K  K  D  E  T  G  H  D  E  E  N  G  S  A  G  G   120  
 
gacctcttctccgacctcaccagcaccctcaaatgcctggtccattacaatcgcagcgcg  K181P 
gatttattttcggatttaacgtcgacgttaaagtgtttagttcattataatcgttcggcg  leop.all 
gacctcttctcggacctcacgtcgacgctcaaatgcctcgtccattacaatcggtcggcc  M70SO
403Cys
 
gacctcttctccgacctcaccagcaccctcaaatgcctggtccattacaatcgcagcgcg  M70
SO155Cys
 
 D  L  F  S  D  L  T  S  T  L  K  C  L  V  H  Y  N  R  S  A    
 
atcttacgctatctcaacaacaccttcctgtcccccacgtccccctcctggttcctgagc  K181P 
attttacgttatttaaataatacgtttttatcgccgacgtcgccgtcgtggtttttatcg  leop.all 
attctccggtatctcaacaacacgttcctctcgcccacgtcgccctcgtggttcctctcg  M70SO
403Cys
 
atcttacgctatctcaacaacaccttcctgtcccccacgtccccctcctggttcctgagc  M70
SO155Cys
 
 I  L  R  Y  L  N  N  T  F  L  S  P  T  S  P  S  W  F  L  S   160  
 
acgtacgggacccacgagggtaccctgatcctgaccatgtcctactatctgttcgagagg  K181P 
acgtatggtacgcatgaaggtacgttaattttaacgatgtcgtattatttatttgaacgt  leop.all 
acgtacgggacgcacgaggggacgctcattctcacgatgtcgtactatctcttcgagcgg  M70SO
403Cys
 
acgtacgggacccacgagggtaccctgatcctgaccatgtcctactatctgttcgagagg  M70
SO155Cys
 
 T  Y  G  T  H  E  G  T  L  I  L  T  M  S  Y  Y  L  F  E  R    
 
cagtatagtacgattcagaccacccgcgattacacgaaatgtttcaccgccgaccccggc  K181P   
caatattcgacgattcaaacgacgcgtgattatacgaagtgttttacggcggatccgggt  leop.all 
cagtattcgacgattcagacgacgcgggattacacgaaatgtttcacggccgaccccggg  M70SO
403Cys
 
cagtatagtacgattcagaccacccgcgattacacgaaatgtttcaccgccgaccccggc  M70
SO155Cys
   
 Q  Y  S  T  I  Q  T  T  R  D  Y  T  K  C  F  T  A  D  P  G   200  
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cgcaacctgttcacgtacatcaacatgcgcgatttcatggcgaccatgaacggctcgcgg  K181P 
cgtaatttatttacgtatattaatatgcgtgattttatggcgacgatgaatggttcgcgt  leop.all 
cggaacctcttcacgtacattaacatgcgggatttcatggccacgatgaacgggtcgcgg  M70SO
403Cys
 
cgcaacctgttcacgtacatcaacatgcgcgatttcatggcgaccatgaacggctcgcgg  M70
SO155Cys
 
 R  N  L  F  T  Y  I  N  M  R  D  F  M  A  T  M  N  G  S  R   
 
ttccgcaagcagaccgcgcggttcgcggcgttcgccaaggcgagaaacgcccgagaccgg  K181P 
tttcgtaagcaaacggcgcgttttgcggcgtttgcgaaggcgcgtaatgcgcgtgatcgt  leop.all 
ttccggaagcagacggcccggttcgccgccttcgccaaggcccggaacgcccgggaccgg  M70SO
403Cys
 
ttccgcaagcagaccgcgcggttcgcggcgttcgccaaggcgagaaacgcccgagaccgg  M70
SO155Cys
 
 F  R  K  Q  T  A  R  F  A  A  F  A  K  A  R  N  A  R  D  R   240 
 
cgcgagctggaatacgtggacgccaagatcaacgcgttccgcgaggaatcgcgcctggcg  K181P 
cgtgaattagaatatgttgatgcgaagattaatgcgtttcgtgaagaatcgcgtttagcg  leop.all 
cgggagctcgaatacgtcgacgccaagattaacgccttccgggaggaatcgcggctcgcc  M70SO
403Cys
 
cgcgagctggaatacgtggacgccaagatcaacgcgttccgcgaggaatcgcgcctggcg  M70
SO155Cys
 
 R  E  L  E  Y  V  D  A  K  I  N  A  F  R  E  E  S  R  L  A   
 
gccgactcgtgcgtgtactacgtgtacctggcctaccggacggcgctgtgccgggagaag  K181P 
gcggattcgtgtgtttattatgtttatttagcgtatcgtacggcgttatgtcgtgaaaag  leop.all 
gccgactcgtgcgtctactacgtctacctcgcctaccggacggccctctgccgggagaag  M70SO
403Cys
 
gccgactcgtgcgtgtactacgtgtacctggcctaccggacggcgctgtgccgggagaag  M70
SO155Cys
 
 A  D  S  C  V  Y  Y  V  Y  L  A  Y  R  T  A  L  C  R  E  K   280 
 
ttcctgcagtactgcgagcacacggcgtacgacaagaacctgccggacgatcagcagtgc  K181P 
tttttacaatattgtgaacatacggcgtatgataagaatttaccggatgatcaacaatgt  leop.all 
ttcctccagtactgcgagcacacggcctacgacaagaacctccccgacgatcagcagtgc  M70SO
403Cys
 
ttcctgcagtactgcgagcacacggcgtacgacaagaacctgccggacgatcagcagtgc  M70
SO155Cys
 
 F  L  Q  Y  C  E  H  T  A  Y  D  K  N  L  P  D  D  Q  Q  C   
 
gcggcggaggagaactacctggggcgcagcctggacgccgaactgatctccatcatgaat  K181P 
gcggcggaagaaaattatttaggtcgttcgttagatgcggaattaatttcgattatgaat  leop.all 
gccgccgaggagaactacctcgggcggtcgctcgacgccgaactcatttcgattatgaat  M70SO
403Cys
 
gcggcggaggagaactacctggggcgcagcctggacgccgaactgatctccatcatgaat  M70
SO155Cys
 
 A  A  E  E  N  Y  L  G  R  S  L  D  A  E  L  I  S  I  M  N   320  
 
acctacttttcggtggagggctattttggcagctacatccacgtcgaccgcgcgaagctg  K181P 
acgtatttttcggttgaaggttattttggttcgtatattcatgttgatcgtgcgaagtta  leop.all 
acgtacttttcggtcgaggggtattttgggtcgtacattcacgtcgaccgggccaagctc  M70SO
403Cys
 
acctacttttcggtggagggctattttggcagctacatccacgtcgaccgcgcgaagctg  M70
SO155Cys
 
 T  Y  F  S  V  E  G  Y  F  G  S  Y  I  H  V  D  R  A  K  L   
 
agcccgccccacagctaccgcggctacgactggaacacggaagccgacacgatggtgggc  K181P 
tcgccgccgcattcgtatcgtggttatgattggaatacggaagcggatacgatggttggt  leop.all 
tcgcccccccactcgtaccgggggtacgactggaacacggaagccgacacgatggtcggg  M70SO
403Cys
 
agcccgccccacagctaccgcggctacgactggaacacggaagccgacacgatggtgggc  M70
SO155Cys
 
 S  P  P  H  S  Y  R  G  Y  D  W  N  T  E  A  D  T  M  V  G   360 
 
tactcttccaccgcgacgaacctggccatctcgctgcgcaagctgaactcgacgtgcgag  K181P 
tattcgtcgacggcgacgaatttagcgatttcgttacgtaagttaaattcgacgtgtgaa  leop.all 
tactcgtcgacggccacgaacctcgccatttcgctccggaagctcaactcgacgtgcgag  M70SO
403Cys
 
tactcttccaccgcgacgaacctggccatctcgctgcgcaagctgaactcgacgtgcgag  M70
SO155Cys
 
 Y  S  S  T  A  T  N  L  A  I  S  L  R  K  L  N  S  T  C  E  
 
tccctgttctcgccgctgccgccgacgctgatggggctgctgaagctgtgcgcctcggac  K181P 
tcgttattttcgccgttaccgccgacgttaatgggtttattaaagttatgtgcgtcggat  leop.all 
tcgctcttctcgcccctcccccccacgctcatggggctcctcaagctctgcgcctcggac  M70SO
403Cys
 
tccctgttctcgccgctgccgccgacgctgatggggctgctgaagctgtgcgcctcggac  M70
SO155Cys
 
 S  L  F  S  P  L  P  P  T  L  M  G  L  L  K  L  C  A  S  D   400 
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cggtacgtgccgcgggcggaaaaaagccgcaagcgcaccagcggcggcagagaaaaagaa  K181P 
cgttatgttccgcgtgcggaaaagtcgcgtaagcgtacgtcgggtggtcgtgaaaaggaa  leop.all 
cggtacgtcccccgggccgaaaaatcgcggaagcggacgtcgggggggcgggaaaaagaa  M70SO
403Cys
 
cggtacgtgccgcgggcggaaaaaagccgcaagcgcaccagcggcggcagagaaaaagaa  M70
SO155Cys
 
 R  Y  V  P  R  A  E  K  S  R  K  R  T  S  G  G  R  E  K  E  
 
gacgagacgcgcgtgtgccggcgcaactacctgctgaacgacacgagccgtccgatcggg  K181P 
gatgaaacgcgtgtttgtcgtcgtaattatttattaaatgatacgtcgcgtccgattggt  leop.all 
gacgagacgcgggtctgccggcggaactacctcctcaacgacacgtcgcggcccattggg  M70SO
403Cys
 
gacgagacgcgcgtgtgccggcgcaactacctgctgaacgacacgagccgtccgatcggg  M70
SO155Cys
 
 D  E  T  R  V  C  R  R  N  Y  L  L  N  D  T  S  R  P  I  G   440  
 
ccgatgccggtgttccgggtggagatgccggagaagcggcacgtgttctgcgcggtcagc  K181P 
ccgatgccggtttttcgtgttgaaatgccggaaaagcgtcatgttttttgtgcggtttcg  leop.all 
cccatgcccgtcttccgggtcgagatgcccgagaagcggcacgtcttctgcgccgtctcg  M70SO
403Cys
 
ccgatgccggtgttccgggtggagatgccggagaagcggcacgtgttctgcgcggtcagc  M70
SO155Cys
 
 P  M  P  V  F  R  V  E  M  P  E  K  R  H  V  F  C  A  V  S  
 
gcggagaactggacccgccggctgctgcccaaggacctgatgaaaaacctgccgtccgag  K181P 
gcggaaaattggacgcgtcgtttattaccgaaggatttaatgaagaatttaccgtcggaa  leop.all 
gccgagaactggacgcggcggctcctccccaaggacctcatgaaaaacctcccctcggag  M70SO
403Cys
 
gcggagaactggacccgccggctgctgcccaaggacctgatgaaaaacctgccgtccgag  M70
SO155Cys
 
 A  E  N  W  T  R  R  L  L  P  K  D  L  M  K  N  L  P  S  E   480 
 
tacgtctcggacgagtgtctgacggacgcggtgtggctgcgcgaagacatcgcggcctcg  K181P 
tatgtttcggatgaatgtttaacggatgcggtttggttacgtgaagatattgcggcgtcg  leop.all 
tacgtctcggacgagtgtctcacggacgccgtctggctccgggaagacattgccgcctcg  M70SO
403Cys
 
tacgtctcggacgagtgtctgacggacgcggtgtggctgcgcgaagacatcgcggcctcg  M70
SO155Cys
 
 Y  V  S  D  E  C  L  T  D  A  V  W  L  R  E  D  I  A  A  S  
 
tgcgaggtgggcgagcagctgtaccgcacgcgtcacgagatgttcaacgagaacctgccc  K181P 
tgtgaagttggtgaacaattatatcgtacgcgtcatgaaatgtttaatgaaaatttaccg  leop.all 
tgcgaggtcggggagcagctctaccggacgcggcacgagatgttcaacgagaacctcccc  M70SO
403Cys
 
tgcgaggtgggcgagcagctgtaccgcacgcgtcacgagatgttcaacgagaacctgccc  M70
SO155Cys
 
 C  E  V  G  E  Q  L  Y  R  T  R  H  E  M  F  N  E  N  L  P 520 
 
gtgttcaacttcgtgggcgacgtggacctcaagctgcgcgaggacctgcagggtctgagc  K181P 
gtttttaattttgttggtgatgttgatttaaagttacgtgaagatttacaaggtttatcg  leop.all 
gtcttcaacttcgtcggggacgtcgacctcaagctccgggaggacctccaggggctctcg  M70SO
403Cys
 
gtgttcaacttcgtgggcgacgtggacctcaagctgcgcgaggacctgcagggtctgagc  M70
SO155Cys
 
 V  F  N  F  V  G  D  V  D  L  K  L  R  E  D  L  Q  G  L  S  
 
cgtcaggaggtgttcgacctgtgccgcgcgctgcggcggaccctgatcggggcctggcgg  K181P 
cgtcaagaagtttttgatttatgtcgtgcgttacgtcgtacgttaattggtgcgtggcgt  leop.all 
cggcaggaggtcttcgacctctgccgggccctccggcggacgctcattggggcctggcgg  M70SO
403Cys
 
cgtcaggaggtgttcgacctgtgccgcgcgctgcggcggaccctgatcggggcctggcgg  M70
SO155Cys
 
 R  Q  E  V  F  D  L  C  R  A  L  R  R  T  L  I  G  A  W  R   560 
 
cacctgtttcccgaggtagacccggactcccaccccgtcttcttcttcaagagcgcgtgt  K181P 
catttatttccggaagttgatccggattcgcatccggtttttttttttaagtcggcgtgt  leop.all 
cacctctttcccgaggtcgaccccgactcgcaccccgtcttcttcttcaagtcggcctgt  M70SO
403Cys
 
cacctgtttcccgaggtagacccggactcccaccccgtcttcttcttcaagagcgcgtgt  M70
SO155Cys
 
 H  L  F  P  E  V  D  P  D  S  H  P  V  F  F  F  K  S  A  C  
 
ccgcagaacgccgcgggggcggcggacgaggcgatgctgtacggcggcggcggctacgac  K181 
ccgcaaaatgcggcgggtgcggcggatgaagcgatgttatatggtggtggtggttatgat  leop.all 
ccccagaacgccgccggggccgccgacgaggccatgctctacggggggggggggtacgac  M70SO
403Cys
 
ccgcagaacgccgcgggggcggcggacgaggcgatgctgtacggcggcggcggctacgac  BAC
155Cys
 
 P  Q  N  A  A  G  A  A  D  E  A  M  L  Y  G  G  G  G  Y  D   600 
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gaagacgacgacccgcggcccgagcacgccgcggcgatggtcgactacggcgatgccgtt  K181P 
gaagatgatgatccgcgtccggaacatgcggcggcgatggttgattatggtgatgcggtt  leop.all 
gaagacgacgacccccggcccgagcacgccgccgccatggtcgactacggggatgccgtc  M70SO
403Cys
 
gaagacgacgacccccggcccgagcacgccgccgccatggtcgactacggggatgccgtc  M70
SO155Cys
 
 E  D  D  D  P  R  P  E  H  A  A  A  M  V  D  Y  G  D  A  V  
 
cggcgcccgcccttctgtgtctgtcggcgcaagctgggcctgagggtgatcatccctttc  K181P 
cgtcgtccgccgttttgtgtttgtcgtcgtaagttaggtttacgtgttattattccgttt  leop.all 
cggcggccccccttctgtgtctgtcggcggaagctcgggctccgggtcattattcccttc  M70SO
403Cys
 
cggcggccccccttctgtgtctgtcggcggaagctcgggctccgggtcattattcccttc  M70
SO155Cys
 
 R  R  P  P  F  C  V  C  R  R  K  L  G  L  R  V  I  I  P  F   640 
 
ccccctcgcacggcggcgatcggggcgcagacgctgaaacgcctggccggcatcctcgat  K181P 
ccgccgcgtacggcggcgattggtgcgcaaacgttaaagcgtttagcgggtattttagat  leop.all 
cccccccggacggccgccattggggcccagacgctcaaacggctcgccgggattctcgat  M70SO
403Cys
 
cccccccggacggccgccattggggcccagacgctcaaacggctcgccgggattctcgat  M70
SO155Cys
 
P  P  R  T  A  A  I  G  A  Q  T  L  K  R  L  A  G  I  L  D  
 
cacactctgtgcctcgatcgagacctggtgtgcaaactcaacgccatctcgcaccccggc  K181P 
catacgttatgtttagatcgtgatttagtttgtaagttaaatgcgatttcgcatccgggt  leop.all 
cacacgctctgcctcgatcgggacctcgtctgcaaactcaacgccatttcgcaccccggg  M70SO
403Cys
 
cacacgctctgcctcgatcgggacctcgtctgcaaactcaacgccatttcgcaccccggg  M70
SO155Cys
 
 H  T  L  C  L  D  R  D  L  V  C  K  L  N  A  I  S  H  P  G   680 
 
gagtgtttcgacacggggatctacagccacgggcgctcgatccgcatgccgctgatgtac  K181P 
gaatgttttgatacgggtatttattcgcatggtcgttcgattcgtatgccgttaatgtat  leop.all 
gagtgtttcgacacggggatttactcgcacgggcggtcgattcggatgcccctcatgtac  M70SO
403Cys
  
gagtgtttcgacacggggatttactcgcacgggcggtcgattcggatgcccctcatgtac  M70
SO155Cys
 
 E  C  F  D  T  G  I  Y  S  H  G  R  S  I  R  M  P  L  M  Y  
 
aagctggacgaggccagcgggctgattctgcacagccgattaaaccccatcttcatcgtc  K181P 
aagttagatgaagcgtcgggtttaattttacattcgcgtttaaatccgatttttattgtt  leop.all 
aagctcgacgaggcctcggggctcattctccactcgcggctcaaccccattttcattgtc  M70SO
403Cys
 
aagctcgacgaggcctcggggctcattctccactcgcggctcaaccccattttcattgtc  M70
SO155Cys
 
 K  L  D  E  A  S  G  L  I  L  H  S  R  L  N  P  I  F  I  V   720 
 
cccgccgggtatcgcgaccgtccggcggaattcgtgctgcagcagctgtgcccccagaac  K181P 
ccggcgggttatcgtgatcgtccggcggaatttgttttacaacaattatgtccgcaaaat  leop.all 
cccgccgggtatcgggaccggcccgccgaattcgtcctccagcagctctgcccccagaac  M70SO
403Cys
 
cccgccgggtatcgggaccggcccgccgaattcgtcctccagcagctctgcccccagaac  M70
SO155Cys
 
 P  A  G  Y  R  D  R  P  A  E  F  V  L  Q  Q  L  C  P  Q  N  
 
ctgacgcaccacggccgtccgccgcggcgagacgggagcgccgaccagctgacggaggtg  K181P 
ttaacgcatcatggtcgtccgccgcgtcgtgatggttcggcggatcaattaacggaagtt  leop.all 
ctcacgcaccacgggcggcccccccggcgggacgggtcggccgaccagctcacggaggtc  M70SO
403Cys
 
ctcacgcaccacgggcggcccccccggcgggacgggtcggccgaccagctcacggaggtc  M70
SO155Cys
 
 L  T  H  H  G  R  P  P  R  R  D  G  S  A  D  Q  L  T  E  V   760 
 
gtgttgcacatcaccgaccgcgcatgcgccgacagcgacggcaactttctgcaatcgcgg  K181P 
gttttacatattacggatcgtgcgtgtgcggattcggatggtaattttttacaatcgcgt  leop.all 
gtcctccacattacggaccgggcctgcgccgactcggacgggaactttctccaatcgcgg  M70SO
403Cys
 
gtcctccacattacggaccgggcctgcgccgactcggacgggaactttctccaatcgcgg  M70
SO155Cys
 
 V  L  H  I  T  D  R  A  C  A  D  S  D  G  N  F  L  Q  S  R  
 
gcgaggcgcgcgatgtcgaggcggcgtctgccgctcgggcccctgctgcgagcgcacctg  K181P 
gcgcgtcgtgcgatgtcgcgtcgtcgtttaccgttaggtccgttattacgtgcgcattta  leop.all  
gcccggcgggccatgtcgcggcggcggctccccctcgggcccctcctccgggcccacctc  M70SO
403Cys
 
gcccggcgggccatgtcgcggcggcggctccccctcgggcccctcctccgggcccacctc  M70
SO155Cys
 
 A  R  R  A  M  S  R  R  R  L  P  L  G  P  L  L  R  A  H  L 800 
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tcgctcgagtcgggacagtcggcgccgtcgctgccaacgctcgtcgggcgaggaggcgga  K181P 
tcgttagaatcgggtcaatcggcgccgtcgttaccgacgttagttggtcgtggtggtggt  leop.all 
tcgctcgagtcggggcagtcggccccctcgctccccacgctcgtcgggcggggggggggg  M70SO
403Cys
 
tcgctcgagtcggggcagtcggccccctcgctccccacgctcgtcgggcggggggggggg  M70
SO155Cys
 
 S  L  E  S  G  Q  S  A  P  S  L  P  T  L  V  G  R  G  G  G  
 
ggagaaggaggcgcgtcgagcgattacgaggaggagagggcggtgggatcggacgaggag  K181P 
ggtgaaggtggtgcgtcgtcggattatgaagaagaacgtgcggttggttcggatgaagaa  leop.all 
ggggaagggggggcctcgtcggattacgaggaggagcgggccgtcgggtcggacgaggag  M70SO
403Cys
 
ggggaagggggggcctcgtcggattacgaggaggagcgggccgtcgggtcggacgaggag  M70
SO155Cys
 
 G  E  G  G  A  S  S  D  Y  E  E  E  R  A  V  G  S  D  E  E   840 
 
gaggacgacgacgacgtcgagaacctgcaggcgttcgcgaggcggatcgcctggccggcg  K181P 
gaagatgatgatgatgttgaaaatttacaagcgtttgcgcgtcgtattgcgtggccggcg  leop.all 
gaggacgacgacgacgtcgagaacctccaggccttcgcccggcggattgcctggcccgcc  M70SO
403Cys
 
gaggacgacgacgacgtcgagaacctccaggccttcgcccggcggattgcctggcccgcc  M70
SO155Cys
 
 E  D  D  D  D  V  E  N  L  Q  A  F  A  R  R  I  A  W  P  A  
 
ctgttgagacacacgcgtaaccactaccgcgaggaggtgcagcagcagctggaggcggcc  K181P 
ttattacgtcatacgcgtaatcattatcgtgaagaagttcaacaacaattagaagcggcg  leop.all 
ctcctccggcacacgcggaaccactaccgggaggaggtccagcagcagctcgaggccgcc  M70SO
403Cys
 
ctcctccggcacacgcggaaccactaccgggaggaggtccagcagcagctcgaggccgcc  M70
SO155Cys
 
 L  L  R  H  T  R  N  H  Y  R  E  E  V  Q  Q  Q  L  E  A  A   880 
 
acggtgtttaccgccgtcggccgcacctgcgttgccgtcaaacggggtttatacggccgc  K181P 
acggtttttacggcggttggtcgtacgtgtgttgcggttaagcgtggtttatatggtcgt  leop.all 
acggtctttacggccgtcgggcggacgtgtgtcgccgtcaaacgggggctctacgggcgg  M70SO
403Cys
  
acggtctttacggccgtcgggcggacgtacgtcgccgtcaaacgggggctctacgggcgg  M70SO
403Tyr
  
acggtctttacggccgtcgggcggacgtgtgtcgccgtcaaacgggggctctacgggcgg  M70
SO155Cys
  
acggtctttacggccgtcgggcggacgtacgtcgccgtcaaacgggggctctacgggcgg  M70
SO155Tyr
 
 T  V  F  T  A  V  G  R  T C/Y  V  A  V  K  R  G  L  Y  G  R  
 
gcccgagacttctcgtgtctagcgcgcgagcactacactcgccaggagacggtgcaggta  K181P 
gcgcgtgatttttcgtgtttagcgcgtgaacattatacgcgtcaagaaacggttcaagtt  leop.all 
gcccgggacttctcgtgtctcgcccgggagcactacacgcggcaggagacggtccaggtc  M70SO
403Cys
 
gcccgggacttctcgtgtctcgcccgggagcactacacgcggcaggagacggtccaggtc  M70
SO155Cys
 
 A  R  D  F  S  C  L  A  R  E  H  Y  T  R  Q  E  T  V  Q  V   920 
 
ttcctggacatccgcggagaccagcggcggaacgtgtgggcgaccctgtggagcaggtgt  K181P 
tttttagatattcgtggtgatcaacgtcgtaatgtttgggcgacgttatggtcgcgttgt  leop.all 
ttcctcgacattcggggggaccagcggcggaacgtctgggccacgctctggtcgcggtgt  M70SO
403Cys
 
ttcctcgacattcggggggaccagcggcggaacgtctgggccacgctctggtcgcggtgt  M70
SO155Cys
 
 F  L  D  I  R  G  D  Q  R  R  N  V  W  A  T  L  W  S  R  C  
 
ttcacccggcgatgcaattctaacgcgaaacagacccacctctcgctgaagatctccctg  K181P 
tttacgcgtcgttgtaattcgaatgcgaagcaaacgcatttatcgttaaagatttcgtta  leop.all 
ttcacgcggcggtgcaattcgaacgccaaacagacgcacctctcgctcaagatttcgctc  M70SO
403Cys
 
ttcacgcggcggtgcaattcgaacgccaaacagacgcacctctcgctcaagatttcgctc  M70
SO155Cys
 
 F  T  R  R  C  N  S  N  A  K  Q  T  H  L  S  L  K  I  S  L    960 
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ccctcgcagtat                                                  K181P 
ccgtcgcaatat                                                  leop.all 
ccctcgcagtat                                                  M70SO
403Cys
 
ccctcgcagtat                                                  M70
SO155Cys 
 P  S  Q  Y  
 
Figure  3.45: Nucleotide sequence of K181 M70 ORF. The K181P is published M70 
sequence for K181(Perth) variant (EMBL Acc. No. AM886412), Leop.all = all codons changed 
to those used least optimally, i.e. the least frequent codon for that amino acid, M70
SO403Cys
 
and M70
SOTyr
  are the cysteine and tyrosine versions respectively where only the 9 amino 
acids with more than 2 codons were changed to codons used suboptimally with the highest 
CG content, M70
SO155Cys
 and M70
SO155Tyr
 are the cysteine and tyrosine versions respectively 
where the 9 amino acids were changed in the carboxy terminus only (Table  3.6).     
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K181P    MTVVLFATEYDTPNIVVNMLSETPTEHHLFPLMIKYKPSNRIEFVLQTQRCPDSTRVRPV 60 
leop.all MTVVLFATEYDTPNIVVNMLSETPTEHHLFPLMIKYKPSNRIEFVLQTQRCPDSTRVRPV 60 
M70SO
403Cys 
MTVVLFATEYDTPNIVVNMLSETPTEHHLFPLMIKYKPSNRIEFVLQTQRCPDSTRVRPV 60 
M70
SO155Cys 
MTVVLFATEYDTPNIVVNMLSETPTEHHLFPLMIKYKPSNRIEFVLQTQRCPDSTRVRPV 60 
         ************************************************************ 
K181P    FICDARRLSLSEYVSTNTPLPARVICAGIDADATRELYEHLFDRKKDETGHDEENGSAGG 120 
Leop.all FICDARRLSLSEYVSTNTPLPARVICAGIDADATRELYEHLFDRKKDETGHDEENGSAGG 120 
M70SO
403Cys 
FICDARRLSLSEYVSTNTPLPARVICAGIDADATRELYEHLFDRKKDETGHDEENGSAGG 120 
M70
SO155Cys 
FICDARRLSLSEYVSTNTPLPARVICAGIDADATRELYEHLFDRKKDETGHDEENGSAGG 120 
         ************************************************************ 
K181P    DLFSDLTSTLKCLVHYNRSAILRYLNNTFLSPTSPSWFLSTYGTHEGTLILTMSYYLFER 180 
Leop.all DLFSDLTSTLKCLVHYNRSAILRYLNNTFLSPTSPSWFLSTYGTHEGTLILTMSYYLFER 180 
M70SO
403Cys 
DLFSDLTSTLKCLVHYNRSAILRYLNNTFLSPTSPSWFLSTYGTHEGTLILTMSYYLFER 180 
M70
SO155Cys 
DLFSDLTSTLKCLVHYNRSAILRYLNNTFLSPTSPSWFLSTYGTHEGTLILTMSYYLFER 180 
         ************************************************************ 
K181P    QYSTIQTTRDYTKCFTADPGRNLFTYINMRDFMATMNGSRFRKQTARFAAFAKARNARDR 240 
Leop.all QYSTIQTTRDYTKCFTADPGRNLFTYINMRDFMATMNGSRFRKQTARFAAFAKARNARDR 240 
M70SO
403Cys 
QYSTIQTTRDYTKCFTADPGRNLFTYINMRDFMATMNGSRFRKQTARFAAFAKARNARDR 240 
M70
SO155Cys 
QYSTIQTTRDYTKCFTADPGRNLFTYINMRDFMATMNGSRFRKQTARFAAFAKARNARDR 240 
         ************************************************************ 
K181P    RELEYVDAKINAFREESRLAADSCVYYVYLAYRTALCREKFLQYCEHTAYDKNLPDDQQC 300 
Leop.all RELEYVDAKINAFREESRLAADSCVYYVYLAYRTALCREKFLQYCEHTAYDKNLPDDQQC 300 
M70SO
403Cys 
RELEYVDAKINAFREESRLAADSCVYYVYLAYRTALCREKFLQYCEHTAYDKNLPDDQQC 300 
M70
SO155Cys 
RELEYVDAKINAFREESRLAADSCVYYVYLAYRTALCREKFLQYCEHTAYDKNLPDDQQC 300 
         ************************************************************ 
K181P    AAEENYLGRSLDAELISIMNTYFSVEGYFGSYIHVDRAKLSPPHSYRGYDWNTEADTMVG 360 
Leop.all AAEENYLGRSLDAELISIMNTYFSVEGYFGSYIHVDRAKLSPPHSYRGYDWNTEADTMVG 360 
M70SO
403Cys 
AAEENYLGRSLDAELISIMNTYFSVEGYFGSYIHVDRAKLSPPHSYRGYDWNTEADTMVG 360 
M70
SO155Cys 
AAEENYLGRSLDAELISIMNTYFSVEGYFGSYIHVDRAKLSPPHSYRGYDWNTEADTMVG 360 
         ************************************************************ 
K181P    YSSTATNLAISLRKLNSTCESLFSPLPPTLMGLLKLCASDRYVPRAEKSRKRTSGGREKE 420 
Leop.all YSSTATNLAISLRKLNSTCESLFSPLPPTLMGLLKLCASDRYVPRAEKSRKRTSGGREKE 420 
M70SO
403Cys 
YSSTATNLAISLRKLNSTCESLFSPLPPTLMGLLKLCASDRYVPRAEKSRKRTSGGREKE 420 
M70
SO155Cys 
YSSTATNLAISLRKLNSTCESLFSPLPPTLMGLLKLCASDRYVPRAEKSRKRTSGGREKE 420 
         ************************************************************ 
K181P    DETRVCRRNYLLNDTSRPIGPMPVFRVEMPEKRHVFCAVSAENWTRRLLPKDLMKNLPSE 480 
Leop.all DETRVCRRNYLLNDTSRPIGPMPVFRVEMPEKRHVFCAVSAENWTRRLLPKDLMKNLPSE 480 
M70SO
403Cys 
DETRVCRRNYLLNDTSRPIGPMPVFRVEMPEKRHVFCAVSAENWTRRLLPKDLMKNLPSE 480 
M70
SO155Cys 
DETRVCRRNYLLNDTSRPIGPMPVFRVEMPEKRHVFCAVSAENWTRRLLPKDLMKNLPSE 480 
         ************************************************************ 
K181P    YVSDECLTDAVWLREDIAASCEVGEQLYRTRHEMFNENLPVFNFVGDVDLKLREDLQGLS 540 
Leop.all YVSDECLTDAVWLREDIAASCEVGEQLYRTRHEMFNENLPVFNFVGDVDLKLREDLQGLS 540 
M70SO
403Cys 
YVSDECLTDAVWLREDIAASCEVGEQLYRTRHEMFNENLPVFNFVGDVDLKLREDLQGLS 540 
M70
SO155Cys 
YVSDECLTDAVWLREDIAASCEVGEQLYRTRHEMFNENLPVFNFVGDVDLKLREDLQGLS 540 
         ************************************************************ 
K181P    RQEVFDLCRALRRTLIGAWRHLFPEVDPDSHPVFFFKSACPQNAAGAADEAMLYGGGGYD 600 
Leop.all RQEVFDLCRALRRTLIGAWRHLFPEVDPDSHPVFFFKSACPQNAAGAADEAMLYGGGGYD 600 
M70SO
403Cys 
RQEVFDLCRALRRTLIGAWRHLFPEVDPDSHPVFFFKSACPQNAAGAADEAMLYGGGGYD 600 
M70
SO155Cys 
RQEVFDLCRALRRTLIGAWRHLFPEVDPDSHPVFFFKSACPQNAAGAADEAMLYGGGGYD 600 
         ************************************************************ 
 
K181P    EDDDPRPEHAAAMVDYGDAVRRPPFCVCRRKLGLRVIIPFPPRTAAIGAQTLKRLAGILD 660 
Leop.all EDDDPRPEHAAAMVDYGDAVRRPPFCVCRRKLGLRVIIPFPPRTAAIGAQTLKRLAGILD 660 
M70SO
403Cys 
EDDDPRPEHAAAMVDYGDAVRRPPFCVCRRKLGLRVIIPFPPRTAAIGAQTLKRLAGILD 660 
M70
SO155Cys 
EDDDPRPEHAAAMVDYGDAVRRPPFCVCRRKLGLRVIIPFPPRTAAIGAQTLKRLAGILD 660 
         ************************************************************ 
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K181P    HTLCLDRDLVCKLNAISHPGECFDTGIYSHGRSIRMPLMYKLDEASGLILHSRLNPIFIV 720 
Leop.all HTLCLDRDLVCKLNAISHPGECFDTGIYSHGRSIRMPLMYKLDEASGLILHSRLNPIFIV 720 
M70SO
403Cys 
HTLCLDRDLVCKLNAISHPGECFDTGIYSHGRSIRMPLMYKLDEASGLILHSRLNPIFIV 720 
M70
SO155Cys 
HTLCLDRDLVCKLNAISHPGECFDTGIYSHGRSIRMPLMYKLDEASGLILHSRLNPIFIV 720 
         ************************************************************ 
 
 
K181P    PAGYRDRPAEFVLQQLCPQNLTHHGRPPRRDGSADQLTEVVLHITDRACADSDGNFLQSR 780 
Leop.all PAGYRDRPAEFVLQQLCPQNLTHHGRPPRRDGSADQLTEVVLHITDRACADSDGNFLQSR 780 
M70SO
403Cys 
PAGYRDRPAEFVLQQLCPQNLTHHGRPPRRDGSADQLTEVVLHITDRACADSDGNFLQSR 780 
M70
SO155Cys 
PAGYRDRPAEFVLQQLCPQNLTHHGRPPRRDGSADQLTEVVLHITDRACADSDGNFLQSR 780 
         ************************************************************ 
 
K181P    ARRAMSRRRLPLGPLLRAHLSLESGQSAPSLPTLVGRGGGGEGGASSDYEEERAVGSDEE 840 
Leop.all ARRAMSRRRLPLGPLLRAHLSLESGQSAPSLPTLVGRGGGGEGGASSDYEEERAVGSDEE 840 
M70SO
403Cys 
ARRAMSRRRLPLGPLLRAHLSLESGQSAPSLPTLVGRGGGGEGGASSDYEEERAVGSDEE 840 
M70
SO155Cys 
ARRAMSRRRLPLGPLLRAHLSLESGQSAPSLPTLVGRGGGGEGGASSDYEEERAVGSDEE 840 
         ************************************************************ 
 
K181P    EDDDDVENLQAFARRIAWPALLRHTRNHYREEVQQQLEAATVFTAVGRTCVAVKRGLYGR 900 
Leop.all EDDDDVENLQAFARRIAWPALLRHTRNHYREEVQQQLEAATVFTAVGRTCVAVKRGLYGR 900 
M70SO
403Cys 
EDDDDVENLQAFARRIAWPALLRHTRNHYREEVQQQLEAATVFTAVGRTCVAVKRGLYGR 900 
M70SO
403Tyr 
EDDDDVENLQAFARRIAWPALLRHTRNHYREEVQQQLEAATVFTAVGRTYVAVKRGLYGR 900 
M70
SO155Cys 
EDDDDVENLQAFARRIAWPALLRHTRNHYREEVQQQLEAATVFTAVGRTCVAVKRGLYGR 900 
M70
SO155Tyr 
EDDDDVENLQAFARRIAWPALLRHTRNHYREEVQQQLEAATVFTAVGRTYVAVKRGLYGR 900 
         ************************************************* ********** 
 
K181P    ARDFSCLAREHYTRQETVQVFLDIRGDQRRNVWATLWSRCFTRRCNSNAKQTHLSLKISL 960 
Leop.all ARDFSCLAREHYTRQETVQVFLDIRGDQRRNVWATLWSRCFTRRCNSNAKQTHLSLKISL 960 
M70SO
403Cys 
ARDFSCLAREHYTRQETVQVFLDIRGDQRRNVWATLWSRCFTRRCNSNAKQTHLSLKISL 960 
M70
SO155Cys 
ARDFSCLAREHYTRQETVQVFLDIRGDQRRNVWATLWSRCFTRRCNSNAKQTHLSLKISL 960 
         ************************************************************ 
 
K181P    PSQY 964   G+C = 64%    CpG = 381 
Leop.all PSQY 964   G+C = 43% 
M70SO
403Cys 
PSQY 964   G+C = 66%    CpG = 378 
M70
SO155Cys 
PSQY 964   G+C = 65%    CpG = 367 
         **** 
 
Figure  3.46: Translated amino acids sequences of, Leop.all, M70
SO403Cys, M70
SO403Tyr, 
M70
SO155Cys and M70
SO155Tyr compared to the wt K181 (Perth) sequence.  
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Table  3.6: Number of codons changed in the constructed mutants, M70
SO403Cys
, M70
SO403Tyr
, 
M70
SO155Cys
 and M70
SO155Tyr
, where only the 9 amino acids (indicated with *) with more 
than 2 codons were changed to codons used suboptimally with the highest GC content. 
 
 
Amino 
Acid 
Codon 
Mouse 
frequency 
(per 1,000) 
K181 BAC
403Cys
 BAC
403Tyr
 BAC
155Cys
 BAC
155Tyr
 
Ala* 
GCT 13.3 1 0 0 1 1 
GCC 20.5 30 78 78 50 50 
GCA 17.3 1 0 0 0 0 
GCG 6.1 46 0 0 27 27 
Arg* 
CGT 3.4 9 0 0 5 5 
CGC 7.3 42 0 0 27 27 
CGA 5.5 8 0 0 1 1 
CGG 7.5 26 96 96 59 59 
AGA 19.2 3 0 0 2 2 
AGG 14 8 0 0 2 2 
Asn 
AAT 18.3 5 5 5 5 5 
AAC 26.4 31 31 31 31 31 
Asp 
GAT 18.4 9 9 9 9 9 
GAC 29.1 54 54 54 54 54 
Cys 
TGT 9.6 8 9 8 9 8 
TGC 11.6 20 19 19 19 19 
Gln 
CAA 16 1 1 1 1 1 
CAG 49.3 27 27 27 27 27 
Glu 
GAA 31.6 15 15 15 15 15 
GAG 32.9 47 47 47 47 47 
Gly* 
GGT 9.4 4 0 0 3 3 
GGC 17.3 27 0 0 17 17 
GGA 15.7 7 0 0 0 0 
GGG 11.7 15 53 53 33 33 
His 
CAT 11.3 2 2 2 2 2 
CAC 21.4 24 24 24 24 24 
Ile* 
ATT 15.8 3 32 32 16 16 
ATC 25.2 26 0 0 13 13 
ATA 17.1 3 0 0 3 3 
Leu* 
TTA 6.3 3 0 0 1 1 
TTG 9.1 3 0 0 1 1 
CTT 11.6 1 0 0 1 1 
CTC 18.6 13 99 99 45 45 
CTA 12.6 2 0 0 1 1 
CTG 31 77 0 0 50 50 
Lys 
AAA 44.8 13 13 13 13 13 
AAG 32.1 16 16 16 16 16 
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Amino 
Acid 
Codon 
Mouse 
frequency 
(per 1,000) 
K181 BAC
403Cys
 BAC
403Tyr
 BAC
155Cys
 BAC
155Tyr
 
Met ATG 22.4 19 19 19 19 19 
Pro* 
CCT 14.1 2 0 0 0 0 
CCC 16.5 20 50 50 32 32 
CCA 18.8 2 0 0 1 1 
CCG 5.8 26 0 0 17 17 
Phe 
TTT 15 5 5 5 5 5 
TTC 23.3 36 36 36 36 36 
Ser* 
TCT 11.1 2 0 0 1 1 
TCC 14.3 15 0 0 14 14 
TCA 14.8 0 0 0 0 0 
TCG 4.2 26 64 64 35 35 
AGT 9.2 1 0 0 1 1 
AGC 16 20 0 0 13 13 
Thr* 
ACT 13.3 3 0 0 1 1 
ACC 15.6 28 0 0 22 22 
ACA 22.8 2 0 0 2 2 
ACG 4.6 27 60 60 35 35 
Trp TGG 15.1 8 8 8 8 8 
Tyr 
TAT 12.4 6 6 6 6 6 
TAC 17.6 35 35 36 35 36 
Val* 
GTT 6.1 4 0 0 2 2 
GTC 10.2 15 51 51 28 28 
GTA 8.1 4 0 0 3 3 
GTG 18.7 28 0 0 18 18 
 
Both the cysteine and tyrosine versions of the suboptimal M70 ORF sequence (plus 
50 base homology arms at both terminals) were synthesised by ShineGene Molecular 
Biotech, Inc., Shangai, China and cloned into the multiple cloning site of the pPCR-Script 
Amp SK(+) plasmid. These modified ORFs were then used to replace the wt M70 ORF in 
the K181 (Perth) BAC using two-step homologous recombination mutagenesis (Section 2.7). 
In the first step, the wt M70 gene was replaced with the RpsL-neo cassette and in the second 
step the cassette was replaced with either the cysteine or the tyrosine version of the synthetic 
M70 gene [obtained by BamHI/HindIII digestion of the pPCR-Script Amp SK(+) plasmid]. 
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Isolated recombinant BACs were PCR screened and analysed using RpsL-neo cassette 
primers and primers for the synthetic M70 genes (Table 2.3). Revertants were generated 
using a similar approach (Section 2.7). PCR products of the inserted M70 gene (cysteine and 
tyrosine versions) were sequenced to verify that no changes had occurred in the inserted 
sequence and BAC RFLPs were analysed in comparison to the wt and revertant BAC (data 
not shown).  
Several attempts to transfect NIH3T3 or MEF cells (Section 2.3.1) with the 
recombinant BACs containing the synthetic M70 genes were made, but neither the cysteine 
nor the tyrosine version of the modified BACs produced virus despite successful transfection  
(Figure 3.50). Fluorescent cells were detected and continued to fluoresce for more than 12 
days post infection but the infection did not spread from the initially infected cells and no 
infectious virus was produced although the cells were monitored for up to 30 days until the 
cells started to detach from the plastic surface. Attempts to infect fresh NIH 3T3 cells with 
culture supernatant from the transfected cells produced neither florescence nor cytopathic 
effect. 
Based on this outcome, another strategy was investigated in which only the amino 
acids at the carboxy terminal end of the M70 ORF were changed suboptimally using two 
step homologous recombination (Section 2.7). The RpsL-neo cassette was amplified using  
M70HA FOR + M70HA-RpsL-neo Rev1 primers (Table 2.8), whereas the M70 fragments 
for both M70
SO155Cys
 and M70
SO155Tyr
  (Figure 3.45 and Figure 3.46) were amplified from 
the pPCR-Script Amp SK(+) plasmid containing the synthetic M70 gene using M70HA FOR 
+ M70HAwt-Rev1 primers (Table 2.8). Insertion of the amplified regions (M70
SO155Cys
 and 
M70
SO155Tyr
) from the modified M70 ORFs resulted in M70 ORFs with a G + C content of 
66% (CpG 367) for the cysteine ORF and 66% (368) for the tyrosine ORF; 155 codons were 
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changed (16% of the ORF). DNA from mutant BACs Mt[M70
SO155Cys
] and Mt[M70
SO155 Tyr
] 
as well as their revertant BACs were amplified by PCR and sequenced (data not shown) and 
an RFLP analysis carried out on the mutants (Figures 3.47 – 3.49). 
Again, NIH 3T3 cells were successfully transfected with both constructs as detected 
by the green florescence of the infected cells (Figure 3.50), but only the cysteine construct 
Mt[M70
SO155Cys
] produced infectious virus. Replication of this virus was examined in the 
next section. 
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Figure  3.47: Recombinant MCMV BAC genomes RFLP analysis using EcoRI and AseI 
restriction enzymes digestion. Recombinant and wt K181 Perth BAC DNA (~2 µg) was 
digested with 1 µl of EcoRI or AseI restriction enzyme and resulting fragments were 
separated on a 0.4% agarose gel for ~19 hours at 2 V/cm. No genome rearrangements were 
detected in either of the recombinant BACs compared to the wt K181 BAC. Molecular size 
markers (lanes M), in kilobases, are indicated. 
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Figure  3.48: Recombinant MCMV BAC genomes RFLP analysis using DraI and HindIII 
restriction enzymes digestion. Recombinant and wt K181 (Perth) BAC DNA (~2 µg) was 
digested with 1 µl of DraI or HindIII restriction enzyme and resulting fragments were 
separated on a 0.4% agarose gel for ~19 hours at 2 V/cm. No genome rearrangements were 
detected in either of the recombinant BACs compared to the wt K181 BAC. Molecular size 
markers (lanes M), in kilobases, are indicated. 
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Figure  3.49: RFLP analysis of recombinant MCMV BAC genomes using HpaI, SpeI and 
BamHI restriction enzymes digestion. Recombinant and wt K181 (Perth) BAC DNA (~2 µg) 
was digested with 1 µl of HpaI, SpeI or BamHI restriction enzyme and resulting fragments 
were separated on a 0.4% agarose gel for ~19 hours at 2 V/cm. No genome rearrangements 
were detected in either of the recombinant BACs compared to the wt K181 BAC. Molecular 
size markers (lanes M), in kilobases, are indicated. 
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Figure  3.50 : Transfection of NIH 3T3 cells with the wt K181 (Perth) BAC and modified 
BACs containing the re-constructed M70 ORFs. 
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3.5.1 Replication of Mt[M70SO155Cys] mutant virus 
The replication pattern of the mutant Mt[M70
SO155Cys
] virus at 37°C was very similar 
to that of that of wt virus (Figure 3.51). The maximum yield was 10
5.54 
PFU/ml on day 5 
compared to 10
5.83
 PFU/ml for the K181 (Perth) virus. No significant differences were 
identified between mutant and wt virus yields at any day post infection (p>0.05).  
At 40°C the mutant virus replicated with the same efficiency as the wt K181(Perth) 
virus (Figure 3.51). No significant differences were identified between mutant and wt virus 
yields on days 2 to 7 post infection (p>0.05). 
In conclusion, mutant Mt[M70
SO155Cys
]  does not show a phenotype different from wt 
at either 37°C or 40°C and therefore changing the 155 codons at the distal terminal of the 
M70 gene in the presence of cysteine does not affect replication of the virus in vitro in MEF 
cells at37°C or 40°C.  
Furthermore, and to study the tendency for reversion of the changed codons in 
recombinant Mt[M70
155C
], the virus was passaged 10 times in tissue culture. Sequence 
analysis revealed that none of the altered codons had mutated (data not shown). 
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Figure  3.51: Replication of mutant Mt[M70
SO155Cys
] compared to K181 (Perth) and 
Mt[M70
C890Y
]  viruses at the permissive (37°C) and non-permissive (40°C) temperatures. 
MEF cells were infected with virus at an MOI of 0.05 PFU per cell and incubated at: [A] 
37°C or [B] 40°C. Viral titres were determined in cell culture supernatants 1-7 days post 
infection by plaque assay. Results are the mean ± standard deviation (SD) of three replicates.   
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3.5.2 Metagenomic analysis of M70 structure 
 The lack of viability of Mt[M70
SO155Tyr
] mutant was unexpected as it was previously 
suggested that the ability of amino acid residue 890 to interact chemically with other amino 
acids in the structure was not important (Timoshenko et al., 2009b). Although no structure 
for any herpes virus primase is available, we have used PredictProtein to examine the 
possible effect of the cysteine to tyrosine mutation on the secondary structure of the M70 
protein (Figure 3.52). 
While it is unknown what effect this change will actually have it appears that the 
change from cysteine (M70 Cys) to tyrosine (M70 Tyr) has a marked effect on predicted 
solvent accessibility (PROFacc), secondary structure (PROFsec), amino acid subsequences 
that are most likely to switch between different types of secondary structure (ASP), DNA 
interaction sites (ISIS), protein disorder prediction-unstructured loops (NORSnet) prediction 
of residue mobility (PROFbval), and prediction of meta-disorder (MD) but shows no 
obvious changes in the prediction of natively unstructured regions (Ucon). It is interesting 
that when the cysteine residue is replaced by serine (M70Ser) or methionine (M70Met), 
which produced mutant viruses with a wild-type phenotype (Timoshenko et al., 2009b), the 
predicted structure was similar to the wild-type structure (Figure 3.52).  
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3.6 HCMV Merlin BAC 
A  C to T nucleotide substitution introduced into the M70 ORF of the K181 (Perth) 
variant of MCMV at base position 99,286 leads to tyrosine substitution for cysteine at 
residue 890 and results in attenuation of virus growth in vitro (at 40ºC) and in vivo 
(Timoshenko et al., 2009b).  In MEF cells, the mutant was not detectable until day 5 post 
infection compared to the parent and revertant viruses that were readily detectable from day 
1 post infection. Furthermore, DNA synthesis of the mutant virus at the non-permissive 
temperature was 100-1000 fold lower than that of the wt and revertant (Timoshenko et al., 
2009b). 
Studies in  BALB/c mice infected with the mutant virus revealed that no infectious 
virus was detectable in the salivary glands for up to three weeks post inoculation 
(Timoshenko et al., 2009b). These findings suggested that the M70 protein is vital for 
MCMV growth and pathogenicity and the mutant could be an excellent candidate for a live 
attenuated virus model within mice. Introduction of the same mutation into the UL70 of 
HCMV might reveal whether this mutation also produces an attenuated human 
cytomegalovirus that may hold the potential for the production of a successful HCMV 
vaccine. 
The UL70 homologue, together with UL102 and UL105, are predicted to encode 
proteins important for the formation of the replicative helicase-primase complex 
(McMahon & Anders, 2002). UL70 is the human cytomegalovirus equivalent of the M70 
protein within the helicase-primase complex. UL70 encodes a 974 amino acid protein 
approximately 107 kDa in size.  
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This part of the study was carried out as a summer student project in which I 
prepared most of the constructs and did the planning with some help from the student. We 
planned to introduce a single point mutation (C to T) at base position 102,094 within the 
UL70 gene of HCMV Merlin BAC. This mutation will result in a cytosine to tyrosine 
substitution at position 865, the homologous region to position 99,286 of C890Y within 
MCMV. This in turn will affect the interactions of the complex, potentially reducing DNA 
synthesis. The mutation was produced using site directed mutagenesis (Section 2.6.2) and 
introduced into the wt HCMV Merlin BAC using two-step homologous recombination 
(Section 2.7).  
Linear DNA of UL70 was prepared using UL70 primers (Table 2.3), cloned into 
pGEM®-T Easy Vector (Section 2.6.1) and the mutation introduced into the cloned 
segment using the site directed mutagenesis technique (Section 2.6.2). PAL1111 (SW102 
containing the HCMV Merlin BAC) was used for construction of the Mt[UL70
C890Y
] BAC. 
The RpsL-neo cassette flanked with 50 bases of homology arms at its 5‟and 3‟termini was 
prepared using UL70 RpsL-Fwd and UL70 RpsL-Rev primers (Table 2.10). The RpsL-neo 
cassette was inserted successfully into the UL70 gene of the HCMV Merlin BAC and 
isolates were selected on LBA plates containing kanamycin that were then screened and 
analysed by PCR (Figure 3.53 and Figure 3.55). Mutated linear DNA segments were then 
used to replace the cassette. Isolates were selected on streptomycin, PCR screened and 
analysed using pairs of virus specific and RpsL-neo specific primers (Figure 3.54 and 
Figure 3.55). Furthermore, PCR amplified segments of the UL70 gene of the promising 
isolates were sequenced and the mutation was confirmed (Figure 3.55).  RFLP analysis was 
performed to ensure that no rearrangements had occurred elsewhere in the BAC (Figure 
3.56 and Figure 3.57). 
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Revertants of the HCMV mutants were also constructed to ensure that the 
phenotypic properties of the constructed mutants were attributed to the mutations not to 
other factors or mistakes during their construction. In a similar way, the revertants were 
constructed using the two-step homologous recombination technique. They were then PCR 
analysed and sequenced as described for the mutant. Mutant Mt[UL70
C865Y
], revertant 
Rv[UL70
Y865C
] and wt Merlin BACs were extracted as described in section 2.5.3.2. 
Viruses have been rescued from these BAC construct and the study of their properties will 
be investigated by Dr Brian Martin in the College of Medical and Dental Sciences at The 
University of Birmingham.  
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Figure  3.53: PCR screening of the rpsL-neo cassette insertion into the HCMV BAC using 
primers outside the recombination region.  A. schematic diagram showing the difference in 
the expected product size before and after insertion or replacement of RpsL-neo cassette 
using primers outside the recombination region.  B. PCR screening of 11 different isolates 
for replacement of the wild-type region of the UL70 gene segment with the RpsL-neo 
cassette in the UL70 gene. This gives PCR products that are about 800 bp larger than the 
PCR products produced from the wt HCMV Merlin BAC. Isolates with non-successful 
RpsL-neo cassette insertion are indicated by the stars. (wt) is wt HCMV UL70 gene 
segment negative control for RpsL-neo cassette insertion and (C) is a PCR negative control  
(PCR with no DNA). M is a 1kb molecular size marker (Ladder), in kilobases. 
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Figure  3.54: PCR screening for the RpsL-neo cassette replacement with the mutated linear 
DNA segment in the HCMV Merlin BAC using primers outside the recombination region.  
A. Schematic representation of the primer binding sites. ha – homology arms. B. PCR 
screening of 12 different isolates for replacement of RpsL-neo cassette in the UL70 gene 
segment with the HCMV sequence containing the desired mutation which gives PCR 
products that are about 800 bp smaller than the PCR products of the RpsL-neo cassette    [(-
)ve]. [(+)ve] is HCMV segment positive control. M is a 1kb molecular size marker 
(Ladder), in kilobases. 
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Figure  3.55: Mt[UL70
C865Y
] BAC construction. [A] shows the detailed PCR analysis (see 
Figure 3.10 for further explanation) and the steps of UL70  mutant construction starting 
with wt HCMV Merlin BAC, the UL70 RpsL-neo cassette (insertion of the RpsL-neo 
cassette), Mt[UL70
C865Y
] BAC (replacement of the RpsL-neo cassette with the mutated 
UL70 ORF) using UL70 specific primers in the 1
st
  and 2
nd
 PCR reactions, and RpsL-neo 
specific primers in 3
rd
  and 4
th
  PCR reactions. Lanes M show 1 kb ladder. B. The sequence 
profile of region of interest in the UL70 gene in the Mt[UL70
C865Y
] BAC showing that the 
mutation of interest (C to T) has been inserted at base position 102,094 of the HCMV 
Merlin BAC. 
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Figure  3.56: RFLP analysis of the recombinant HCMV Merlin BAC using AseI  and DraI 
restriction enzymes digestion. Three recombinant mutant isolates (C1-C3) and the wt 
HCMV Merlin BAC DNA (~2 µg) was digested with 1 µl of AseI or DraI restriction 
enzyme and the resulting fragments were separated on a 0.4% agarose gel for ~19 hours at 
2 V/cm. No genome rearrangements were detected in either of the recombinant BACs 
compared to the wt HCMV Merlin BAC. Molecular size markers (lanes M), in kilobases, 
are indicated. 
  
H
C
M
V
 M
er
li
n
 B
A
C
M
t[
U
L
7
0
C
8
9
0
Y
] 
C
1
M
t[
U
L
7
0
C
8
9
0
Y
] 
C
2
M
t[
U
L
7
0
C
8
9
0
Y
] 
C
3
H
C
M
V
 M
er
li
n
 B
A
C
M
t[
U
L
7
0
C
8
9
0
Y
] 
C
1
M
t[
U
L
7
0
C
8
9
0
Y
] 
C
2
M
t[
U
L
7
0
C
8
9
0
Y
] 
C
3
Kb
10.0
8.0
6.0
5.0
4.0
3.0
2.0
1.5
1.0
M M
AseI DraI
Eco
Kb
10.0
8.0
6.0
5.0
4.0
3.0
2.0
1.5
1.0
Chapter 3: Results (Section VI) 
210 
 
 
 
Figure  3.57: RFLP analysis of the recombinant HCMV Merlin BAC using EcoRI and HpaI 
restriction enzyme digestion. Three recombinant mutant isolates (C1-C3) and the wt 
HCMV Merlin BAC DNA (~2 µg) was digested with 1 µl of EcoRI or HpaI restriction 
enzyme and the resulting fragments were separated on a 0.4% agarose gel for ~19 hours at 
2 V/cm. No genome rearrangements were detected in either of the recombinant BACs 
compared to the wt HCMV Merlin BAC. Molecular size markers (lanes M), in kilobases, 
are indicated. 
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Chapter 4:  General Discussion 
4.1 The sequence polymorphism of tsm5 mutant virus 
Chemical mutagenesis of the wt K181 (Birmingham) variant of MCMV resulted in 
the isolation of many temperature-sensitive mutant viruses. One of them, tsm5, was 
defective in replication in immunocompetent BALB/c mice but able to induce an immune 
response and to protect animals from a subsequent challenge with a sublethal dose of wt 
K181 (Birmingham) virus (Bevan et al., 1996; Furrarah & Sweet, 1994; Morley et al., 
2002; Sammons & Sweet, 1989). The identification of mutations responsible for this 
phenotype was a necessary requirement to understand the basis of tsm5 attenuation and to 
apply this knowledge to the development of an HCMV vaccine. DNA synthesis in tsm5 
virus-infected cells was reduced by approximately 90% at 40°C compared to that at 37°C 
and to that of the K181 (Birmingham) variant at either temperature. An electron 
microscopic study revealed that there were no C capsids in the tsm5-infected cells (Sweet et 
al., 2007). 
 Previously, five non-synonymous mutations were identified in tsm5 compared to its 
parent K181 (Birmingham) virus (Sweet et al., 2007). Two mutations were identified in 
immune evasion genes: a C to A mutation leading to an A658S residue change in the 
inhibitor of IFN-γ signalling (M27) and a C to T mutation (V54I) in the inhibitor of 
apoptosis (M36). Three mutations were found in DNA replication, processing and 
packaging genes: a C to T mutation (G439R) in the large terminase subunit (M56), a C to T 
mutation (C890Y) in the primase component (M70) of the helicase-primase complex and a 
C to T mutation (P324S) in the alkaline nuclease (M98) (Sweet et al., 2007).  In addition, 
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many other mutations have been identified in this study (Table 3.2 and Table 3.3) using 
CGS.  
In a previous study, it was shown that the mutation in the M70 gene made the virus 
temperature-sensitive, as its growth was drastically reduced at 40°C (Figure 3.30). In 
addition, the chimaeric Smith/tsm5 DGIK virus (contains the central region of the tsm5 
genome and its 3‟and 5‟ends from the  MCMV Smith genome), is temperature-sensitive, 
although less so than tsm5. It does not have a mutation in its M70 gene, but it still does not 
replicate similar to wt virus (Sweet et al., 2007; Timoshenko et al., 2009b). This suggested 
that there may be mutations other than the M70 mutation that contribute to the ts phenotype 
of tsm5. Based on these results, the present study was to introduce the mutations identified 
in M27, M36, m139, m141 and m143 of tsm5 into the wt K181 (Perth) virus to identify 
their role in the tsm5 temperature-sensitive phenotype. 
From sequence analysis of mutations present in all available tsm5 stocks, it was 
found that tsm5 was polymorphic, as both mutant and wt nucleotides were present as a 
double peak at the positions of the mutations identified previously. In total, six tsm5 stocks, 
the earliest produced in 1990 and the latest in 2004, were available for this study. 
Sequencing revealed that all tsm5 stocks were polymorphic in at least two out of the five 
loci and the proportion of the wt and mutant variants varied between the stocks (Table 3.1). 
In the 1990 stock, the M36 and M70 mutations were confirmed by sequencing, but 
following one passage, for the preparation of a seed stock, both mutations showed double 
peaks. The tsm5 stock has been passaged in vitro (Thesis; by Dr. Olga Timoshenko) 11 
times at 37°C and 4 times at 40°C, but this did not lead to the loss of either of the variants, 
wt or mutant, at any of the five loci, and a mixed population was obtained. Likewise, 
Varicella zoster virus vaccine strains Oka Biken and V-Oka-GSK contain mixtures of 
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strains represented in variable proportion from lot to lot, where sequence analysis has 
revealed that there are SNPs in twelve genes and eight nucleotide substitutions in ORF 62 
(Sauerbrei et al., 2004). 
The presence of both mutations as a single peak in the first passage excludes the 
possibility that the tsm5 polymorphism is due to contamination with wt virus. However, it is 
difficult to differentiate between the tsm5 polymorphism being due to the presence of 
different tsm5 viruses, in the original plaque when the virus was created, or due to reversion 
of these mutations to wild type during subsequent passages. The presence of the M27 and 
M36 gene mutations with clear single peaks in cosmid H (one of 11 cosmids generated 
from tsm5) (Sweet et al., 2007) might suggest that these double peaks are due to reversion 
of these mutations to the wt. Similarly, reversion of the T nucleotide at base position 99,286 
to the wt C nucleotide (double peaks) in the BAC derived mutant Mt[M98
P324S
70
C890Y
] in 
vitro at 40ºC supports this view. Again, the T to G mutation of the M70 triple mutant 
Mt[M98
324S
70
890Y
56
439R
] virus,  which resulted in a codon change that led to substitution of 
tyrosine in the mutant by serine instead of the wt cysteine, which occurred one-day post 
infection of mouse fibroblasts at 37ºC (Timoshenko et al., 2009b), also argues in support of 
the view that these double peaks resulted from reversion rather than due to a mixed 
population in tsm5.  
On the other hand, passage of the tsm5 stock created on 27/07/2004 for 11 times did 
not result in complete reversion of any of the identified mutations.  Furthermore, the M36 
and M56 mutations were still mutants as single peaks in this stock. Absence of the wt 
nucleotide excludes the possibility that double peaks are due to contamination with wt virus 
and supports the view that the tsm5 stocks are polymorphic and contain several mutant 
viruses. Similarly, sequence of VZV vaccine virus (GlaxoSmithKline Oka vaccine) isolated 
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from patients with zoster disease revealed that it had six wt SNP and 62 mutations. 
However, none of the six revertant SNPs was able to dominate or discriminate the Oka 
vaccine virus from the wt (Sauerbrei et al., 2004). 
Tsm5 was produced using N-methyl-N'-nitro-N-nitrosoguanidine, which results in 
random mutagenesis, and thus progeny viruses need to be purified by plaque purification to 
eliminate wt contaminants and mutants (Tonari & Minamishima, 1983). In addition, it is 
difficult to isolate pure MCMV because of its ability to form multicapsid virions in tissue 
culture (Weiland et al., 1986) and in vivo, for example, in the lungs (Reddehase et al., 
1985). These multicapsid virions can hold up to fifteen capsids surrounded by a single 
membrane (Chong & Mims, 1981; Reddehase et al., 1985) and might constitute up to 40% 
of multicapsid virions in the purified virion preparation (Kurz et al., 1997). In the original 
study (Sammons and Sweet, 1989) precautions were taken to try and eliminate multicapsid 
virions by sonication and filtration, but it appears this was not successful.  
Furthermore, quantifying genome copies present in cells infected with equal PFU 
numbers of wt and mutated  HCMV, using real-time PCR prior to onset of virus replication, 
revealed that one PFU of mutant virus corresponded to ~2.8x10
4
 viral genomes and one 
PFU of wt virus corresponded to 80 viral genomes. Apparently, due to mutant virus 
defectiveness,  300 times more mutant virions than wt virions  are required to enter the cell 
to produce lytic virus infection and plaque formation  (Heider et al., 2002).  
As plaque picking is not a precise method for isolation of clonal tsm5 virus 
containing single mutations to study the possibility of reversion, it could be addressed by 
cloning tsm5 DNA into a BAC.  Progeny viruses from a single tsm5 genome could then be 
passaged in different cells and at permissive and non-permissive temperatures to study 
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precisely the possibility of reversion of the tsm5 mutations. However, this would not be a 
rapid procedure as BACs take some time to produce. 
4.2 BAC mutagenesis by Red-mediated homologous recombination: 
Manipulation of herpesvirus genomes was made easier after cloning of herpesvirus 
genomes as BACs in E. coli to allow the use of powerful techniques of bacterial genetics 
for mutagenesis of viral genes to study gene function and phenotype separately.  
In the current study, mutagenesis performed in the MCMV K181 (Perth) variant 
BAC using homologous recombination (through pKD46 plasmid products) in E. coli, has 
been shown to be very effective and we were able to produce all the required mutant and 
revertant virus constructs. However, some difficulties were experienced during this project 
and knowledge of these might help the inexperienced researcher in the future.  
One difficulty was the presence of the wt BAC together with the recombinant BAC, 
during the process of successful RpsL-neo cassette insertion, in the same bacterial clone 
thus giving PCR products with both viral as well as RpsL-neo primers (data not shown). 
This suggests the presence of two copies of the BAC in the same bacterial cell during the 
transformation. Therefore, introduction of RpsL-neo into one of the two BAC copies while 
the other BAC remains as wt enables the bacterial cell to survive the antibiotic selection. If 
such a clone is used for the second round (mutant construction), it will result in 
contamination with wt BAC. 
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The second step of screening for BAC recombinants, where the RpsL-neo cassette is 
replaced with the viral gene fragment carrying the mutation or wt sequence, often reveals 
that the majority of recombinants do not yield any PCR product with screening primers. 
The reason for this is that in the second step, the antibiotic selection is aimed at identifying 
BACs that have lost the RpsL-neo cassette and any unwanted rearrangements resulting in 
the loss of the RpsL-neo cassette would produce streptomycin resistant isolates and would 
thus be selected. In addition, unwanted nucleotide substitutions can be found in the re-
introduced gene fragment when the RpsL-neo cassette is replaced with the PCR amplified 
product. The mismatches are most likely introduced during the PCR amplification step. In 
some cases, rearrangement happens where most of the viral genome in the BAC is lost 
although the BAC cassette is still present (data not shown). Here, the isolates can be 
selected on chloramphenicol containing plates, but PCR of the manipulated ORF and other 
ORFs on either side gives no product at all. So occasionally, more than 50 clones need to be 
characterized to obtain a BAC with an intact genome and the desired mutation and without 
unwanted mismatches.  
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4.3 Recombinant virus growth phenotypes 
4.3.1 The M27 mutant Mt[M27
A658S
] 
The M27 gene encodes a 79-kD protein (length 682 aa) shown to bind selectively to 
and down-regulate, the signal transducer and activator of transcription (STAT)-2, but it has 
no effect on STAT1 activation or signalling. STAT2 inhibition by the M27 protein confers 
resistance to IFN- for viral replication in tissue culture and in mice. An M27 deletion 
mutant (ΔM27) was completely inhibited by IFN-(Khan et al., 2004b). This inhibition 
was assumed to be caused by the inability of the mutant virus to neutralize the effect of 
IFN-- mediated gene expression and hence inhibition of viral replication caused by 
downregulation of STAT2. This provides good evidence that viral interference with IFN- 
signalling is accountable for preventing immunopreatosome expression (Khan et al., 
2004b). In addition to the role of M27 in supporting viral growth in the presence of IFN-, 
it was shown that there is an immunomodulatory proviral effect for the M27 gene where 
IFN- stimulates a large number of genes involved in antigen presentation, cell adhesion, 
chemotaxis and inflammation (Boehm et al., 1997). So, in vivo, a dramatic replication 
deficiency of MCMV resulted from deletion of the M27 ORF (Abenes et al., 2001). 
The growth curve of the Mt[M27
A658S
] mutant showed that this single mutation has 
no effect on virus growth in vitro in MEF cells at either permissive or non-permissive 
temperatures compared to both the wild-type and M27 revertant viruses (Figure 3.31). 
Thus, this mutation does not show a ts phenotype. Furthermore, mutant Mt[M27
A658S
] 
showed similar growth kinetics in macrophages to the revertant and the wt K181 (Perth) 
variant at 37ºC (Figure 3.39).  
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The mutation introduced into the M27 gene was at nucleotide position 32,302 in 
which an adenosine substitution for cytosine results in replacement of an alanine with a 
serine at residue 658 (A658S) at the carboxyl-terminal end of the protein. Analysis of the 
M27 peptide sequence suggested this substitution is not located in any conserved or 
consensus regions.  This result is consistent with studies suggesting that the M27 carboxyl-
terminal sequence is dispensable for viral replication in fibroblasts in vitro (Abenes et al., 
2001). However, the M27 deleted mutant was attenuated for replication in both BALB/c 
and SCID mice that were infected intraperitoneally with virus. Titres of the M27 deleted 
mutant virus in the salivary glands, lungs, spleens, livers, and kidneys of infected SCID 
mice at 21 days post infection were 50- to 500-fold lower than those of the wild-type virus 
and the rescued virus (Abenes et al., 2001). In addition, the virulence of the mutant virus 
was lower as deaths in infected SCID mice occurred for up to 37 days post infection 
compared to wild type and rescued virus-infected mice that died within 27 days. These 
results suggest that a disruption of M27 expression results in reduced viral growth and 
attenuated viral virulence in infected animals (Abenes et al., 2001). The tsm5 mutant is also 
attenuated for mice and the M27 mutation could contribute to this. However, its ability to 
replicate like wt virus in macrophages might suggest otherwise, but studies in mice are 
necessary to confirm this. 
4.3.2 Murine cytomegalovirus US22 genes: 
One of the characteristic features of betaherpesviruses, in which they differ from 
alpha- and gamma-herpesviruses, is the presence of additional gene families such as the 
US22 gene family. These families are usually found at the ends of the genome (Neipel et 
al., 1991; Nicholas, 1996). The US22 gene family was initially described in HCMV. It 
consists of 12 members in both HCMV and MCMV and 11 in rat CMV (Chee et al., 1990). 
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These members are characterized by stretches of hydrophobic and charged residues and up 
to four conserved sequence motifs that are specific for betaherpesviruses. In HCMV, motif 
I varies between US and UL family members (Nicholas, 1996). MCMV genes M23, M24, 
m25.1, m25.2, M 36 and M43 have UL-like motif I whereas m128, and m139 to m143 
genes have the HCMV US-like motif I. Motifs I and II sequences contain short stretches of 
hydrophobic and charged residues, whereas, motifs III and IV are less well-defined and 
have stretches of non-polar residues (Hanson et al., 1999; Kouzarides et al., 1988).  
Many US22 gene products are viral tegument components and the functions of most 
US22 genes are unknown (Adair et al., 2002). However, five of the twelve members of the 
US22 gene family (M36, M43, m139, m140 and m141) products of MCMV are important 
for virus replication in macrophages (Menard et al., 2003). The M36 gene has an anti-
apoptotic function where it encodes an anti-apoptotic protein that inhibits death receptor-
mediated induction of apoptosis by binding to procaspase 8 (Menard et al., 2003). UL36 in 
HCMV, the positional and sequence homologue of M36, was initially anticipated to 
function as a transcriptional transactivator (Colberg-Poley et al., 1992). A later study 
showed that the function of UL36 is similar to that of M36, where it encodes a viral 
inhibitor of caspase 8 activation (vICA) (Menard et al., 2003; Skaletskaya et al., 2001). 
Genes m139-m141 have all four motifs, while m142 and m143 (and IRS1/TRS1 of 
HCMV) do not have motif II. It is also shown that m139, m141, m142 and m143 have an 
acidic domain which is common to herpesvirus transcriptional activators and specifically to 
MCMV immediate-early proteins 1 and 2 (Cardin et al., 1995; Munch et al., 1992). Among 
these genes, UL36 and TRS1/IRS1 in HCMV, and m128, m142, and m143 in MCMV, and 
positional homologues of HCMV UL36 to UL38, and UL43 of human herpesvirus 6 
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(Cardin et al., 1995; Munch et al., 1992; Nicholas & Martin, 1994), are found to be 
transcribed with immediate-early kinetics. 
4.3.2.1 The M36 mutant Mt[M36
V54I
] 
Studies have suggested that the M36-encoded protein has an antiapoptotic function 
where it interacts with procaspase-8. Deletion of the M36 gene resulted in apoptosis of 
infected macrophages (Menard et al., 2003). Also, deletion of M36 resulted in enhanced 
apoptosis after pro-apoptotic stimulation of infected fibroblasts. Study of the anti-apoptotic 
function of wild-type and M36 deleted MCMV infected NIH 3T3 fibroblasts and IC-21 
macrophages and mock-infected cells after pro-apoptotic anti-Fas treatment revealed that 
there was a 4.5-fold difference in the number of surviving cells after infection with wild-
type and ∆M36 MCMV, whereas the difference was 65-fold in IC-21 macrophages 
(Menard et al., 2003). 
The growth kinetics of mutant Mt[M36
V54I
] showed no ts effect on virus growth in 
vitro in MEF cells at either permissive or non-permissive temperatures compared to both 
the wt K181 (Perth) parent virus and M36 mutant revertant (Figure 3.32). Thus, this 
mutation does not show a ts phenotype as it replicated to similar titre to its revertant and the 
wt virus. Moreover, mutant Mt[M36
V54I
] showed similar growth kinetics in Raw 
macrophages to the revertant and the wt K181 (Perth) variant at 37ºC (Figure 3.40). 
Our results for replication of mutant Mt[M36
V54I
] are consistent with other studies 
which showed that the M36 ORF is dispensable for growth in MEF and NIH3T3 cells 
(Menard et al., 2003). However, the M36 ORF protein plays a role in viral growth in 
macrophages, as M36 transposon mutants with transposon insertions 98 bp downstream of 
the ATG and 363 bp downstream of the start of exon2 resulted in impairment of virus 
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growth in M36 infected IC-21 macrophages and titres were three logs lower in semi-
permissive J774-A1 macrophages compared to wild-type virus (Menard et al., 2003). The 
mutation introduced into the M36 gene in the present study was into exon1. Little is known 
of the functional domains of M36 but it appears that the mutation identified in the tsm5 
M36 plays little role in the function of M36.  
4.3.2.2 The double mutant Mt[M27
A658S
 M36
V54I
] virus 
As discussed above, the M27 protein plays a role in binding selectively to and then 
downregulation of STAT2, which explains why wt virus replication is resistant to IFN- in 
tissue culture and in mice. Thus, a mutant in which the M27 gene was deleted (ΔM27) was 
completely inhibited by IFN-(Khan et al., 2004b).  
On the other hand, the anti-apoptotic function of the M36 gene product and its 
interaction with procaspase-8 supports the replication of the virus in cells and allows the 
production of virus progeny. Deletion of the M36 gene resulted in apoptosis of infected 
macrophages (Menard et al., 2003). Induction of apoptosis resulted in abortive viral 
infection and shut-down of virus replication. Deletion of the M36 ORF also resulted in an 
enhanced apoptosis after pro-apoptotic stimulation of infected fibroblasts. 
Although the presence of individual M27 and M36 mutations in the constructs of 
Mt[M27
A658S
] and Mt[M36
V54I
]  respectively did not affect virus replication in MEFs or 
macrophages (Section 3.4.1 and 3.4.2), the presence of both mutations in one virus, the 
Mt[M27
A658S
 M36
V54I
] mutant, attenuated virus growth in MEF cells at 40ºC and in 
macrophages at 37ºC. These results suggest that the two mutations might have a synergistic 
effect whereby previously undetected inhibition of viral replication as a result of IFN- 
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mediated gene expression in the M27 mutant and the undetected increased apoptosis in the 
M36 mutant now combine to suppress virus replication in the double mutant. This might 
explain the low titre of the Mt[M27
A658S
 M36
V54I
] mutant during production of seed and 
working stocks and the small plaque size (Figure 3.34) produced by the double mutant 
compared to its revertant as well as the M27, M36 and wt viruses. 
Activation of the IFN signalling pathways results in transcription of target genes 
whose products have an antiviral activity. The eIF2 Protein kinase R (PKR) and the 2‟-5‟ 
oligoadenylate synthetases are two well-known IFN-inducible components that exert the 
antiviral response. Each is an essential factor that independently acts to inhibit virus 
replication and thus results in the establishment of an antiviral state. In interferon-
stimulated primary human cells infected with HSV-1, 2‟-5‟ oligoadenylate synthetase 
production is blocked late in the virus‟ productive life cycle by the US11 gene product 
(Sanchez & Mohr, 2007). Other factors, such as IFN-inducible enzymes and molecules 
involved in the cell cycle or cell death might limit viral replication. These IFN-inducible 
enzymes are present in cells in an inactive form that can be activated when the cells are 
virally infected. It is thought that viral co-factors such as dsRNA can play a role in the IFN-
inducible enzyme activation (Jacobs & Langland, 1996). It might be that apoptosis enzymes 
are among the IFN-inducible molecules involved in cell death and thus M27 mutation 
potentiates the effect of the M36 mutation.  
The M27 and M36 proteins might also have activities other than inhibition of IFN- 
mediated gene expression and apoptosis or they might interact together in either IFN 
signalling or apoptosis pathways that promote virus growth. For example, recent evidence 
suggests that reduced expression of STAT2 in cancer cells leads to resistance to type I IFN-
induced apoptosis. STAT2 deficient cells were defective in activating the mitochondrial-
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dependent death pathway (Romero-Weaver et al., 2010; Scarzello et al., 2007). Similarly, 
in multiple myeloma, members of the Bcl-2 family such as Bax and Bak have been 
implicated in mediating type I IFN-induced apoptosis (Panaretakis et al., 2003; Thyrell et 
al., 2004). A small set of IFN-inducible, STAT2-dependent apoptotic genes have recently 
been identified on human chromosome 22 (Hartman et al., 2005). It is likely that expression 
of these genes requires transcriptionally competent STAT2 for mediating type I IFN-
induced apoptosis. Thus, a minor increase in STAT2 expression by the M27 mutation 
coupled with increased IFN induction resulting from the M36 mutation may produce the 
synergistic effect observed.  
It will be interesting to study the effect of presence of both mutations in the mouse 
where it was shown that deletion of the M27 gene had a dramatic effect on virus replication 
in vivo (Abenes et al., 2001). This effect was attributed to the immunomodulatory proviral 
effect for M27 gene where IFN- stimulates a large number of genes involved in antigen 
presentation, cell adhesion, chemotaxis, and inflammation (Boehm et al., 1997). 
4.3.3 m139, 141 and 143 mutants 
In infected fibroblasts and macrophages, the protein products of the m139 (72 and 
61 kDa), m140 (56 kDa) and m141 (52 kDa) ORFs are expressed abundantly at early and 
late times in the nucleus and cytoplasm of infected fibroblasts and macrophages  (Hanson et 
al., 1999; 2001). The products of m139, m140 and m141 function to regulate, directly or 
indirectly, the replication of MCMV in macrophages, that play a role in CMV pathogenesis 
and in supporting productive and latent infections (Henry et al., 2000). Deletion or 
mutation in these genes results in attenuation of virus replication in activated macrophages 
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in vitro and in severe combined immunodeficient (SCID) mice (Hanson et al., 1999; 2001; 
Menard et al., 2003). 
Studies described a transcriptional transactivation function for all US22 genes 
except m142 and m143 (Cardin et al., 1995; Colberg-Poley, 1996). Studies with MCMV 
showed that the IE2 product of m128 is dispensable for growth in vitro and in vivo (Cardin 
et al., 1995).  A mutant with a deletion that included genes m137 through to m143 was not 
able to grow like wt MCMV, which might indicate that one or more of these genes are 
important for virus replication (Cavanaugh et al., 1996).  
MCMV mutants RV7 (m137 through to m141 genes deleted) and RV10 (m139 
through to m141 genes deleted) failed to grow in macrophages in vitro and demonstrated 
altered tissue type distribution in vivo (Cavanaugh et al., 1996; Hanson et al., 1999). 
Hanson and colleagues showed that this phenotype of growth in macrophages was not a 
property of the product of the m139 where deletion of m139 alone had no influence on viral 
replication in IC-21 macrophages. However, deletion of the m141 ORF resulted in a 2 log10 
reduction in virus growth in IC-21 macrophages. Furthermore, they showed that m140 and 
m141 influenced viral pathogenesis by functioning both cooperatively and independently to 
regulate MCMV replication in a cell type-specific manner (Hanson et al., 2001). The 
product of m139 interacts with the complex formed of m140 and m141 gene products to 
form a complex that co-localized predominantly at the perinuclear region of the cell 
(Karabekian et al., 2005). 
The m139 ORF encodes two proteins, one of 72 kDa (p72m139) and one of 61 kDa 
(p61m139), which can be detected by 6 h.p.i. in either fibroblasts  or macrophages, and 
remain at steady-state levels increased throughout the course of infection. However, 
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p61m139 was consistently less abundant at all times post infection. The 72-kDa m139 
protein closely matched the predicted size of 71.8 kDa, suggesting that this protein is a full-
length product. The smaller protein may be a processed product derived from p72m139 or 
may arise from the second transcript (Hanson et al., 2001). 
In a comprehensive mutational analysis of all 12 US22 gene family members of 
MCMV, only m142 and m143 were essential for virus replication in vitro (Menard et al., 
2003). Mutants with a m142 or m143 deletion were both unable to replicate in non-
complementing cells at low and high MOI. It was shown that in cells infected with these 
mutants, proteins of viral IE and E were expressed, whereas viral DNA replication and 
synthesis of the late-gene product glycoprotein B were inhibited although late gene mRNAs 
were present (Valchanova et al., 2006).  
Furthermore, synthesis of global protein was diminished in these cells, which is 
linked with phosphorylation of the double-stranded RNA-dependent protein kinase R 
(PKR) and its target protein, the eukaryotic translation initiation factor 2. These findings 
propose that m142 and m143 are essential for blocking the PKR-mediated shutdown of 
protein synthesis. Expression of the human cytomegalovirus TRS1 gene, the double-
stranded-RNA-binding protein that inhibits PKR activation, partially restored replication of 
these mutants. This suggests that m142 and m143 were both important for inhibition of the 
PKR-mediated host antiviral response (Valchanova et al., 2006). 
4.3.3.1 The m139 mutant Mt[m139
Y565X
] 
In infected fibroblasts and macrophages, the protein products of  m139, m140 and 
m141 are abundantly expressed in co-ordinate fashion  from 3‟co-terminal transcripts at 
early and late times in the nucleus and cytoplasm (Hanson et al., 1999; 2001). 
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Compared to the wt K181 (Perth) parent virus and the m139 revertant, the 
replication of mutant Mt[M139
Y656X
] showed no deficiency in virus growth in vitro in MEF 
cells at 37ºC. However, at 40ºC the virus yields were lower  and similar to those of tsm5 
(stock 2004) (Figure 3.35). Surprisingly, mutant Mt[M139
Y656X
] showed similar growth 
kinetics in Raw macrophages to the revertant and the wt K181 (Perth) variant virus at 37ºC 
(Figure  3.42). This suggests that the  M139Y656X mutation contributes to the ts phenotype of 
tsm5. 
 In our study, the mutation introduced into the Mt[M139
Y656X
] mutant  resulted in a 
stop codon and then truncation of the m139 protein;  this resulted in a slight temperature 
sensitivity where its replication at 40ºC in MEFs was reduced compared to its revertant and 
the wt. However, its replication in macrophages at 37ºC was similar to that of the wt, which 
might indicate that truncation of m139 at residue 656 affects folding of its product at an 
elevated temperature. 
4.3.3.2 The m141 mutant Mt[m141
V195M
]] 
Introduction of the T to C mutation at position 198,731 of the m141 gene did not 
affect the growth kinetics of the Mt[m141
V195M
] mutant and showed no ts effect on virus 
growth in vitro in MEF cells compared to wt K181 (Perth) (Figure 3.36). Moreover, 
Mt[m141
V195M
] showed similar growth kinetics in Raw macrophages to the revertant and 
the wt K181 (Perth) variant at 37ºC (Figure 3.43).  
Our observation that the m141 mutation has no ts phenotype as the mutant replicated 
to similar titres as its revertant and the wt indicates that the introduced mutation has no 
effect on virus growth in MEFs and macrophages in vitro and possibly does  not affect the 
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interaction between m139 and m140 products. An in vivo study of m141 mutant may reveal 
an effect of the introduced mutation on the pathogenicity of the virus. 
4.3.3.3 The m143 mutant Mt[m143
M232I
] 
As for the m139 and m141 mutants, the growth kinetics of mutant Mt[m143
M232I
] 
were similar to its revertant virus and the wt K181 (Perth) virus in MEF cells at both the 
permissive and non-permissive temperature (Figure 3.37). Thus, this mutation does not 
show a ts phenotype. Moreover, mutant Mt[m143
M232I
] showed similar growth kinetics in 
Raw macrophages to the revertant and the wt K181 (Perth) variant at 37ºC (Figure 3.44) 
The m143 mutation (T to C at position 201, 944) has no effect on  virus growth in 
vitro in MEF cells at either 37ºC or 40ºC compared to both the wt K181 (Perth) parent virus 
and its revertant (Figure 3.37). In addition, Mt[m143
M232I
] showed similar growth kinetics 
in Raw macrophages to the revertant and the wt K181 (Perth) variant at 37ºC (Figure  3.44). 
Thus, the T to C at position 201, 944 mutation in m143 gene of MCMV possibly has 
no effect on virus replication in vitro in MEFs and macrophages.  
  
Chapter 4: General discussion   
228 
4.4 Changing codon preferences of the M70 ORF 
Our working hypothesis in this project was that the replacement of preferred codons 
with non-preferred codons might lower replicative fitness primarily by reducing the rate of 
translation (at the level of polypeptide chain elongation) of the MCMV M70 primase 
potentially disrupting viral DNA synthesis in infected cells. To test this hypothesis, two 
viruses were constructed with a synthetic M70 gene (cysteine and tyrosine versions) in 
which 403 of the wt codons were changed to the non-preferred codons. Both BACs were 
not able to produce viable viruses upon transfection into MEF cells although the 
transfections were successful as they were monitored for 12 day post infection (Figure 
3.50). These results suggest that changing 403 of the 964 codons (42%) resulted in shut-off 
of primase protein synthesis and thus no virus production or CPE was detected although the 
revertant BACs produced viruses like the wt parent virus.  
Based on this, another two MCMV BACs (cysteine and tyrosine versions) were 
produced with 155 out of 964 codons (16%) of the distal region of M70 ORF (at nt 99,061-
100081) or 155 out of 359 codons (43.2%) in that segment changed to the non-preferred 
codons. Upon reduction of the number of codons changed to non-preferred codons the M70 
gene primase was produced in sufficient amount to allow the virus to replicate like the wild 
type virus. However, the presence of tyrosine at residue 890 aggravated the situation for the 
virus and shut-off primase protein synthesis and thus no virus production or CPE were 
detected. 
Studies with the poliovirus vaccine strain Sabin type 2 where codons in the capsid 
region were changed to suboptimal codons also showed that attenuation of the virus was 
proportional to the number of codons changed to the non-preferred or least used ones 
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(Burns et al., 2006).  Thus, reduction of the number of the suboptimal codons in the M70 
gene from 403 to 155 allowed mutant Mt[M70
SO155Cys
] to yield infectious virus and to 
produce a detectable CPE on MEFs. However, its ability to replicate in macrophage cell 
culture and in vivo still needs to be examined. 
The presence of tyrosine at residue 890 in the Mt[M70
C890Y
] attenuated replication 
of the virus in MEFs at 40ºC and in macrophages at 37
o
C (Section 3.4.1.3 and 3.4.2.2), but 
it replicated similarly to wt virus at 37ºC  in MEFs (Timoshenko et al., 2009b). However, in 
Mt[M70
SO155Tyr
], changing 155 out of 964 codons (16%) into suboptimal codons resulted in 
combination of two factors that exerted a stress in the expression and function of the M70 
primase protein that resulted in its inability to replicate.  
Interestingly, serial passage of mutant Mt[M70
SO155Cys
] 10 times in MEF tissue 
culture cells revealed that no mutations occurred in the synthetic segment of the M70 gene. 
Similar results were observed for poliovirus where serial passage (for 25 passages in HeLa 
cells) of the virus with altered codon composition showed that the relative fitness of the 
modified virus remained lower than that of the unmodified wt virus (Burns et al., 2006). 
Furthermore, infection of mice, transgenic for the poliovirus receptor (CD155tg mice), with 
equal amounts of virus particles of wt virus or virus with altered codons, revealed that the 
mutated virus was over 100-fold neuro-attenuated compared to the wt virus (Mueller et al., 
2006).  
The synthetic poliovirus with synonymous non-preferred codons was stable and may 
prove suitable as an attenuated virus for the production of a poliovirus vaccine (Mueller et 
al., 2006). Thus, virus containing the modified M70 gene with less than 20-40% of its wt 
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codons might produce a virus suitable for a model vaccine study, especially if the correct 
combination of non-preferred codons and tyrosine 890 can be found. 
4.4.1 M70 gene growth at 37oC 
It is generally accepted that the difference in physical properties resulting from a 
base substitution leading to an amino acid change in the protein product of a mutated gene, 
which results in a temperature-sensitive mutant, is due to a temperature sensitive folding 
event that does not influence the properties of the native form of the protein (Smith et al., 
1980). At the permissive temperature, the temperature sensitive polypeptide chains reach 
their final native state, while at higher temperature they fail to reach this state (Smith & 
King, 1981). Furthermore, following maturation of the mutant protein into its native state at 
the permissive temperature, it will have a similar thermal stability and biological activity to 
the wild-type protein (Sturtevant et al., 1989). Based on this it was assumed that the residue 
substitution in a polypeptide chain resulting in a temperature sensitive mutation is not 
essential for the maintenance of the native form of the protein but plays a significant role in 
the stability and/or kinetic fates of the folding intermediates (Mitraki & King, 1992).  
The zinc finger motif (cys–his–cys–cys) in the M70 protein is conserved in all 
herpesviruses and is involved in DNA binding and helicase activity as well as primase 
activity, where mutations within this motif of the HSV-1 homologue of M70/UL70 affects 
these functions (Chen et al., 2005).  The C890 residue is located 16 amino acids upstream 
of the zinc finger and is conserved in all cytomegaloviruses and hence it might affect the 
activities of the zinc finger. Cytosine substitution with tyrosine at residue 890 in the M70 
gene in mutant Mt[M70
C890Y
], did not affect replication of the virus in MEF cells at 37ºC 
but attenuated its replication in MEFs at 40ºC and in vivo (Timoshenko et al., 2009b). 
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Surprisingly, replication of mutant Mt[M70
C890Y
] was also attenuated in macrophages at 
37ºC (Section 3.4.2.2).  Based on these findings, attenuation of the virus in macrophages 
and at the non-permissive temperature in MEFs was not necessarily due to improper folding 
of the M70 protein, but may be due to a defective protein which manifests itself during 
stress situations, such as the state of the host cells at the non-permissive temperature or 
between the different cell culture types. As in the cytomegalovirus infection in humans, 
circulating leukocytes, particularly monocytes, play an important role in the dissemination 
of MCMV in the mouse in many stages during the infection (Collins et al., 1994), and thus 
attenuation of mutant Mt[M70
C890Y
] replication in macrophages probably plays a role in the 
attenuation of the virus infection in vivo. 
It was suggested previously that substitution of the cysteine with a tyrosine may 
have introduced a tyrosine kinase phosphorylation site and the phosphorylated tyrosine 
could markedly affect primase conformation and stability, but prediction analysis using the 
ScanProsite software from the Expert Protein Analysis System (ExPASy) proteomics server 
did not identify Y890 as a predicted tyrosine kinase phosphorylation site (Timoshenko et 
al., 2009b). It is possible that the large side chain of tyrosine could affect and destabilise the 
primase protein structure although upon substitution of cysteine with a much smaller amino 
acid with a chemically active side chain, serine, the virus grew similarly to the wt virus. 
Furthermore, replacement of cysteine with a relatively inactive amino acid, methionine, 
also re-established wt activity (Timoshenko et al., 2009b). 
However, prediction of the structure of the M70 primase using PredictProtein 
(http://www.predictprotein.org), showed that replacement of cysteine with tyrosine has a 
marked effect on predicted solvent accessibility (PROFacc), secondary structure 
(PROFsec), amino acid subsequences that are most likely to switch between different types 
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of secondary structure (ASP), DNA interaction sites (ISIS), protein disorder prediction-
unstructured loops (NORSnet) prediction of residue mobility (PROFbval), and prediction 
of meta-disorder (MD) but shows no obvious changes in the prediction of natively 
unstructured regions (Ucon). It is interesting that when the cysteine residue is replaced by 
serine (M70Ser) or methionine (M70Met), which produced mutant viruses with a wt 
phenotype (Timoshenko et al., 2009b), the predicted structure was similar to the wild-type 
structure (Figure 3.52). According to these results, understanding the factors resulting in the 
M70 mutated virus attenuation will be possible only when the primase protein structure is 
available. 
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